<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00977</drugbank-id>
  <drugbank-id>APRD00691</drugbank-id>
  <name>Ethinylestradiol</name>
  <description>A semisynthetic alkylated estradiol with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally and is often used as the estrogenic component in oral contraceptives. Ethinyl estradiol is marketed mostly as a combination oral contraceptive under several brand names such as Alesse, Tri-Cyclen, Triphasil, and Yasmin. The FDA label includes a black box warning that states that combination oral contraceptives should not be used in women over 35 years old who smoke due to the increased risk of serious cardiovascular side effects.</description>
  <cas-number>57-63-6</cas-number>
  <unii>423D2T571U</unii>
  <average-mass>296.4034</average-mass>
  <monoisotopic-mass>296.177630012</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Andreas Sachse, "Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol." U.S. Patent US20060079491, issued April 13, 2006.</synthesis-reference>
  <indication>For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.</indication>
  <pharmacodynamics>Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent.</pharmacodynamics>
  <mechanism-of-action>Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).</mechanism-of-action>
  <toxicity>Oral, mouse LD&lt;sub&gt;50&lt;/sub&gt;: 1737 mg/kg. Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females. The FDA label includes a black box warning that states that combination oral contraceptives with ethinyl estradiol should not be used in women over 35 years old who smoke due to the increased risk of serious cardiovascular side effects. </toxicity>
  <metabolism>Hepatic. Quantitatively, the major metabolic pathway for ethinyl estradiol, both in rats and in humans, is aromatic hydroxylation, as it is for the natural estrogens.</metabolism>
  <absorption>Rapid and complete absorption follows oral intake of ethinyl estradiol (bioavailability 43%).</absorption>
  <half-life>36 +/- 13 hours</half-life>
  <protein-binding>97%</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.</description>
    <direct-parent>Estrogens and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Steroids and steroid derivatives</class>
    <subclass>Estrane steroids</subclass>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>17-hydroxysteroids</alternative-parent>
    <alternative-parent>3-hydroxysteroids</alternative-parent>
    <alternative-parent>Acetylides</alternative-parent>
    <alternative-parent>Cyclic alcohols and derivatives</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Phenanthrenes and derivatives</alternative-parent>
    <alternative-parent>Tertiary alcohols</alternative-parent>
    <alternative-parent>Tetralins</alternative-parent>
    <alternative-parent>Ynones</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>17-hydroxysteroid</substituent>
    <substituent>3-hydroxysteroid</substituent>
    <substituent>Acetylide</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Aromatic homopolycyclic compound</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Cyclic alcohol</substituent>
    <substituent>Estrogen-skeleton</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Hydroxysteroid</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Phenanthrene</substituent>
    <substituent>Tertiary alcohol</substituent>
    <substituent>Tetralin</substituent>
    <substituent>Ynone</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">17-ethinyl-3,17-estradiol</synonym>
    <synonym language="english" coder="">17-ethinyl-3,17-oestradiol</synonym>
    <synonym language="english" coder="">17-ethinylestradiol</synonym>
    <synonym language="english" coder="">17alpha-Ethinyl estradiol</synonym>
    <synonym language="english" coder="">17Î±-ethynylestradiol</synonym>
    <synonym language="english" coder="">Ethinyl estradiol</synonym>
    <synonym language="english" coder="inn">Ethinylestradiol</synonym>
    <synonym language="latin" coder="inn">Ethinylestradiolum</synonym>
    <synonym language="english" coder="">Ethinyloestradiol</synonym>
    <synonym language="english" coder="">Ethynyl estradiol</synonym>
    <synonym language="spanish" coder="inn">Etinilestradiol</synonym>
  </synonyms>
  <products>
    <product>
      <name>Afirmelle</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-849</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206886</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alesse 21</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02236974</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-01-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alesse 28</name>
      <labeller>Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0008-2576</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-04-01</started-marketing-on>
      <ended-marketing-on>2008-02-29</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020683</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alesse 28</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02236975</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-01-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Altavera</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5583</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA079102</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Altavera</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA079102</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alyacen 1/35</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-394</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091634</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alyacen 1/35</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1477</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091634</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alyacen 1/35</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091634</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alyacen 7/7/7</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-556</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091636</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alyacen 7/7/7</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-556</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091636</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alyacen 7/7/7</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-556</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091636</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alyacen 7/7/7</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1734</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091636</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alyacen 7/7/7</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1478</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091636</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alysena 21</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02387875</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alysena 28</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02387883</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Amethia</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-268</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-31</started-marketing-on>
      <ended-marketing-on>2018-05-04</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078834</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Amethia</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-268</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-31</started-marketing-on>
      <ended-marketing-on>2018-05-04</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078834</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Amethia</name>
      <labeller>Mayne Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>51862-047</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078834</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Amethia</name>
      <labeller>Mayne Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>51862-047</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078834</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Amethia Lo</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-228</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-07</started-marketing-on>
      <ended-marketing-on>2018-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200407</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Amethia Lo</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-228</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-07</started-marketing-on>
      <ended-marketing-on>2018-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200407</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Amethia Lo</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-10</started-marketing-on>
      <ended-marketing-on>2021-03-31</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022262</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Amethia Lo</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-10</started-marketing-on>
      <ended-marketing-on>2021-03-31</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022262</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Amethyst</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-295</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA079218</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Annovera</name>
      <labeller>TherapeuticsMD, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50261-313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ring</dosage-form>
      <strength/>
      <route>Vaginal</route>
      <fda-application-number>NDA209627</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Annovera</name>
      <labeller>QPharma AB</labeller>
      <ndc-id/>
      <ndc-product-code>12822-0313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ring</dosage-form>
      <strength/>
      <route>Vaginal</route>
      <fda-application-number>NDA209627</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Apri</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4754</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075256</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Apri 21</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02317192</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apri 28</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02317206</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apri 28 Day</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2481</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075256</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Apri 28 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9043</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075256</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranelle</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9066</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076783</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranelle</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9066</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076783</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ashlyna</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2097</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-23</started-marketing-on>
      <ended-marketing-on>2017-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203163</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ashlyna</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-646</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203163</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ashlyna</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-646</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203163</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aubra</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1692</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200245</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aubra</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200245</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aubra EQ</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-220</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206886</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aurovela 1.5/30</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-935</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207581</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aurovela 1/20</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-939</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207506</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aurovela 24 Fe</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-934</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207504</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>AUROVELA Fe</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-941</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207580</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aurovela Fe 1/20</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-940</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207505</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aviane</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5356</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-07-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075796</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aviane</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075796</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aviane</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-889</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075796</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aviane 21</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02298538</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aviane 28</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02298546</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aviane 28 Day</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-995</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075796</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ayuna</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-848</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206866</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Azurette</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-940</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Azurette</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-940</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Azurette</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1600</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Azurette</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-072</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Azurette</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-072</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Balcoltra</name>
      <labeller>Avion Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>75854-602</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA208612</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Balziva</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9034</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-10-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bekyree</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-880</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202226</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bekyree</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-880</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202226</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bekyree</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-880</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-26</started-marketing-on>
      <ended-marketing-on>2019-08-01</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202226</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bekyree</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-880</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-26</started-marketing-on>
      <ended-marketing-on>2019-08-01</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202226</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bekyree</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-879</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202226</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bekyree</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-879</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202226</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Beyaz</name>
      <labeller>Bayer HealthCare Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50419-407</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022532</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Blisovi 24 Fe</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-864</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091398</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Blisovi Fe 1.5/30</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-866</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201585</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Blisovi Fe 1/20</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-865</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-07</started-marketing-on>
      <ended-marketing-on>2020-08-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201584</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Brevicon</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-254</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-03-29</started-marketing-on>
      <ended-marketing-on>2018-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017743</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Brevicon 0.5/35 21 Tab</name>
      <labeller>Syntex Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00373265</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Brevicon 0.5/35 28 Tab</name>
      <labeller>Syntex Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00373273</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Brevicon 0.5/35 Tablets (21-day Pack)</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02187086</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Brevicon 0.5/35 Tablets (28-day Pack)</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02187094</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Brevicon 1/35 21 Tab</name>
      <labeller>Syntex Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00531006</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Brevicon 1/35 28 Tab</name>
      <labeller>Syntex Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00531014</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Brevicon 1/35 Tablets (21-day Pack)</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02189054</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Brevicon 1/35 Tablets (28-day Pack)</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02189062</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-09-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Briellyn</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Camrese</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-3134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021840</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Camrese</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-3134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021840</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>camrese Lo</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-6148</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022262</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>camrese Lo</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-6148</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022262</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-385</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-27</started-marketing-on>
      <ended-marketing-on>2017-04-14</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077182</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-385</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-27</started-marketing-on>
      <ended-marketing-on>2017-04-14</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077182</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-385</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-27</started-marketing-on>
      <ended-marketing-on>2017-04-14</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077182</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-959</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-31</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077182</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-959</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-31</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077182</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-959</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-31</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077182</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant Triphasic Regimen</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1628</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant Triphasic Regimen</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0059</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant Triphasic Regimen</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0059</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant Triphasic Regimen</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0059</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant Triphasic Regimen</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-238</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant Triphasic Regimen</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-238</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caziant Triphasic Regimen</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-238</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Centrisa 21</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411199</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Centrisa 21</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411199</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Centrisa 21</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411199</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Centrisa 28</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411202</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Centrisa 28</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411202</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Centrisa 28</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411202</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Centrisa Lo 21</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411431</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Centrisa Lo 21</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411431</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Centrisa Lo 21</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411431</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Centrisa Lo 28</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411458</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Centrisa Lo 28</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411458</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Centrisa Lo 28</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411458</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cesia</name>
      <labeller>Prasco, Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-615</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cesia</name>
      <labeller>Prasco, Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-615</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cesia</name>
      <labeller>Prasco, Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-615</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chateal</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091663</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chateal</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091663</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Chateal EQ</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-230</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206866</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ClÃ©o -35</name>
      <labeller>Altius Healthcare Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02436736</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cryselle</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4851</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075840</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cryselle</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075840</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cryselle</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1214</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075840</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cryselle</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9049</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075840</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclafem 1/35</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076337</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclafem 1/35</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1648</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076337</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclafem 1/35</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7521</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076337</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclafem 7/7/7</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076338</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclafem 7/7/7</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076338</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclafem 7/7/7</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076338</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclafem 7/7/7</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076338</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclafem 7/7/7</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076338</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclafem 7/7/7</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076338</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclafem 7/7/7</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076338</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclen Tablets (21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01968440</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cyclen Tablets (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01992872</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cyclessa</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4911</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-02</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021090</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclessa</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4911</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-02</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021090</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclessa</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4911</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-02</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021090</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclessa</name>
      <labeller>Organon</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-20</started-marketing-on>
      <ended-marketing-on>2016-10-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021090</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclessa</name>
      <labeller>Organon</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-20</started-marketing-on>
      <ended-marketing-on>2016-10-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021090</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclessa</name>
      <labeller>Organon</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-20</started-marketing-on>
      <ended-marketing-on>2016-10-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021090</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclessa</name>
      <labeller>Aspen Global Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76388-283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-31</started-marketing-on>
      <ended-marketing-on>2017-12-15</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021090</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclessa</name>
      <labeller>Aspen Global Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76388-283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-31</started-marketing-on>
      <ended-marketing-on>2017-12-15</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021090</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyclessa</name>
      <labeller>Aspen Global Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76388-283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-31</started-marketing-on>
      <ended-marketing-on>2017-12-15</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021090</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyestra-35</name>
      <labeller>Paladin Labs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02290308</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cyonanz</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-899</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207055</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyred</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1722</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202085</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyred</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-154</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202085</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cyred EQ</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-254</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dasetta 1/35</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-348</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090948</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dasetta 7/7/7</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-346</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090946</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dasetta 7/7/7</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-346</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090946</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dasetta 7/7/7</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-346</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090946</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Daysee</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-846</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091467</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Daysee</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-846</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091467</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Delyla</name>
      <labeller>Ohm Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51660-572</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201108</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Demulen 30 (21 Day Pack)</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00469327</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>2019-07-04</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Demulen 30 (28 Day Pack)</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00471526</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>2019-07-04</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Demulen 50 (21 Day Pack)</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00028630</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on>2005-04-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Demulen 50 (28 Day Pack)</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00343536</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on>2005-04-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Desogen</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3863</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-10</started-marketing-on>
      <ended-marketing-on>2010-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020071</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desogen</name>
      <labeller>Organon</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0261</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-10</started-marketing-on>
      <ended-marketing-on>2018-07-25</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020071</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desogestrel and Ethinyl Estradiol</name>
      <labeller>North Star Rx Llc</labeller>
      <ndc-id/>
      <ndc-product-code>16714-367</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091234</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desogestrel and Ethinyl Estradiol</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-382</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-27</started-marketing-on>
      <ended-marketing-on>2016-07-27</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076675</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desogestrel and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7282</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202085</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desogestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7296</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202296</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desogestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7296</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202296</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desogestrel/Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>16729-356</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-05</started-marketing-on>
      <ended-marketing-on>2017-06-05</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209170</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desogestrel/Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>16729-356</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-05</started-marketing-on>
      <ended-marketing-on>2017-06-05</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209170</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Diane-35</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02233542</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201663</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-733</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204848</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204296</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Pharmaceutics International, Inc. (Pii)</labeller>
      <ndc-id/>
      <ndc-product-code>61916-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203291</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl estradiol</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>16729-314</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-22</started-marketing-on>
      <ended-marketing-on>2016-11-22</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207245</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2594</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-17</started-marketing-on>
      <ended-marketing-on>2018-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204296</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2494</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204848</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1735</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204296</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7299</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202594</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>59746-763</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209423</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>59746-764</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA210017</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and ethinyl estradiol</name>
      <labeller>Camber Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>31722-934</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA211944</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and ethinyl estradiol</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-4183</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-20</started-marketing-on>
      <ended-marketing-on>2021-08-21</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205876</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Nivagen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75834-115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202015</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and ethinyl estradiol</name>
      <labeller>Nivagen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75834-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202016</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-144</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204296</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201663</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol Tablets 21</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02424452</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol Tablets 28</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02424460</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol Tablets USP (21-day Regimen)</name>
      <labeller>Glenmark Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02421437</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Drospirenone and Ethinyl Estradiol Tablets USP (28-day Regimen)</name>
      <labeller>Glenmark Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02421445</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Drospirenone, Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-894</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205947</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-4075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022532</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-4103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022574</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Elinest</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-365</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EluRyng</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-469</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ring</dosage-form>
      <strength/>
      <route>Vaginal</route>
      <fda-application-number>ANDA210830</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emoquette</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1646</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076675</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emoquette</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0474</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076675</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emoquette</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0254-2033</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202789</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emoquette</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2137</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202789</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Emoquette</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-25</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076675</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enpresse</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-855</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enpresse</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-855</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enpresse</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-855</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enpresse</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enpresse</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enpresse</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enpresse</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9047</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enpresse</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9047</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enpresse</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9047</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075809</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enskyce</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201887</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enskyce</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-07</started-marketing-on>
      <ended-marketing-on>2020-11-01</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201887</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enskyce</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-891</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201887</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Esme 21</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02388138</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-05</started-marketing-on>
      <ended-marketing-on>2018-07-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Esme 28</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02388146</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-05</started-marketing-on>
      <ended-marketing-on>2018-07-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Estarylla</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-4058</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Estarylla</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-119</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Estinyl Tab 0.05mg</name>
      <labeller>Schering Plough</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00028223</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>2000-07-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Estinyl Tab 0.5mg</name>
      <labeller>Schering Plough</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00028231</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>2000-07-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Estinyl Tablets 0.02 Mg.</name>
      <labeller>Schering Plough</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00028215</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>1998-11-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>ESTROSTEP Fe</name>
      <labeller>Warner Chilcott</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on>2018-10-24</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ESTROSTEP Fe</name>
      <labeller>Warner Chilcott</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on>2018-10-24</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ESTROSTEP Fe</name>
      <labeller>Warner Chilcott</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on>2018-10-24</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ESTROSTEP Fe</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3948</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on>2010-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ESTROSTEP Fe</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3948</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on>2010-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ESTROSTEP Fe</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3948</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on>2010-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ESTROSTEP Fe</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ESTROSTEP Fe</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ESTROSTEP Fe</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ethynodiol Diacetate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204704</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ethynodiol Diacetate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7307</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204703</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Etonogestrel/Ethinyl Estradiol</name>
      <labeller>Prasco Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-605</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Insert, extended release</dosage-form>
      <strength/>
      <route>Vaginal</route>
      <fda-application-number>NDA021187</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Evra</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248297</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Evra -(6/0.75)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246340</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-10-24</started-marketing-on>
      <ended-marketing-on>2006-02-22</ended-marketing-on>
      <dosage-form>Patch, extended release</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Falessa</name>
      <labeller>Avion Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>75854-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Falmina</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-359</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090721</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fayosim</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205943</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fayosim</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205943</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fayosim</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205943</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fayosim</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205943</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>FEMCON Fe</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6161</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021490</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>FEMCON Fe</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-01</started-marketing-on>
      <ended-marketing-on>2015-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021490</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>FEMCON Fe</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0482</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-01</started-marketing-on>
      <ended-marketing-on>2015-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021490</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>FEMCON Fe</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0023-5970</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021490</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Femhrt</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4679</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021065</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Femhrt</name>
      <labeller>Warner Chilcott (US), LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0544</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-01</started-marketing-on>
      <ended-marketing-on>2008-10-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021065</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Femhrt</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0145</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021065</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Femhrt</name>
      <labeller>Warner Chilcott</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242531</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-10-05</started-marketing-on>
      <ended-marketing-on>2016-08-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Femynor</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1551</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203865</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Freya 21</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02396491</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Freya 28</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02396610</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fyavolv</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-827</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204213</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fyavolv</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-828</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204213</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Generess</name>
      <labeller>Actavis Specialty Pharmaceuticals Co</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02435659</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet, chewable</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>GENERESS Fe</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-204</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-23</started-marketing-on>
      <ended-marketing-on>2019-10-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022573</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GENERESS Fe</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0023-6030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022573</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gianvi</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-470</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021676</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gianvi</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6162</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078515</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gianvi</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5661</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-01</started-marketing-on>
      <ended-marketing-on>2012-02-29</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078515</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gianvi</name>
      <labeller>Teva Pharmaceuticals USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5423</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021676</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gildagia</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-3590</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078376</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gildess 1.5/30</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7606</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-24</started-marketing-on>
      <ended-marketing-on>2018-03-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077075</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gildess 1/20</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7607</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-24</started-marketing-on>
      <ended-marketing-on>2018-03-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gildess 24 Fe</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7610</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090293</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gildess Fe 1.5/30</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7608</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-28</started-marketing-on>
      <ended-marketing-on>2018-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077075</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gildess Fe 1/20</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7609</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-20</started-marketing-on>
      <ended-marketing-on>2018-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hailey 1.5/30</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-504</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209297</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hailey 1.5/30</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209031</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hailey 24 Fe</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-731</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204847</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HAILEY Fe 1/20</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-419</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206597</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Iclevia</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-865</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206850</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Indayo</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02398869</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Introvale</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5584</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA079064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Introvale</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA079064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isibloom</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-4066</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202789</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isibloom</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-113</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202789</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Jaimiess</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203770</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Jaimiess</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203770</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Jasmiel</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-240</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209632</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Jevantique</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-15</started-marketing-on>
      <ended-marketing-on>2012-08-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021065</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Jevantique Lo</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-236</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-09</started-marketing-on>
      <ended-marketing-on>2019-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021065</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Jinteli</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076221</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Jinteli</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-3122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076221</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Jolessa</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6044</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021544</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Jolessa</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021544</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Juleber</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-464</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091234</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Junel 1.5/30</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6272</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076381</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Junel 21 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9025</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076380</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Junel 21 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9027</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076381</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Junel Fe 1.5/30</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5935</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Junel Fe 1.5/30</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>42254-242</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Junel Fe 1.5/30</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-890</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Junel Fe 1/20</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5326</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Junel Fe 1/20</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6832</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Junel Fe 24</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5328</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090938</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Junel Fe 28 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9026</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Junel Fe 28 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kaitlib Fe</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-903</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203448</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kaitlib Fe</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-903</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203448</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kalliga</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-887</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kariva</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kariva</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kariva</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kariva</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kelnor 1/35</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5942</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kelnor 1/35</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kelnor 1/35</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9064</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kelnor 1/50</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-8073</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072723</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kimidess</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-08</started-marketing-on>
      <ended-marketing-on>2021-01-31</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076681</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kimidess</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-08</started-marketing-on>
      <ended-marketing-on>2021-01-31</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076681</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kurvelo</name>
      <labeller>LUPIN LIMITED</labeller>
      <ndc-id/>
      <ndc-product-code>57297-844</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091408</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kurvelo</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-844</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091408</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Larin 1.5/30</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-407</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202996</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Larin 1/20</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-408</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202995</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Larin 24 Fe</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-416</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202994</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Larin Fe 1.5/30</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Larin Fe 1.5/30</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2559</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091453</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Larin Fe 1/20</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091454</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Larin Fe 1/20</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-406</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091454</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Larissia</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1531</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201108</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Layolis Fe</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-064</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022573</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leena</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-219</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-12</started-marketing-on>
      <ended-marketing-on>2018-04-27</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018977</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leena</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-219</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-12</started-marketing-on>
      <ended-marketing-on>2018-04-27</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018977</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leena</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-471</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018977</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leena</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-471</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018977</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lessina</name>
      <labeller>Barr Laboratories Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-25</started-marketing-on>
      <ended-marketing-on>2011-01-24</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lessina</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075803</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levlite</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>50419-408</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-07-13</started-marketing-on>
      <ended-marketing-on>2009-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020860</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonest</name>
      <labeller>Novast Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>34908-620</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090719</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonest</name>
      <labeller>Novast Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>34908-620</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090719</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonest</name>
      <labeller>Novast Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>34908-620</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090719</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonest</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-29</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090719</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonest</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090719</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonest</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090719</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonest</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090719</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091425</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-843</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091440</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-854</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091425</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-857</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200248</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-857</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200248</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-857</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200248</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Jai Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>57994-008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Jai Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>57994-008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-857</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200248</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-857</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200248</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-857</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200248</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2534</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200245</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7298</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-20</started-marketing-on>
      <ended-marketing-on>2019-05-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202247</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-843</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091440</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6550</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091663</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7287</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200245</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>60219-1531</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201108</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>60219-1554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201095</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-854</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-14</started-marketing-on>
      <ended-marketing-on>2021-03-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091425</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202507</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202507</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202507</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7281</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200490</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-672</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-637</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202791</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-848</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091674</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-848</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091674</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-848</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091674</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-848</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091674</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7284</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7284</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200493</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206053</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206053</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206053</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206053</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7285</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200492</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7285</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200492</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol Tablets, 0.1 Mg/0.02 mg</name>
      <labeller>LUPIN LIMITED</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02424282</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradiol Tablets, 0.1 Mg/0.02 mg</name>
      <labeller>LUPIN LIMITED</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02424290</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Levonorgestrel and Ethinyl Estradoil</name>
      <labeller>Avion Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>75854-401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-11</started-marketing-on>
      <ended-marketing-on>2014-09-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090721</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levora</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4607</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA073594</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levora</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>42254-260</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA073594</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levora</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-279</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-04-01</started-marketing-on>
      <ended-marketing-on>2018-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA073594</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levora</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1565</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA073594</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levora</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-097</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA073594</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lillow</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201095</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Linessa 21</name>
      <labeller>Aspen Pharmacare Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02272903</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Linessa 21</name>
      <labeller>Aspen Pharmacare Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02272903</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Linessa 21</name>
      <labeller>Aspen Pharmacare Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02272903</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Linessa 28</name>
      <labeller>Aspen Pharmacare Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02257238</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Linessa 28</name>
      <labeller>Aspen Pharmacare Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02257238</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Linessa 28</name>
      <labeller>Aspen Pharmacare Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02257238</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lo Loestrin Fe</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1456</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022501</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo Loestrin Fe</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0420</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022501</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo Loestrin Fe</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0420</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022501</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo Minastrin Fe</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0537</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204654</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo Minastrin Fe</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0537</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204654</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo Simpesse</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-866</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206852</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo Simpesse</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-866</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206852</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo-femenal 21 Tablets</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02215640</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-05-14</started-marketing-on>
      <ended-marketing-on>2014-04-04</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lo-ovral-28</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-03-01</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017802</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo-Zumandimine</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>59651-029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209632</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo/Ovral</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0008-0078</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-04-01</started-marketing-on>
      <ended-marketing-on>2008-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017612</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo/Ovral-28</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0679</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017802</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo/Ovral-28</name>
      <labeller>Akrimax Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>24090-801</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-03-01</started-marketing-on>
      <ended-marketing-on>2014-05-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017802</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lo/ovral-28</name>
      <labeller>Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0008-2514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-03-01</started-marketing-on>
      <ended-marketing-on>2010-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017802</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loestrin 1.5/30</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00297143</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1974-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Loestrin 1.5/30</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00353027</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>LOESTRIN 1.5/30 21 Day</name>
      <labeller>Teva Women's Health</labeller>
      <ndc-id/>
      <ndc-product-code>51285-082</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-01</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076381</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LOESTRIN 1/20 21 Day</name>
      <labeller>Teva Women's Health</labeller>
      <ndc-id/>
      <ndc-product-code>51285-079</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-01</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076380</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loestrin 21 1.5/30</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0916</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-10-01</started-marketing-on>
      <ended-marketing-on>2009-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017875</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loestrin 21 1/20</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0915</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-10-01</started-marketing-on>
      <ended-marketing-on>2009-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017876</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loestrin 21 Day</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076380</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loestrin 21 Day</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076381</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loestrin 24 Fe</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021871</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loestrin 24 Fe</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0530</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-01</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021871</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LOESTRIN Fe 1.5/30</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0917</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1973-04-30</started-marketing-on>
      <ended-marketing-on>2009-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017355</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LOESTRIN Fe 1.5/30 28 Day</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-24</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LOESTRIN Fe 1.5/30 28 Day</name>
      <labeller>Teva Women's Health</labeller>
      <ndc-id/>
      <ndc-product-code>51285-083</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-01</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LOESTRIN Fe 1.5/30 28 Day</name>
      <labeller>Teva Women's Health</labeller>
      <ndc-id/>
      <ndc-product-code>51285-084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-01</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LOESTRIN Fe 1/20</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0913</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-04-30</started-marketing-on>
      <ended-marketing-on>2009-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017354</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LOESTRIN Fe 1/20 28 Day</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-07-25</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LOESTRIN Fe 1/20 28 Day</name>
      <labeller>Teva Women's Health</labeller>
      <ndc-id/>
      <ndc-product-code>51285-080</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-01</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LOESTRIN Fe 1/20 28 Day</name>
      <labeller>Teva Women's Health</labeller>
      <ndc-id/>
      <ndc-product-code>51285-081</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-01</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loestrin Fe 28 Day</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-125</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loestrin Fe 28 Day</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loestrin Fe 28 Day</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-22</started-marketing-on>
      <ended-marketing-on>2018-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loestrin Fe 28 Day</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-29</started-marketing-on>
      <ended-marketing-on>2018-09-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LoJaimiess</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LoJaimiess</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lolo</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02417456</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lolo</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02417456</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lomedia 24 Fe</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>65162-316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078267</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loryna</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5656</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA079221</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Loryna</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA079221</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LoSeasonique</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6275</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022262</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LoSeasonique</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6275</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022262</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LoSeasonique</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022262</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>LoSeasonique</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022262</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Low-Ogestrel</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4850</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Low-Ogestrel</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-847</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-07-28</started-marketing-on>
      <ended-marketing-on>2018-03-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Low-Ogestrel</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1637</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Low-Ogestrel</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-564</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075288</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lutera</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076625</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lutera</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-949</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-11-18</started-marketing-on>
      <ended-marketing-on>2018-05-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076625</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lutera</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1632</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076625</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lutera</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076625</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lutera 21</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401185</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-18</started-marketing-on>
      <ended-marketing-on>2018-06-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lutera 28</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401207</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-18</started-marketing-on>
      <ended-marketing-on>2018-06-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lybrel</name>
      <labeller>Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0008-1117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-06-01</started-marketing-on>
      <ended-marketing-on>2013-05-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021864</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Marfem 21</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02328828</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Marfem 28</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02328836</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Marlissa</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1392</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091452</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Marlissa</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-388</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091452</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Marlissa</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6339</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091452</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Marvelon 21</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02042487</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Marvelon 28</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02042479</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Melodetta 24 Fe</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207514</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mercilon</name>
      <labeller>OASIS TRADING</labeller>
      <ndc-id/>
      <ndc-product-code>72689-0020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mibelas 24 Fe</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-911</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206287</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6213</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075647</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-951</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-02-05</started-marketing-on>
      <ended-marketing-on>2015-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075548</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-950</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-02-05</started-marketing-on>
      <ended-marketing-on>2015-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075647</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-276</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017876</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-290</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017875</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-249</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017354</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-233</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017355</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin 1.5/30</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-279</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017875</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin 1/20</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1549</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017876</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin 1/20</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017876</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin 24 Fe</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-167</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-05</started-marketing-on>
      <ended-marketing-on>2018-09-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021871</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin Fe</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4744</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075647</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin Fe</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-630</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-02-05</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075647</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Microgestin Fe</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-631</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-02-05</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075548</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MICROGESTIN Fe 1.5/30</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1567</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017355</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MICROGESTIN Fe 1.5/30</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-292</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017355</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MICROGESTIN Fe 1/20</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1616</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017354</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MICROGESTIN Fe 1/20</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017354</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mili</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3962</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205449</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mili</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-776</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205449</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Min-ovral 21</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02042320</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Min-ovral 21 Tab</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00782432</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Min-ovral 28</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02042339</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Min-ovral 28 Tab</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00782440</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minastrin 24 Fe</name>
      <labeller>Warner Chilcott</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0535</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-14</started-marketing-on>
      <ended-marketing-on>2018-10-24</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA203667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minastrin 24 Fe</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA203667</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minestrin 1/20</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00343838</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minestrin 1/20</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00315966</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minivlar 30</name>
      <labeller>OASIS TRADING</labeller>
      <ndc-id/>
      <ndc-product-code>72689-0011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircette</name>
      <labeller>Teva Women's Health</labeller>
      <ndc-id/>
      <ndc-product-code>51285-114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-24</started-marketing-on>
      <ended-marketing-on>2015-07-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircette</name>
      <labeller>Teva Women's Health</labeller>
      <ndc-id/>
      <ndc-product-code>51285-114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-24</started-marketing-on>
      <ended-marketing-on>2015-07-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircette</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mircette</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mirvala 21</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02410249</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mirvala 28</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02410257</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Modicon</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1714</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017488</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Modicon</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on>2008-05-05</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017735</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Modicon</name>
      <labeller>Ortho Pharmaceutical Division of Janssen Ortho, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>50458-171</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on>2010-12-14</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mono-Linyah</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3426</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090523</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mono-Linyah</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-360</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090523</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MonoNessa</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1563</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MonoNessa</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-166</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MonoNessa</name>
      <labeller>Actavis Pharma, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>52544-247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-01</started-marketing-on>
      <ended-marketing-on>2020-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MonoNessa</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-054</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mya</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02415380</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-cyproterone / Ethinylestradiol</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02491257</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Myvlar</name>
      <labeller>OASIS TRADING</labeller>
      <ndc-id/>
      <ndc-product-code>72689-0012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myzilra</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077502</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myzilra</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077502</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myzilra</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077502</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myzilra</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1376</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-12</started-marketing-on>
      <ended-marketing-on>2017-09-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077502</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myzilra</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-12</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077502</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myzilra</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-12</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077502</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myzilra</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-12</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077502</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-857</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA070687</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon (28 Day Regimen)</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-318</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 0.5/35</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>42254-287</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA070686</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 0.5/35</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-550</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-29</started-marketing-on>
      <ended-marketing-on>2018-05-08</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA070686</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 1/35</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-08-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA070687</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 1/35</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-552</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-29</started-marketing-on>
      <ended-marketing-on>2018-05-08</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA070687</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 1/35 (28 Day Regimen)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-3303</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072696</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 10/11</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-04-01</started-marketing-on>
      <ended-marketing-on>2018-05-08</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA071044</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 10/11</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-04-01</started-marketing-on>
      <ended-marketing-on>2018-05-08</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA071044</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 777</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-936</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-07</started-marketing-on>
      <ended-marketing-on>2016-05-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 777</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-936</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-07</started-marketing-on>
      <ended-marketing-on>2016-05-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 777</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-936</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-07</started-marketing-on>
      <ended-marketing-on>2016-05-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 777</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-165</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-07</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 777</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-165</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-07</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 777</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-165</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-07</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 777 777</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68258-5005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 777 777</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68258-5005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Necon 777 777</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68258-5005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nexesta Fe</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-926</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207535</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nikki</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-886</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201661</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nikki</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-886</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-24</started-marketing-on>
      <ended-marketing-on>2021-05-31</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201661</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nikki</name>
      <labeller>LUPIN LIMITED</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02416492</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nordette</name>
      <labeller>Teva Women's Health</labeller>
      <ndc-id/>
      <ndc-product-code>51285-091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2014-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018782</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-132</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206969</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-656</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-657</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203038</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3395</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>Nivagen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75834-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203435</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>Nivagen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75834-129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203435</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7280</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202771</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>Xiromed, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70700-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209609</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7274</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202770</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2478</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7288</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202741</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <labeller>Warner Chilcott</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0539</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204426</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-376</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA210369</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7315</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-13</started-marketing-on>
      <ended-marketing-on>2019-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206120</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>60219-1031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207514</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-30</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202742</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-058</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA203667</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone and ethinyl estradiol</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>16729-291</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-28</started-marketing-on>
      <ended-marketing-on>2017-04-28</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206864</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone and Ethinyl Estradiol and Ferrous Fumarate</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-897</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021490</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone and Ethinyl Estradiol and Ferrous Fumarate</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7308</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203371</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone and Ethinyl Estradiol and Ferrous Fumarate</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7297</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202086</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norethindrone and Ethinyl Estradiol, and Ferrous Fumarate</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>16729-308</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-29</started-marketing-on>
      <ended-marketing-on>2017-03-29</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207066</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-719</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204057</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-719</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204057</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-719</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204057</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7277</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202132</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7277</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202132</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7277</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202132</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2259</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2603</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-260</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200384</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-261</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-261</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Akorn</labeller>
      <ndc-id/>
      <ndc-product-code>17478-261</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1732</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1733</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3733</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204057</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7286</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201896</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7302</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7302</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7302</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-565</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-565</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-565</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-309</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and ethinyl estradiol</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-838</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-18</started-marketing-on>
      <ended-marketing-on>2020-10-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205588</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and ethinyl estradiol</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-838</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-18</started-marketing-on>
      <ended-marketing-on>2020-10-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205588</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and ethinyl estradiol</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-838</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-18</started-marketing-on>
      <ended-marketing-on>2020-10-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205588</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200494</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201897</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201897</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-7293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201897</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-840</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205630</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norgestrel/Ethinyl Estradiol</name>
      <labeller>Akrimax Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>24090-961</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-03-01</started-marketing-on>
      <ended-marketing-on>2014-07-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017802</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Norinyl</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-259</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1974-12-27</started-marketing-on>
      <ended-marketing-on>2019-10-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017565</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nortrel (21 Day Regimen)</name>
      <labeller>Barr Laboratories Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-02-28</started-marketing-on>
      <ended-marketing-on>2007-06-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072692</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nortrel 21 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072693</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nortrel 28 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072696</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nortrel 28 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072695</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5286</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075478</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5286</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075478</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5286</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075478</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075478</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075478</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075478</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NuvaRing</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4832</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Insert, extended release</dosage-form>
      <strength/>
      <route>Vaginal</route>
      <fda-application-number>NDA021187</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NuvaRing</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Insert, extended release</dosage-form>
      <strength/>
      <route>Vaginal</route>
      <fda-application-number>NDA021187</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nuvaring</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Insert, extended release</dosage-form>
      <strength/>
      <route>Vaginal</route>
      <fda-application-number>NDA021187</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NuvaRing</name>
      <labeller>Organon USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0273</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Insert, extended release</dosage-form>
      <strength/>
      <route>Vaginal</route>
      <fda-application-number>NDA021187</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nuvaring</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02253186</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ring</dosage-form>
      <strength/>
      <route>Vaginal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nylia 1/35</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-898</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207056</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nylia 7/7/7</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-897</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207054</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nylia 7/7/7</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-897</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207054</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nylia 7/7/7</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-897</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207054</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ocella</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5922</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021098</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ocella</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-06-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021098</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ogestrel</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-848</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-08-21</started-marketing-on>
      <ended-marketing-on>2020-11-30</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075406</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orsythia</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1380</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077099</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orsythia</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1647</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077099</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orsythia</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7634</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-11</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077099</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orsythia</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0254-2032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orsythia</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4303</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho 0.5/35 Tablets (21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00317047</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1974-12-31</started-marketing-on>
      <ended-marketing-on>2017-09-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 0.5/35 Tablets (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00340731</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1974-12-31</started-marketing-on>
      <ended-marketing-on>2017-09-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 1/35 Tablets (21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00372846</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-12-31</started-marketing-on>
      <ended-marketing-on>2017-09-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 1/35 Tablets (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00372838</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-12-31</started-marketing-on>
      <ended-marketing-on>2017-09-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 10/11 Tablets (21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00538590</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 10/11 Tablets (21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00538590</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 10/11 Tablets (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00538582</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 10/11 Tablets (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00538582</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 7/7/7 Tablets (21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00602957</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on>2017-09-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 7/7/7 Tablets (21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00602957</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on>2017-09-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 7/7/7 Tablets (21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00602957</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on>2017-09-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 7/7/7 Tablets (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00602965</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on>2017-09-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 7/7/7 Tablets (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00602965</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on>2017-09-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho 7/7/7 Tablets (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00602965</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on>2017-09-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho Cept</name>
      <labeller>Ortho-McNeil-Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1796</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-14</started-marketing-on>
      <ended-marketing-on>2012-05-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020301</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Cept</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-196</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-14</started-marketing-on>
      <ended-marketing-on>2018-09-07</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020301</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Cyclen</name>
      <labeller>Ortho-McNeil-Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1907</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-29</started-marketing-on>
      <ended-marketing-on>2012-10-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Cyclen</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2606</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-29</started-marketing-on>
      <ended-marketing-on>2010-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Cyclen</name>
      <labeller>Johnson &amp; Johnson Pharmaceutical Research</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-30</started-marketing-on>
      <ended-marketing-on>2007-03-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Cyclen</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-197</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Evra</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4670</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-13</started-marketing-on>
      <ended-marketing-on>2011-02-28</ended-marketing-on>
      <dosage-form>Patch, extended release</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number>NDA021180</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Evra</name>
      <labeller>Ortho-McNeil-Janssen Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1920</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-11-20</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Patch, extended release</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number>NDA021180</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Evra</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>50458-192</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-11-20</started-marketing-on>
      <ended-marketing-on>2018-07-12</ended-marketing-on>
      <dosage-form>Patch, extended release</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number>NDA021180</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Novum 1/35</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1761</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017489</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Novum 135</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-176</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-06-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017919</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri Cyclen</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021690</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri Cyclen</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021690</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri Cyclen</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021690</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri Cyclen</name>
      <labeller>Ortho-McNeil-Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1910</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-13</started-marketing-on>
      <ended-marketing-on>2012-08-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021690</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri Cyclen</name>
      <labeller>Ortho-McNeil-Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1910</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-13</started-marketing-on>
      <ended-marketing-on>2012-08-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021690</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri Cyclen</name>
      <labeller>Ortho-McNeil-Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1910</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-13</started-marketing-on>
      <ended-marketing-on>2012-08-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021690</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri Cyclen</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019697</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri Cyclen</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019697</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri Cyclen</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019697</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ORTHO TRI CYCLEN Lo</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4730</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ORTHO TRI CYCLEN Lo</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4730</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ORTHO TRI CYCLEN Lo</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4730</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ORTHO TRI CYCLEN Lo</name>
      <labeller>Ortho-McNeil Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-22</started-marketing-on>
      <ended-marketing-on>2012-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ORTHO TRI CYCLEN Lo</name>
      <labeller>Ortho-McNeil Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-22</started-marketing-on>
      <ended-marketing-on>2012-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ORTHO TRI CYCLEN Lo</name>
      <labeller>Ortho-McNeil Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-22</started-marketing-on>
      <ended-marketing-on>2012-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ORTHO TRI CYCLEN Lo</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ORTHO TRI CYCLEN Lo</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ORTHO TRI CYCLEN Lo</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri-Cyclen</name>
      <labeller>Johnson &amp; Johnson Pharmaceutical Research</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1903</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-30</started-marketing-on>
      <ended-marketing-on>2007-03-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri-Cyclen</name>
      <labeller>Johnson &amp; Johnson Pharmaceutical Research</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1903</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-30</started-marketing-on>
      <ended-marketing-on>2007-03-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho Tri-Cyclen</name>
      <labeller>Johnson &amp; Johnson Pharmaceutical Research</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1903</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-30</started-marketing-on>
      <ended-marketing-on>2007-03-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-cept Tablets (21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02042541</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2007-08-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho-cept Tablets (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02042533</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2015-04-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ortho-novum 10/11</name>
      <labeller>Ortho-McNeil Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1771</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-30</started-marketing-on>
      <ended-marketing-on>2007-03-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-novum 10/11</name>
      <labeller>Ortho-McNeil Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1771</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-30</started-marketing-on>
      <ended-marketing-on>2007-03-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1781</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1781</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0062-1781</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0689</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0689</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0689</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0159</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-178</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-178</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ortho-Novum 777</name>
      <labeller>Janssen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50458-178</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ovcon 35</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0509</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-01</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ovcon 35</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-01</started-marketing-on>
      <ended-marketing-on>2010-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ovcon 35</name>
      <labeller>Warner Chilcott Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0583</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-20</started-marketing-on>
      <ended-marketing-on>2006-09-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ovcon 35</name>
      <labeller>Warner Chilcott Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0582</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-20</started-marketing-on>
      <ended-marketing-on>2006-09-20</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ovcon 50</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3772</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-07-11</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017576</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ovcon 50</name>
      <labeller>Warner Chilcott</labeller>
      <ndc-id/>
      <ndc-product-code>0430-0585</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-07-11</started-marketing-on>
      <ended-marketing-on>2012-07-12</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA017576</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ovima 21</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02387085</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ovima 28</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02387093</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ovral 21</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02043033</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-09-20</started-marketing-on>
      <ended-marketing-on>2010-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ovral 21 Tab</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00034207</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1968-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ovral 28 Tablets</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02043041</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2006-08-04</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ovral 28tab</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00340766</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Philith</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-347</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090947</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pimtrea</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-404</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091247</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pimtrea</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-404</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091247</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pirmella 1/35</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-893</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201512</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pirmella 7/7/7</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pirmella 7/7/7</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pirmella 7/7/7</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pirmella 7/7/7</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-892</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pirmella 7/7/7</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-892</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pirmella 7/7/7</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-892</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201510</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Portia</name>
      <labeller>Barr Laboratories Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-25</started-marketing-on>
      <ended-marketing-on>2011-01-25</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075866</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Portia</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075866</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Portia 21</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02295946</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Portia 28</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02295954</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Preven Emergency Contraceptive</name>
      <labeller>GynÃtics Ltd/LtÃe</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239806</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Preven Tablets</name>
      <labeller>Shire Pharma Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240544</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-09-16</started-marketing-on>
      <ended-marketing-on>2001-08-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Previfem</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076334</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Previfem</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076334</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Previfem</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0254-2029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Previfem</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090794</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Previfem</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7642</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-09</started-marketing-on>
      <ended-marketing-on>2020-02-29</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076334</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Previfem (21day)</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320061</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Previfem (28day)</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320088</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Qismette 21</name>
      <labeller>LUPIN LIMITED</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02416506</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Qismette 28</name>
      <labeller>LUPIN LIMITED</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02416514</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Quartette</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quartette</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quartette</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quartette</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Quasense</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-966</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-06</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rajani</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-298</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203593</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ran-cyproterone/ethinyl Estradiol</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02425017</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Reclipsen</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-954</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-08-01</started-marketing-on>
      <ended-marketing-on>2018-05-08</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076915</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Reclipsen 21</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02420813</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-29</started-marketing-on>
      <ended-marketing-on>2018-04-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Reclipsen 28</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02417464</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-29</started-marketing-on>
      <ended-marketing-on>2018-04-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Reclipsen 28 Day</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1631</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075256</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Reclipsen 28 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-3304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075256</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivelsa</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-6031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivelsa</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-6031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivelsa</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-6031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivelsa</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-6031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204061</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Safyral</name>
      <labeller>Bayer HealthCare Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50419-403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA022574</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sarensis 21</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411466</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sarensis 28</name>
      <labeller>Patriot A Division Of Janssen Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02411474</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Seasonale</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-09</started-marketing-on>
      <ended-marketing-on>2007-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021544</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Seasonale</name>
      <labeller>Duramed Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-058</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-09</started-marketing-on>
      <ended-marketing-on>2013-07-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021544</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Seasonale</name>
      <labeller>Teva Womens Health Inc. Subsidiary Of Teva Pharmaceuticals Usa Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02296659</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Seasonique</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6276</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021840</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Seasonique</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6276</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021840</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Seasonique</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021840</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Seasonique</name>
      <labeller>Teva Women's Health, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51285-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021840</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Seasonique</name>
      <labeller>Teva Womens Health Inc. Subsidiary Of Teva Pharmaceuticals Usa Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02346176</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Seasonique</name>
      <labeller>Teva Womens Health Inc. Subsidiary Of Teva Pharmaceuticals Usa Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02346176</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Select 1/35 (21-day)</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02197502</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Select 1/35 (28-day)</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02199297</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Setlakin</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-366</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090716</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Simliya</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-886</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206853</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Simliya</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-886</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206853</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Simpesse</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-864</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206851</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Simpesse</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-864</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA206851</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solia</name>
      <labeller>Prasco, Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-611</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-01</started-marketing-on>
      <ended-marketing-on>2012-04-28</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020071</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sprintec</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-769</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075804</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sprintec</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-911</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075804</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sprintec</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075804</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sprintec</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7429</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075804</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sronyx</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-967</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077681</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sronyx</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1539</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077681</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sronyx</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-545</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA077681</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Syeda</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5658</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090114</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Syeda</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090114</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Synphasic 21 Tablets</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02187108</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Synphasic 21 Tablets</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02187108</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Synphasic 21 Tablets</name>
      <labeller>Syntex Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00620947</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Synphasic 21 Tablets</name>
      <labeller>Syntex Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00620947</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Synphasic 28 Tablets</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02187116</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Synphasic 28 Tablets</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02187116</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Synphasic-28 Tablets</name>
      <labeller>Syntex Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00695734</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Synphasic-28 Tablets</name>
      <labeller>Syntex Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00695734</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tarina 24 Fe</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-224</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207504</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TARINA Fe 1/20</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TARINA Fe 1/20</name>
      <labeller>Afaxys Pharma, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>50102-128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tarina Fe 1/20 EQ</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-228</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA207505</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Taytulla</name>
      <labeller>Allergan, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0023-5862</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA204426</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Teva-cyproterone / Ethinyl Estradiol</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309556</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-175</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on>2018-08-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-175</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on>2018-08-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-175</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-01</started-marketing-on>
      <ended-marketing-on>2018-08-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-685</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-685</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-685</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6274</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6274</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6274</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-054</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on>2018-07-10</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-054</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on>2018-07-10</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-054</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on>2018-07-10</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-143</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on>2016-07-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-143</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on>2016-07-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-143</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-01</started-marketing-on>
      <ended-marketing-on>2016-07-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076629</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-284</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-284</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tilia Fe</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-284</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA020130</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri Femynor</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203870</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri Femynor</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3413</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203870</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri Femynor</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1607</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203870</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri Femynor</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1607</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203870</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri Femynor</name>
      <labeller>Amneal Pharmaceuticals NY LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69238-1607</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA203870</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-cyclen Lo (-21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258560</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-cyclen Lo (-21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258560</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-cyclen Lo (-21 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258560</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-cyclen Lo (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258587</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-cyclen Lo (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258587</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-cyclen Lo (28 Day)</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258587</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-cyclen Tablets - 21-day</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02028700</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-cyclen Tablets - 21-day</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02028700</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-cyclen Tablets - 21-day</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02028700</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-cyclen Tablets - 28-day</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02029421</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-cyclen Tablets - 28-day</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02029421</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-cyclen Tablets - 28-day</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02029421</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-Estarylla</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-4060</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090793</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Estarylla</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-4060</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090793</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Estarylla</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-4060</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090793</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Estarylla</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090793</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Estarylla</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090793</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Estarylla</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090793</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-jordyna 21</name>
      <labeller>Glenmark Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02486296</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-jordyna 21</name>
      <labeller>Glenmark Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02486296</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-jordyna 21</name>
      <labeller>Glenmark Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02486296</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-jordyna 28</name>
      <labeller>Glenmark Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02486318</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-jordyna 28</name>
      <labeller>Glenmark Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02486318</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-jordyna 28</name>
      <labeller>Glenmark Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02486318</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-Legest Fe 28 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Legest Fe 28 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Legest Fe 28 Day</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-lena 21</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443597</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-lena 21</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443597</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-lena 21</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443597</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-lena 28</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443600</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-lena 28</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443600</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-lena 28</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443600</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-lena Lo 21</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443457</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-lena Lo 21</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443457</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-lena Lo 21</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443457</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-lena Lo 28</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443465</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-lena Lo 28</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443465</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-lena Lo 28</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02443465</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-Linyah</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-363</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090524</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Linyah</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-363</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090524</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Linyah</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-363</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090524</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo- Estarylla</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-4062</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo- Estarylla</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-4062</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo- Estarylla</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-4062</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo- Estarylla</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo- Estarylla</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo- Estarylla</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-LO-marzia</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200541</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-LO-marzia</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200541</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-LO-marzia</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200541</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-LO-marzia</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200541</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-LO-marzia</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200541</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-LO-marzia</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200541</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-LO-marzia</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2429</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200541</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-LO-marzia</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-754</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200541</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-LO-marzia</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-754</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200541</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-LO-marzia</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-754</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA200541</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Mili</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-778</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205762</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Mili</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-778</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205762</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Mili</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-778</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205762</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Barr Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-30</started-marketing-on>
      <ended-marketing-on>2010-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Barr Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-30</started-marketing-on>
      <ended-marketing-on>2010-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Barr Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-30</started-marketing-on>
      <ended-marketing-on>2010-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-2140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-2140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-2140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2326</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-287</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-287</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Lo-Sprintec</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-287</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076784</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Mili</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3793</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205441</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Mili</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-777</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205441</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Mili</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-777</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205441</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Mili</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-777</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205441</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Norinyl</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-274</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-13</started-marketing-on>
      <ended-marketing-on>2018-07-10</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018977</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Norinyl</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-274</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-04-13</started-marketing-on>
      <ended-marketing-on>2018-07-10</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018977</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Norinyl</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-470</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on>2019-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018977</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Norinyl</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-470</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on>2019-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018977</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Previfem</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076335</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Previfem</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0254-2030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090793</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Previfem</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0254-2030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090793</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Previfem</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0254-2030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090793</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Previfem</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7663</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-26</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076335</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Previfem</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7663</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-26</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076335</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Previfem</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0603-7663</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-26</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076335</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-previfem (21 Day)</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320096</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-previfem (21 Day)</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320096</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-previfem (21 Day)</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320096</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-previfem (28 Day)</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320118</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-previfem (28 Day)</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320118</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-previfem (28 Day)</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02320118</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-770</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-770</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-770</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-436</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-436</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-436</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-128</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-458</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-458</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-458</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0842</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0842</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0842</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9018</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9018</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9018</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6325</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6325</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-Sprintec</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6325</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA075808</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-VyLibra</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-233</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205441</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-VyLibra</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-233</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205441</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-VyLibra</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-233</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205441</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-VyLibra Lo</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205762</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-VyLibra Lo</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205762</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tri-VyLibra Lo</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-231</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205762</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricira Lo</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401975</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tricira Lo</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401975</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tricira Lo</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401975</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tricira Lo</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401967</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tricira Lo</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401967</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tricira Lo</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401967</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-407</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019697</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-407</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019697</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-407</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019697</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5826</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019697</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5826</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019697</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5826</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019697</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1564</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Actavis Pharma, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>52544-248</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-11</started-marketing-on>
      <ended-marketing-on>2020-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Actavis Pharma, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>52544-248</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-11</started-marketing-on>
      <ended-marketing-on>2020-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Actavis Pharma, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>52544-248</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-02-11</started-marketing-on>
      <ended-marketing-on>2020-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Preferred Pharmaceuticals Inc,</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Preferred Pharmaceuticals Inc,</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa</name>
      <labeller>Preferred Pharmaceuticals Inc,</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019653</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa Lo</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-943</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-09</started-marketing-on>
      <ended-marketing-on>2011-03-10</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090479</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa Lo</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-943</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-09</started-marketing-on>
      <ended-marketing-on>2011-03-10</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090479</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa Lo</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-943</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-09</started-marketing-on>
      <ended-marketing-on>2011-03-10</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090479</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa Lo</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1454</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa Lo</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-31</started-marketing-on>
      <ended-marketing-on>2020-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa Lo</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-31</started-marketing-on>
      <ended-marketing-on>2020-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriNessa Lo</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-31</started-marketing-on>
      <ended-marketing-on>2020-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021241</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triphasil 21</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02043726</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2007-10-23</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil 21</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02043726</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2007-10-23</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil 21</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02043726</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2007-10-23</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil 21 Tab</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00782416</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil 21 Tab</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00782416</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil 21 Tab</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00782416</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil 28</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02043734</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2007-10-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil 28</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02043734</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2007-10-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil 28</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02043734</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2007-10-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil 28 Tab</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00782424</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil 28 Tab</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00782424</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil 28 Tab</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00782424</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triphasil-21</name>
      <labeller>Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0008-2535</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-01</started-marketing-on>
      <ended-marketing-on>2008-02-29</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019192</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triphasil-21</name>
      <labeller>Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0008-2535</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-01</started-marketing-on>
      <ended-marketing-on>2008-02-29</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019192</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triphasil-21</name>
      <labeller>Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0008-2535</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-01</started-marketing-on>
      <ended-marketing-on>2008-02-29</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019192</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triquilar 21</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00707600</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triquilar 21</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00707600</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triquilar 21</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00707600</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triquilar 28</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00707503</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triquilar 28</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00707503</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triquilar 28</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00707503</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Trivora</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-291</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-12-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trivora</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-291</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-12-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trivora</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-291</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-12-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trivora</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trivora</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trivora</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4239</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trivora</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1566</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trivora</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trivora</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trivora</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA074538</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tydemy</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68180-904</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205948</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Velivet Triphasic Regimen</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Velivet Triphasic Regimen</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Velivet Triphasic Regimen</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Velivet Triphasic Regimen</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9051</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Velivet Triphasic Regimen</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9051</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Velivet Triphasic Regimen</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0555-9051</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vestura</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-982</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078833</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vienva TM</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5575</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vienva TM</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1325</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vienva TM</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201088</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Viorele</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-318</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091346</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Viorele</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-318</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091346</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Viorele</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1395</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091346</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Volnea</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Volnea</name>
      <labeller>Xiromed, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>70700-122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vyfemla</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57297-875</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201886</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vyfemla</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-875</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA201886</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>VyLibra</name>
      <labeller>Afaxys Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>50102-235</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA205449</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Wera</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-370</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091204</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Wera</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091204</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Wymzya Fe</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-898</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021490</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Wymzya Fe</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-899</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021490</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>WYMZYA Fe</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68180-873</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA091332</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xulane</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number>ANDA200910</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xulane</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number>ANDA200910</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Yasmin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4590</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021098</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Yasmin</name>
      <labeller>Central Texas Community Health Centers</labeller>
      <ndc-id/>
      <ndc-product-code>76413-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021098</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Yasmin</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0764</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-05-11</started-marketing-on>
      <ended-marketing-on>2017-05-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021098</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Yasmin</name>
      <labeller>Bayer HealthCare Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50419-402</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021098</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Yasmin 21</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02261723</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Yasmin 28</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02261731</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Yasmin Plus</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02442744</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Yaz</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5535</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-16</started-marketing-on>
      <ended-marketing-on>2006-06-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021676</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Yaz</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5828</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021676</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Yaz</name>
      <labeller>Bayer HealthCare Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50419-405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021676</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Yaz</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02321157</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Yaz Plus</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02387433</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zamine 21</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02410788</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zamine 28</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02410796</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zarah</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1627</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zarah</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-981</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-07</started-marketing-on>
      <ended-marketing-on>2019-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zarah</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090081</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zarah 21</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02385058</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-04</started-marketing-on>
      <ended-marketing-on>2018-11-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zarah 28</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02385066</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-04</started-marketing-on>
      <ended-marketing-on>2018-11-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zenchent</name>
      <labeller>Watson Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-953</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078323</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zenchent</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6273</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078323</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zenchent</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-01</started-marketing-on>
      <ended-marketing-on>2011-08-23</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zenchent 0.4/35</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-3305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-01</started-marketing-on>
      <ended-marketing-on>2019-01-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076238</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zenchent FE</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>65162-347</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zenchent FE</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-292</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-26</started-marketing-on>
      <ended-marketing-on>2014-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zeosa</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-2090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-25</started-marketing-on>
      <ended-marketing-on>2013-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078965</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zovia 1/35</name>
      <labeller>Rpk Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53002-1591</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zovia 1/35</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-260</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA076785</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zovia 1/35E-28</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4240</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-06-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072721</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zovia 1/35E-28</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>52544-383</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-06</started-marketing-on>
      <ended-marketing-on>2017-05-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072721</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zovia 1/50E-28</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4778</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072723</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zovia 1/50E-28</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52544-384</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-06</started-marketing-on>
      <ended-marketing-on>2019-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA072723</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zumandimine</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>59651-030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA209407</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Estinyl</name>
      <company>Schering</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Cesia</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cesia</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cesia</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Femhrt</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Zenchent</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lo/Ovral</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>ESTROSTEP Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>ESTROSTEP Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>ESTROSTEP Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Trivora</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Trivora</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Trivora</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Sprintec</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Jinteli</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Yaz</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Amethia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Amethia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Aviane</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Apri</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cryselle</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Aviane 28 Day</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonest</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonest</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonest</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Zenchent</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Seasonique</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Seasonique</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>ORTHO TRI CYCLEN Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>ORTHO TRI CYCLEN Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>ORTHO TRI CYCLEN Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Necon 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Enpresse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Enpresse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Enpresse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Evra</name>
      <ingredients>Ethinylestradiol + Norelgestromin</ingredients>
    </mixture>
    <mixture>
      <name>Ocella</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Kariva</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Kariva</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Kelnor 1/35</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone and Ethinyl Estradiol and Ferrous Fumarate</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 777 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 777 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 777 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Gianvi</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Enpresse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Enpresse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Enpresse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>FEMCON Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Gianvi</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Jolessa</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Gianvi</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Desogen</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>NuvaRing</name>
      <ingredients>Ethinylestradiol + Etonogestrel</ingredients>
    </mixture>
    <mixture>
      <name>Seasonale</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Wymzya Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Evra</name>
      <ingredients>Ethinylestradiol + Norelgestromin</ingredients>
    </mixture>
    <mixture>
      <name>Sronyx</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Cyclessa</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cyclessa</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cyclessa</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Lo-ovral-28</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Velivet Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Velivet Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Velivet Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin Fe</name>
      <ingredients>Ethinylestradiol + Ferrous fumarate + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lutera</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Low-Ogestrel</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Yasmin</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Yaz</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Levora</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Novum 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Modicon</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Zovia 1/35E-28</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Zovia 1/50E-28</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Junel 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Junel Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Junel Fe 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ovcon 50</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ovcon 35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Cyclen</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Trivora</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Trivora</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Trivora</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>LoSeasonique</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>LoSeasonique</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Cept</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>LOESTRIN Fe 1/20 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>LOESTRIN Fe 1.5/30 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nordette</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Seasonale</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ovcon 50</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Minastrin 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Junel Fe 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Levora</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Cyclen</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Necon 0.5/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Modicon</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>ESTROSTEP Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>ESTROSTEP Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>ESTROSTEP Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Jevantique</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>ORTHO TRI CYCLEN Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>ORTHO TRI CYCLEN Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>ORTHO TRI CYCLEN Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Lo/Ovral-28</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin Fe</name>
      <ingredients>Ethinylestradiol + Ferrous fumarate + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin Fe</name>
      <ingredients>Ethinylestradiol + Ferrous fumarate + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Zenchent FE</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Leena</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Leena</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Wymzya Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lo/Ovral-28</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradoil</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Desogestrel and Ethinyl Estradiol</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Falessa</name>
      <ingredients>Ethinylestradiol + Folic acid + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Solia</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>LOESTRIN 1/20 21 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>LOESTRIN Fe 1/20 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>LOESTRIN 1.5/30 21 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>LOESTRIN Fe 1.5/30 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>LOESTRIN Fe 1/20 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>LOESTRIN Fe 1.5/30 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norgestrel/Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levlite</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin</name>
      <ingredients>Ethinylestradiol + Ferrous fumarate + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin</name>
      <ingredients>Ethinylestradiol + Ferrous fumarate + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Mircette</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Mircette</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Delyla</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lomedia 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Norinyl</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Norinyl</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Cyclafem 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Zeosa</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Myzilra</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Myzilra</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Myzilra</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Previfem</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Yasmin</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>NuvaRing</name>
      <ingredients>Ethinylestradiol + Etonogestrel</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Kaitlib Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Vyfemla</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Nikki</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Tri-LO-marzia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-LO-marzia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-LO-marzia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Enskyce</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Bekyree</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Bekyree</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Reclipsen</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cyclafem 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Cyclafem 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Cyclafem 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lybrel</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>FEMCON Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Kaitlib Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>FEMCON Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Low-Ogestrel</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Alyacen 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Alyacen 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Alyacen 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Alyacen 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Pirmella 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Pirmella 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Pirmella 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ovcon 35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Desogestrel and Ethinyl Estradiol</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Altavera</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Vienva TM</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Zenchent</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Briellyn</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Viorele</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Viorele</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Caziant</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Caziant</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Caziant</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Rajani</name>
      <ingredients>Drospirenone + Ethinylestradiol + Levomefolic acid + Levomefolic acid</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>HAILEY Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Brevicon</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norinyl</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Estarylla</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo- Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo- Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo- Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Syeda</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Necon 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 0.5/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 10/11</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 10/11</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Cyclessa</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cyclessa</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cyclessa</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Gildess 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Gildess Fe 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Gildess Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Gildess 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Gildess 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Zenchent FE</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Yasmin</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Necon 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>WYMZYA Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Gildagia</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Zovia 1/35E-28</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Isibloom</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Myzilra</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Marlissa</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Orsythia</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Viorele</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Alyacen 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin 21 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>LOESTRIN Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin 21 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>LOESTRIN Fe 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Vyfemla</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Hailey 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-LO-marzia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-LO-marzia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-LO-marzia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Caziant</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Caziant</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Caziant</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone and ethinyl estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone and Ethinyl Estradiol, and Ferrous Fumarate</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Desogestrel/Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Desogestrel/Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Kelnor 1/35</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Alesse 28</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Vestura</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Mibelas 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lo/ovral-28</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Amethia Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Amethia Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone and Ethinyl Estradiol and Ferrous Fumarate</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Cyclessa</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cyclessa</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cyclessa</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cryselle</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ashlyna</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levora</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Azurette</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Azurette</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Introvale</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Loryna</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Larin Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Levonest</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil-21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil-21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil-21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Evra</name>
      <ingredients>Ethinylestradiol + Norelgestromin</ingredients>
    </mixture>
    <mixture>
      <name>Lutera</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Alyacen 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Cryselle</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-LO-marzia</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Hailey 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>ESTROSTEP Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>ESTROSTEP Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>ESTROSTEP Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Desogen</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Cyclafem 7/7/7</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Cept</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Tri Femynor</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri-Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri-Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri-Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Cyclen</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ovcon 35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ovcon 35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-novum 10/11</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-novum 10/11</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nortrel (21 Day Regimen)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Modicon</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Femhrt</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lessina</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Portia</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levora</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Alyacen 7/7/7</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Cyred</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Previfem</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>MICROGESTIN Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Emoquette</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Previfem</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Low-Ogestrel</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Trivora</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>TARINA Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cyclafem 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa Lo</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>MICROGESTIN Fe 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Chateal</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Zovia 1/35</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Azurette</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>MonoNessa</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Orsythia</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Lutera</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Zarah</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Caziant Triphasic Regimen</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Aubra</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Reclipsen 28 Day</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Tri Femynor</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Mono-Linyah</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Sronyx</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Jevantique Lo</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Desogestrel and Ethinyl Estradiol</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Reclipsen 28 Day</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Hailey 1.5/30</name>
      <ingredients>Ethinylestradiol + Ferrous fumarate + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 1/35 (28 Day Regimen)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Zenchent 0.4/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Rivelsa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Rivelsa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Rivelsa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Rivelsa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Mili</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Minivlar 30</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Myvlar</name>
      <ingredients>Ethinylestradiol + Gestodene</ingredients>
    </mixture>
    <mixture>
      <name>Wera</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Mono-Linyah</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Levonest</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonest</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonest</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ethynodiol Diacetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Setlakin</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Juleber</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Pimtrea</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Pimtrea</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Dasetta 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Larin Fe 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Falmina</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Low-Ogestrel</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Leena</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Leena</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Dasetta 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Dasetta 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Dasetta 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Larin 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Elinest</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Larin 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Larin 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone and Ethinyl Estradiol and Ferrous Fumarate</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ethynodiol Diacetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Sronyx</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Philith</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Norinyl</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Norinyl</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Linyah</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Linyah</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Linyah</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Xulane</name>
      <ingredients>Ethinylestradiol + Norelgestromin</ingredients>
    </mixture>
    <mixture>
      <name>Trivora</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Trivora</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Trivora</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Wera</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Apri 28 Day</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Mercilon</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Zarah</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Zovia 1/50E-28</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Previfem</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Lo Minastrin Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lo Minastrin Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Femhrt</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>MonoNessa</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>FEMCON Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nuvaring</name>
      <ingredients>Ethinylestradiol + Etonogestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Previfem</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Previfem</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Previfem</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Mili</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Kurvelo</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Caziant Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Caziant Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Caziant Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Beyaz</name>
      <ingredients>Drospirenone + Ethinylestradiol + Levomefolic acid + Levomefolic acid</ingredients>
    </mixture>
    <mixture>
      <name>Yasmin</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Alyacen 7/7/7</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lo Loestrin Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>MonoNessa</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Larin Fe 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Xulane</name>
      <ingredients>Ethinylestradiol + Norelgestromin</ingredients>
    </mixture>
    <mixture>
      <name>Emoquette</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Azurette</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Azurette</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Emoquette</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>TriNessa</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Previfem</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>ORTHO TRI CYCLEN Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>ORTHO TRI CYCLEN Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>ORTHO TRI CYCLEN Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Larin Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Jinteli</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Myzilra</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Myzilra</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Myzilra</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Desogestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Desogestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Femynor</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Blisovi Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Tri Cyclen</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Cyclen</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Melodetta 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Larissia</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri Femynor</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri Femynor</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri Femynor</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Lillow</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>NuvaRing</name>
      <ingredients>Ethinylestradiol + Etonogestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-Novum 777</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho Novum 135</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin 21 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin Fe 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin 21 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin Fe 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin Fe 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin Fe 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Marlissa</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Kurvelo</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>TARINA Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Aubra</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Cyred</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Chateal</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Emoquette</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and ethinyl estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Safyral</name>
      <ingredients>Drospirenone + Ethinylestradiol + Levomefolic acid + Levomefolic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ocella</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Gianvi</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Amethia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Amethia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and ethinyl estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and ethinyl estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and ethinyl estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and ethinyl estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Annovera</name>
      <ingredients>Ethinylestradiol + Segesterone acetate</ingredients>
    </mixture>
    <mixture>
      <name>Orsythia</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Previfem</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Previfem</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Previfem</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Previfem</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Emoquette</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Amethyst</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Quasense</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Kelnor 1/50</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Annovera</name>
      <ingredients>Ethinylestradiol + Segesterone acetate</ingredients>
    </mixture>
    <mixture>
      <name>Aurovela 24 Fe</name>
      <ingredients>Ethinylestradiol + Ferrous fumarate + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Afirmelle</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Vienva TM</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Balziva</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Aranelle</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Aranelle</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and ethinyl estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Minastrin 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>GENERESS Fe</name>
      <ingredients>Ethinylestradiol + Ferrous fumarate + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>GENERESS Fe</name>
      <ingredients>Ethinylestradiol + Ferrous fumarate + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Necon (28 Day Regimen)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Layolis Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Iclevia</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Lo Loestrin Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lo Loestrin Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Orsythia</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Nylia 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nylia 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nylia 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Kalliga</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cyonanz</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Mili</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Mili</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Mili</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Mili</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Mili</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Mili</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Mili</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Aurovela Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ayuna</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Lo-Zumandimine</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Aurovela 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lo Simpesse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Lo Simpesse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Aurovela 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Simliya</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Simliya</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Zumandimine</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Simpesse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Simpesse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Vienva TM</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Isibloom</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Loryna</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Syeda</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Volnea</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Volnea</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>LoJaimiess</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>LoJaimiess</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Jaimiess</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Jaimiess</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Estarylla</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Altavera</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Introvale</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo- Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo- Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo- Estarylla</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Levora</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Orsythia</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Lo-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Junel Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Nexesta Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium</name>
      <ingredients>Drospirenone + Ethinylestradiol + Levomefolic acid + Levomefolic acid</ingredients>
    </mixture>
    <mixture>
      <name>Yaz</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Nylia 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Taytulla</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Aubra EQ</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Chateal EQ</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-VyLibra Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-VyLibra Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-VyLibra Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tarina Fe 1/20 EQ</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Marlissa</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Cyred EQ</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Tarina 24 Fe</name>
      <ingredients>Ethinylestradiol + Ferrous fumarate + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Jasmiel</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Tri-VyLibra</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-VyLibra</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-VyLibra</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>VyLibra</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Cryselle</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Aviane</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Cyclafem 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Cyclafem 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Cyclafem 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Cyclafem 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Enpresse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Enpresse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Enpresse</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Pirmella 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Pirmella 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Pirmella 7/7/7</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Pirmella 1/35</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium</name>
      <ingredients>Drospirenone + Ethinylestradiol + Levomefolic acid + Levomefolic acid</ingredients>
    </mixture>
    <mixture>
      <name>Kariva</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Kariva</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Junel 21 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Junel Fe 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Junel 21 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Junel Fe 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Kelnor 1/35</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Junel Fe 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Aviane</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Sprintec</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Blisovi Fe 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Sprintec</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nortrel 7/7/7 (28 Day Regimen)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Legest Fe 28 Day</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Legest Fe 28 Day</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Legest Fe 28 Day</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Kimidess</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Kimidess</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Velivet Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Velivet Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Velivet Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Lessina</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Blisovi 24 Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>MICROGESTIN Fe 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Microgestin 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>MICROGESTIN Fe 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lutera</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-Sprintec</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Portia</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Sprintec</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-LO-marzia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-LO-marzia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-LO-marzia</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>MonoNessa</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tilia Fe</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nortrel 21 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nortrel 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nortrel 28 Day</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Tydemy</name>
      <ingredients>Drospirenone + Ethinylestradiol + Levomefolic acid + Levomefolic acid</ingredients>
    </mixture>
    <mixture>
      <name>Daysee</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Daysee</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Fyavolv</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Fyavolv</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Nikki</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ashlyna</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ashlyna</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>AUROVELA Fe</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Caziant Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Caziant Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Caziant Triphasic Regimen</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Zovia 1/35</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Mircette</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Mircette</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Amethia Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Amethia Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Balcoltra</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Norgestimate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>EluRyng</name>
      <ingredients>Ethinylestradiol + Etonogestrel</ingredients>
    </mixture>
    <mixture>
      <name>Fayosim</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Fayosim</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Fayosim</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Fayosim</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ogestrel</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone, Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium</name>
      <ingredients>Drospirenone + Ethinylestradiol + Levomefolic acid + Levomefolic acid</ingredients>
    </mixture>
    <mixture>
      <name>Apri 28 Day</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Norethindrone Acetate and Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Quartette</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Quartette</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Quartette</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Quartette</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Camrese</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Camrese</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>camrese Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>camrese Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>LoSeasonique</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>LoSeasonique</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Seasonique</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Seasonique</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Jolessa</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Etonogestrel/Ethinyl Estradiol</name>
      <ingredients>Ethinylestradiol + Etonogestrel</ingredients>
    </mixture>
    <mixture>
      <name>Bekyree</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Bekyree</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Bekyree</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Bekyree</name>
      <ingredients>Desogestrel + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Enskyce</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Enskyce</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Junel Fe 24</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Zarah</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cyclen Tablets (28 Day)</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Cyclen Tablets (21 Day)</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Tablets - 21-day</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Tablets - 21-day</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Tablets - 21-day</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Tablets - 28-day</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Tablets - 28-day</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Tablets - 28-day</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Marvelon 21</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Marvelon 28</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Min-ovral 21</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Min-ovral 28</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Brevicon 0.5/35 Tablets (21-day Pack)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Minestrin 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Minestrin 1/20</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Loestrin 1.5/30</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Demulen 30 (28 Day Pack)</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Demulen 30 (21 Day Pack)</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Brevicon 0.5/35 Tablets (28-day Pack)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Synphasic 21 Tablets</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Synphasic 21 Tablets</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Synphasic 28 Tablets</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Synphasic 28 Tablets</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Brevicon 1/35 Tablets (21-day Pack)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Brevicon 1/35 Tablets (28-day Pack)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Select 1/35 (21-day)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Select 1/35 (28-day)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Diane-35</name>
      <ingredients>Cyproterone acetate + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Alesse 21</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Alesse 28</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Nuvaring</name>
      <ingredients>Ethinylestradiol + Etonogestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Lo (-21 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Lo (-21 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Lo (-21 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Lo (28 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Lo (28 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-cyclen Lo (28 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Yasmin 21</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Yasmin 28</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Portia 21</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Portia 28</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Aviane 21</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Aviane 28</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Apri 21</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Apri 28</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Yaz</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Triquilar 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triquilar 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triquilar 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triquilar 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triquilar 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triquilar 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Zarah 21</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Zarah 28</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Ovima 21</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ovima 28</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Yaz Plus</name>
      <ingredients>Drospirenone + Ethinylestradiol + Levomefolic acid + Levomefolic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alysena 28</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tricira Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tricira Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tricira Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Mirvala 21</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Mirvala 28</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Zamine 21</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Zamine 28</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Mya</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Ran-cyproterone/ethinyl Estradiol</name>
      <ingredients>Cyproterone acetate + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Demulen 50 (21 Day Pack)</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-cept Tablets (28 Day)</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Ortho-cept Tablets (21 Day)</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Ovral 21 Tab</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ovral 28 Tablets</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Demulen 50 (28 Day Pack)</name>
      <ingredients>Ethinylestradiol + Ethynodiol diacetate</ingredients>
    </mixture>
    <mixture>
      <name>Ovral 28tab</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Brevicon 0.5/35 21 Tab</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Brevicon 0.5/35 28 Tab</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ovral 21</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Estinyl Tablets 0.02 Mg.</name>
      <ingredients>Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Estinyl Tab 0.5mg</name>
      <ingredients>Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Estinyl Tab 0.05mg</name>
      <ingredients>Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Lo-femenal 21 Tablets</name>
      <ingredients>Ethinylestradiol + Norgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 10/11 Tablets (21 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 10/11 Tablets (21 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 10/11 Tablets (28 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 10/11 Tablets (28 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Brevicon 1/35 28 Tab</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Brevicon 1/35 21 Tab</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Preven Tablets</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Synphasic 21 Tablets</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Synphasic 21 Tablets</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Synphasic-28 Tablets</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Synphasic-28 Tablets</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Evra -(6/0.75)</name>
      <ingredients>Ethinylestradiol + Norelgestromin</ingredients>
    </mixture>
    <mixture>
      <name>Min-ovral 28 Tab</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Min-ovral 21 Tab</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 28 Tab</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 28 Tab</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 28 Tab</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 21 Tab</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 21 Tab</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Triphasil 21 Tab</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Levonorgestrel + Levonorgestrel + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Previfem (21day)</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Previfem (28day)</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-previfem (21 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-previfem (21 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-previfem (21 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-previfem (28 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-previfem (28 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-previfem (28 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Nikki</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Qismette 21</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Qismette 28</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol Tablets, 0.1 Mg/0.02 mg</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Levonorgestrel and Ethinyl Estradiol Tablets, 0.1 Mg/0.02 mg</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Generess</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Marfem 21</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Marfem 28</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Yasmin Plus</name>
      <ingredients>Drospirenone + Ethinylestradiol + Levomefolic acid + Levomefolic acid</ingredients>
    </mixture>
    <mixture>
      <name>Reclipsen 21</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Cyestra-35</name>
      <ingredients>Cyproterone acetate + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Femhrt</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol Tablets USP (21-day Regimen)</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol Tablets USP (28-day Regimen)</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Indayo</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tricira Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tricira Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tricira Lo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Seasonale</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Seasonique</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Seasonique</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Freya 21</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Freya 28</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>ClÃ©o -35</name>
      <ingredients>Cyproterone acetate + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa Lo 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa Lo 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa Lo 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa Lo 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa Lo 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Centrisa Lo 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Sarensis 21</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Sarensis 28</name>
      <ingredients>Ethinylestradiol + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Lutera 21</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Lutera 28</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Reclipsen 28</name>
      <ingredients>Desogestrel + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Esme 21</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Esme 28</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Preven Emergency Contraceptive</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena Lo 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena Lo 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena Lo 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena Lo 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena Lo 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena Lo 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-lena 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Evra</name>
      <ingredients>Ethinylestradiol + Norelgestromin</ingredients>
    </mixture>
    <mixture>
      <name>Alysena 21</name>
      <ingredients>Ethinylestradiol + Levonorgestrel</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 1/35 Tablets (21 Day)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 0.5/35 Tablets (21 Day)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 1/35 Tablets (28 Day)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 0.5/35 Tablets (28 Day)</name>
      <ingredients>Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 7/7/7 Tablets (21 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 7/7/7 Tablets (21 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 7/7/7 Tablets (21 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 7/7/7 Tablets (28 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 7/7/7 Tablets (28 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Ortho 7/7/7 Tablets (28 Day)</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norethisterone + Norethisterone + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lolo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lolo</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol Tablets 21</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Drospirenone and Ethinyl Estradiol Tablets 28</name>
      <ingredients>Drospirenone + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Linessa 28</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Linessa 28</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Linessa 28</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Linessa 21</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Linessa 21</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Linessa 21</name>
      <ingredients>Desogestrel + Desogestrel + Desogestrel + Ethinylestradiol + Ethinylestradiol + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Teva-cyproterone / Ethinyl Estradiol</name>
      <ingredients>Cyproterone acetate + Ethinylestradiol</ingredients>
    </mixture>
    <mixture>
      <name>Tri-jordyna 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-jordyna 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-jordyna 21</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-jordyna 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-jordyna 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Tri-jordyna 28</name>
      <ingredients>Ethinylestradiol + Ethinylestradiol + Ethinylestradiol + Norgestimate + Norgestimate + Norgestimate</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-cyproterone / Ethinylestradiol</name>
      <ingredients>Cyproterone acetate + Ethinylestradiol</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amerisource Health Services Corp.</name>
      <url>http://www.amerisourcebergen.com</url>
    </packager>
    <packager>
      <name>Barr Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Bayer Healthcare</name>
      <url>http://www.bayerhealthcare.com</url>
    </packager>
    <packager>
      <name>Dept Health Central Pharmacy</name>
      <url/>
    </packager>
    <packager>
      <name>Duramed</name>
      <url>http://www.duramed.ca</url>
    </packager>
    <packager>
      <name>Mckesson Corp.</name>
      <url>http://www.mckesson.com</url>
    </packager>
    <packager>
      <name>NV Organon</name>
      <url/>
    </packager>
    <packager>
      <name>Organon Pharmaceuticals</name>
      <url>http://www.organonshop.com</url>
    </packager>
    <packager>
      <name>Ortho Mcneil Janssen Pharmaceutical Inc.</name>
      <url>http://www.ortho-mcneil.com</url>
    </packager>
    <packager>
      <name>Ortho-McNeil-Janssen Pharmaceuticals Inc.</name>
      <url>http://www.ortho-mcneil.com</url>
    </packager>
    <packager>
      <name>Pharmaceutical Utilization Management Program VA Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Prasco Labs</name>
      <url>http://www.prasco.com</url>
    </packager>
    <packager>
      <name>Schering Corp.</name>
      <url>http://www.schering.de</url>
    </packager>
    <packager>
      <name>Spectrum Pharmaceuticals</name>
      <url>http://www.spectrumpharm.com</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>Watson Pharmaceuticals</name>
      <url>http://www.watson.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Schering corp sub schering plough corp</manufacturer>
    <manufacturer generic="false" url="">Pharmacia and upjohn co</manufacturer>
    <manufacturer generic="false" url="">Organon usa inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Ortho-cyclen 28 tablet</description>
      <cost currency="USD">1.13</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ortho tri-cyclen lo tablet</description>
      <cost currency="USD">2.68</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ortho-Cyclen (28) 28 0.25-35 mg-mcg tablet Disp Pack</description>
      <cost currency="USD">38.99</cost>
      <unit>disp</unit>
    </price>
    <price>
      <description>Ethinyl estradiol powder</description>
      <cost currency="USD">140.0</cost>
      <unit>g</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adrenal Cortex Hormones</category>
      <mesh-id>D000305</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>BSEP/ABCB11 inducers</category>
      <mesh-id/>
    </category>
    <category>
      <category>BSEP/ABCB11 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Contraceptive Agents, Female</category>
      <mesh-id>D003271</mesh-id>
    </category>
    <category>
      <category>Contraceptives, Oral</category>
      <mesh-id>D003276</mesh-id>
    </category>
    <category>
      <category>Contraceptives, Postcoital</category>
      <mesh-id>D003281</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 Inhibitors</category>
      <mesh-id>D065689</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C19 inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Inhibitors</category>
      <mesh-id>D065687</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Endocrine Therapy</category>
      <mesh-id/>
    </category>
    <category>
      <category>Estradiol Congeners</category>
      <mesh-id>D045166</mesh-id>
    </category>
    <category>
      <category>Estrogen Contraceptives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Estrogenic Steroids, Alkylated</category>
      <mesh-id>D042782</mesh-id>
    </category>
    <category>
      <category>Estrogens</category>
      <mesh-id>D004967</mesh-id>
    </category>
    <category>
      <category>Fused-Ring Compounds</category>
      <mesh-id>D000072473</mesh-id>
    </category>
    <category>
      <category>Genito Urinary System and Sex Hormones</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gonadal Hormones</category>
      <mesh-id>D042341</mesh-id>
    </category>
    <category>
      <category>Gonadal Steroid Hormones</category>
      <mesh-id>D012739</mesh-id>
    </category>
    <category>
      <category>Hormonal Contraceptives for Systemic Use</category>
      <mesh-id>D003270</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones and Related Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Hyperglycemia-Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Natural and Semisynthetic Estrogens, Plain</category>
      <mesh-id/>
    </category>
    <category>
      <category>Norpregnanes</category>
      <mesh-id>D009650</mesh-id>
    </category>
    <category>
      <category>Norpregnatrienes</category>
      <mesh-id>D009651</mesh-id>
    </category>
    <category>
      <category>Norsteroids</category>
      <mesh-id>D009654</mesh-id>
    </category>
    <category>
      <category>P-glycoprotein substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Progestogens and Estrogens, Sequential Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sex Hormones and Modulators of the Genital System</category>
      <mesh-id/>
    </category>
    <category>
      <category>Steroids</category>
      <mesh-id>D013256</mesh-id>
    </category>
    <category>
      <category>Thyroxine-binding globulin inducers</category>
      <mesh-id/>
    </category>
    <category>
      <category>UGT1A1 Inducers</category>
      <mesh-id/>
    </category>
    <category>
      <category>UGT1A1 Substrates</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Ring</form>
      <route>Vaginal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, chewable</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Insert, extended release</form>
      <route>Vaginal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Patch, extended release</form>
      <route>Transdermal</route>
      <strength/>
    </dosage>
    <dosage>
      <form/>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="G03AA15">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA11">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="L02AA03">
      <level code="L02AA">Estrogens</level>
      <level code="L02A">HORMONES AND RELATED AGENTS</level>
      <level code="L02">ENDOCRINE THERAPY</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
    <atc-code code="G03AA12">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA16">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AB02">
      <level code="G03AB">Progestogens and estrogens, sequential preparations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03CA01">
      <level code="G03CA">Natural and semisynthetic estrogens, plain</level>
      <level code="G03C">ESTROGENS</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA03">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA10">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AB04">
      <level code="G03AB">Progestogens and estrogens, sequential preparations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AB01">
      <level code="G03AB">Progestogens and estrogens, sequential preparations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AB07">
      <level code="G03AB">Progestogens and estrogens, sequential preparations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA13">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA06">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA08">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA02">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA04">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA09">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AB09">
      <level code="G03AB">Progestogens and estrogens, sequential preparations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA07">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AB03">
      <level code="G03AB">Progestogens and estrogens, sequential preparations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA05">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AB05">
      <level code="G03AB">Progestogens and estrogens, sequential preparations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AB06">
      <level code="G03AB">Progestogens and estrogens, sequential preparations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03AA01">
      <level code="G03AA">Progestogens and estrogens, fixed combinations</level>
      <level code="G03A">HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:16.04</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>4x1f</pdb-entry>
    <pdb-entry>4x1g</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00977.pdf?1371680618</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00977.pdf?1265922743</msds>
  <patents>
    <patent>
      <number>6156742</number>
      <country>United States</country>
      <approved>2000-12-05</approved>
      <expires>2020-12-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6787531</number>
      <country>United States</country>
      <approved>2004-09-07</approved>
      <expires>2020-08-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6933395</number>
      <country>United States</country>
      <approved>2005-08-23</approved>
      <expires>2017-08-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5876746</number>
      <country>United States</country>
      <approved>1999-03-02</approved>
      <expires>2015-11-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5989581</number>
      <country>United States</country>
      <approved>1999-11-23</approved>
      <expires>2018-04-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6214815</number>
      <country>United States</country>
      <approved>2001-04-10</approved>
      <expires>2019-12-09</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6667050</number>
      <country>United States</country>
      <approved>2003-12-23</approved>
      <expires>2019-04-06</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5898032</number>
      <country>United States</country>
      <approved>1999-04-27</approved>
      <expires>2017-06-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>RE39861</number>
      <country>United States</country>
      <approved>2007-09-25</approved>
      <expires>2017-06-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6987101</number>
      <country>United States</country>
      <approved>2006-01-17</approved>
      <expires>2017-12-22</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7163931</number>
      <country>United States</country>
      <approved>2007-01-16</approved>
      <expires>2021-12-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6958326</number>
      <country>United States</country>
      <approved>2005-10-25</approved>
      <expires>2021-12-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5798338</number>
      <country>United States</country>
      <approved>1998-08-25</approved>
      <expires>2015-07-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7320969</number>
      <country>United States</country>
      <approved>2008-01-22</approved>
      <expires>2024-01-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7615545</number>
      <country>United States</country>
      <approved>2009-11-10</approved>
      <expires>2023-06-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7855190</number>
      <country>United States</country>
      <approved>2010-12-21</approved>
      <expires>2028-12-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7858605</number>
      <country>United States</country>
      <approved>2010-12-28</approved>
      <expires>2023-06-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6500814</number>
      <country>United States</country>
      <approved>2002-12-31</approved>
      <expires>2018-09-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7704984</number>
      <country>United States</country>
      <approved>2010-04-27</approved>
      <expires>2029-02-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6441168</number>
      <country>United States</country>
      <approved>2002-08-27</approved>
      <expires>2022-07-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8617597</number>
      <country>United States</country>
      <approved>2013-12-31</approved>
      <expires>2030-02-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8450299</number>
      <country>United States</country>
      <approved>2013-05-28</approved>
      <expires>2025-10-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8415332</number>
      <country>United States</country>
      <approved>2013-04-09</approved>
      <expires>2029-03-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6652880</number>
      <country>United States</country>
      <approved>2003-11-25</approved>
      <expires>2020-03-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6716814</number>
      <country>United States</country>
      <approved>2004-04-06</approved>
      <expires>2021-08-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB02123</drugbank-id>
      <name>Glycochenodeoxycholic Acid</name>
      <description>Ethinylestradiol may decrease the excretion rate of Glycochenodeoxycholic Acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>Ethinylestradiol may decrease the excretion rate of Pravastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>Ethinylestradiol may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>Ethinylestradiol may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Ethinylestradiol may decrease the excretion rate of Isradipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>Ethinylestradiol may decrease the excretion rate of Olmesartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00301</drugbank-id>
      <name>Flucloxacillin</name>
      <description>Ethinylestradiol may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>Ethinylestradiol may decrease the excretion rate of Atenolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Ethinylestradiol may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>Ethinylestradiol may decrease the excretion rate of Spironolactone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>Ethinylestradiol may decrease the excretion rate of Loratadine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>Ethinylestradiol may decrease the excretion rate of Vincristine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>Ethinylestradiol may decrease the excretion rate of Atropine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>Ethinylestradiol may decrease the excretion rate of Imatinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>Ethinylestradiol may decrease the excretion rate of Nicardipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00693</drugbank-id>
      <name>Fluorescein</name>
      <description>Ethinylestradiol may decrease the excretion rate of Fluorescein which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>Ethinylestradiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>Ethinylestradiol may decrease the excretion rate of Disulfiram which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>Ethinylestradiol may decrease the excretion rate of Cefaclor which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00911</drugbank-id>
      <name>Tinidazole</name>
      <description>Ethinylestradiol may decrease the excretion rate of Tinidazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>Ethinylestradiol may decrease the excretion rate of Repaglinide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>Ethinylestradiol may decrease the excretion rate of Telmisartan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>Ethinylestradiol may decrease the excretion rate of Doxorubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Ethinylestradiol may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>Ethinylestradiol may decrease the excretion rate of Nitrendipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>Ethinylestradiol may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>Ethinylestradiol may decrease the excretion rate of Nifedipine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>Ethinylestradiol may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Ethinylestradiol may decrease the excretion rate of Ofloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>Ethinylestradiol may decrease the excretion rate of Taurocholic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05804</drugbank-id>
      <name>Prasterone sulfate</name>
      <description>Ethinylestradiol may decrease the excretion rate of Prasterone sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>Ethinylestradiol may decrease the excretion rate of Pitavastatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09374</drugbank-id>
      <name>Indocyanine green acid form</name>
      <description>Ethinylestradiol may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12319</drugbank-id>
      <name>Benzbromarone</name>
      <description>Ethinylestradiol may decrease the excretion rate of Benzbromarone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12712</drugbank-id>
      <name>Pilsicainide</name>
      <description>Ethinylestradiol may decrease the excretion rate of Pilsicainide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13345</drugbank-id>
      <name>Dihydroergocristine</name>
      <description>Ethinylestradiol may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13751</drugbank-id>
      <name>Glycyrrhizic acid</name>
      <description>Ethinylestradiol may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00673</drugbank-id>
      <name>Aprepitant</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Aprepitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Prucalopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The metabolism of Deferasirox can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01708</drugbank-id>
      <name>Prasterone</name>
      <description>The risk or severity of adverse effects can be increased when Prasterone is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00990</drugbank-id>
      <name>Exemestane</name>
      <description>The therapeutic efficacy of Exemestane can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00070</drugbank-id>
      <name>Hyaluronidase (ovine)</name>
      <description>The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04938</drugbank-id>
      <name>Ospemifene</name>
      <description>The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Ospemifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>Ethinylestradiol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00930</drugbank-id>
      <name>Colesevelam</name>
      <description>Colesevelam can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Rufinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02691</drugbank-id>
      <name>Glycocholic acid</name>
      <description>The therapeutic efficacy of Glycocholic acid can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic acid</name>
      <description>The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05990</drugbank-id>
      <name>Obeticholic acid</name>
      <description>The therapeutic efficacy of Obeticholic acid can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08834</drugbank-id>
      <name>Tauroursodeoxycholic acid</name>
      <description>The therapeutic efficacy of Tauroursodeoxycholic acid can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08857</drugbank-id>
      <name>Bamet-UD2</name>
      <description>The therapeutic efficacy of Bamet-UD2 can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08858</drugbank-id>
      <name>cis-Diamminechlorocholylglycinateplatinum(II)</name>
      <description>The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11789</drugbank-id>
      <name>Hyodeoxycholic Acid</name>
      <description>The therapeutic efficacy of Hyodeoxycholic Acid can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11860</drugbank-id>
      <name>Aramchol</name>
      <description>The therapeutic efficacy of Aramchol can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14016</drugbank-id>
      <name>Ox bile extract</name>
      <description>The therapeutic efficacy of Ox bile extract can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06777</drugbank-id>
      <name>Chenodeoxycholic acid</name>
      <description>The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08833</drugbank-id>
      <name>Taurochenodeoxycholic acid</name>
      <description>The therapeutic efficacy of Taurochenodeoxycholic acid can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00052</drugbank-id>
      <name>Somatotropin</name>
      <description>The therapeutic efficacy of Somatotropin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00089</drugbank-id>
      <name>Capromab pendetide</name>
      <description>Ethinylestradiol may decrease effectiveness of Capromab pendetide as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Drotrecogin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Streptokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Pentosan polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Desmoteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Defibrotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Beraprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Fibrinolysin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Prasugrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Semuloparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Cangrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Astaxanthin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Amediplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Triflusal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Ditazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Vorapaxar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Potassium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Zinc citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Antithrombin Alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Letaxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Darexaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Betrixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Monteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Brinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Melagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Saruplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Edetate calcium disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Edetate disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Dabigatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08830</drugbank-id>
      <name>Dehydroascorbic acid</name>
      <description>The serum concentration of Dehydroascorbic acid can be decreased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14482</drugbank-id>
      <name>Sodium ascorbate</name>
      <description>The serum concentration of Sodium ascorbate can be decreased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14483</drugbank-id>
      <name>Calcium ascorbate</name>
      <description>The serum concentration of Calcium ascorbate can be decreased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14485</drugbank-id>
      <name>Zinc ascorbate</name>
      <description>The serum concentration of Zinc ascorbate can be decreased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14486</drugbank-id>
      <name>Niacinamide ascorbate</name>
      <description>The serum concentration of Niacinamide ascorbate can be decreased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00024</drugbank-id>
      <name>Thyrotropin alfa</name>
      <description>The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03604</drugbank-id>
      <name>Tiratricol</name>
      <description>The therapeutic efficacy of Tiratricol can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09100</drugbank-id>
      <name>Thyroid, porcine</name>
      <description>The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00302</drugbank-id>
      <name>Tranexamic acid</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tranexamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Clobazam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00375</drugbank-id>
      <name>Colestipol</name>
      <description>Colestipol can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00658</drugbank-id>
      <name>Sevelamer</name>
      <description>Sevelamer can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00400</drugbank-id>
      <name>Griseofulvin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Griseofulvin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The serum concentration of Tixocortol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The serum concentration of Fluocortin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The serum concentration of Fluperolone can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The serum concentration of Formocortal can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The serum concentration of Fluclorolone can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The serum concentration of Loteprednol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The serum concentration of Aldosterone can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The serum concentration of Budesonide can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The serum concentration of Fludrocortisone can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The serum concentration of Trilostane can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The serum concentration of Paramethasone can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The serum concentration of Ciclesonide can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The serum concentration of Fluprednisolone can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The serum concentration of Melengestrol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The serum concentration of Hydrocortisone cypionate can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00162</drugbank-id>
      <name>Vitamin A</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Vitamin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Bexarotene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00459</drugbank-id>
      <name>Acitretin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Acitretin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Alitretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00926</drugbank-id>
      <name>Etretinate</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Etretinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Isotretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02699</drugbank-id>
      <name>4-Oxoretinol</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05076</drugbank-id>
      <name>Fenretinide</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Fenretinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08455</drugbank-id>
      <name>Ro 12-7310</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Ro 12-7310.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12112</drugbank-id>
      <name>Zuretinol acetate</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Zuretinol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13368</drugbank-id>
      <name>Motretinide</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Motretinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>Nabumetone may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>Etodolac may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>Carprofen may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>Lumiracoxib may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>Niflumic acid may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>Cimicoxib may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>Aceclofenac may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>Firocoxib may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>Talniflumate may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>Robenacoxib may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>Polmacoxib may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>Valdecoxib may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>Etoricoxib may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>Parecoxib may increase the thrombogenic activities of Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>Ethinylestradiol may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Bosentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Piperacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00415</drugbank-id>
      <name>Ampicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Ampicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00417</drugbank-id>
      <name>Phenoxymethylpenicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Phenoxymethylpenicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00578</drugbank-id>
      <name>Carbenicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Carbenicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00713</drugbank-id>
      <name>Oxacillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Oxacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00739</drugbank-id>
      <name>Hetacillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Hetacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00895</drugbank-id>
      <name>Benzylpenicilloyl polylysine</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Benzylpenicilloyl polylysine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00948</drugbank-id>
      <name>Mezlocillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Mezlocillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01000</drugbank-id>
      <name>Cyclacillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Cyclacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01053</drugbank-id>
      <name>Benzylpenicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Benzylpenicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01060</drugbank-id>
      <name>Amoxicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Amoxicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01061</drugbank-id>
      <name>Azlocillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Azlocillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01147</drugbank-id>
      <name>Cloxacillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Cloxacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01163</drugbank-id>
      <name>Amdinocillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Amdinocillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01602</drugbank-id>
      <name>Bacampicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Bacampicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01603</drugbank-id>
      <name>Meticillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Meticillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01604</drugbank-id>
      <name>Pivampicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Pivampicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01605</drugbank-id>
      <name>Pivmecillinam</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Pivmecillinam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01607</drugbank-id>
      <name>Ticarcillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Ticarcillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08795</drugbank-id>
      <name>Azidocillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Azidocillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09319</drugbank-id>
      <name>Carindacillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Carindacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09320</drugbank-id>
      <name>Procaine benzylpenicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Procaine benzylpenicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12127</drugbank-id>
      <name>Sultamicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Sultamicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12343</drugbank-id>
      <name>Temocillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Temocillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13300</drugbank-id>
      <name>Epicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Epicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13337</drugbank-id>
      <name>Pheneticillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Pheneticillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13506</drugbank-id>
      <name>Carfecillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Carfecillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13660</drugbank-id>
      <name>Propicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Propicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13686</drugbank-id>
      <name>Clometocillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Clometocillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13693</drugbank-id>
      <name>Sulbenicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Sulbenicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13739</drugbank-id>
      <name>Penamecillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Penamecillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13814</drugbank-id>
      <name>Talampicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Talampicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13816</drugbank-id>
      <name>Aspoxicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Aspoxicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13836</drugbank-id>
      <name>Metampicillin</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Metampicillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The therapeutic efficacy of Fluindione can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The therapeutic efficacy of Clorindione can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The therapeutic efficacy of Diphenadione can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Mycophenolate mofetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Mycophenolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00607</drugbank-id>
      <name>Nafcillin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Nafcillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00745</drugbank-id>
      <name>Modafinil</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Modafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Etravirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06442</drugbank-id>
      <name>Avasimibe</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Avasimibe.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Efavirenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14240</drugbank-id>
      <name>Echinacea</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Echinacea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The bioavailability of Selegiline can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>Exenatide can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Flibanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Cobicistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09101</drugbank-id>
      <name>Elvitegravir</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Elvitegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Rifampicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Nabilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Irbesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Rabeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Pioglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Topiroxostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Abiraterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00549</drugbank-id>
      <name>Zafirlukast</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Zafirlukast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Clopidogrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Candesartan cilexetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Salmeterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08911</drugbank-id>
      <name>Trametinib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Trametinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The metabolism of Felodipine can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The metabolism of Lopinavir can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Trifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Asunaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The risk or severity of liver damage can be increased when Erythromycin is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The risk or severity of liver damage can be increased when Reserpine is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The risk or severity of liver damage can be increased when Progesterone is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The risk or severity of liver damage can be increased when Chlorpromazine is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The risk or severity of liver damage can be increased when Cimetidine is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The risk or severity of liver damage can be increased when Vinblastine is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The risk or severity of liver damage can be increased when Tamoxifen is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00845</drugbank-id>
      <name>Clofazimine</name>
      <description>The risk or severity of liver damage can be increased when Clofazimine is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01586</drugbank-id>
      <name>Ursodeoxycholic acid</name>
      <description>The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Ursodeoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Cholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Fusidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Simeprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Letermovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14057</drugbank-id>
      <name>Valinomycin</name>
      <description>The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Valinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The risk or severity of liver damage can be increased when Troglitazone is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Ethinylestradiol may decrease the excretion rate of Digoxin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>The risk or severity of liver enzyme elevations can be increased when Ethinylestradiol is combined with Paritaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>The risk or severity of liver enzyme elevations can be increased when Ethinylestradiol is combined with Ombitasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00485</drugbank-id>
      <name>Dicloxacillin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Dicloxacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Pegvisomant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00136</drugbank-id>
      <name>Calcitriol</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Calcitriol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00357</drugbank-id>
      <name>Aminoglutethimide</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Aminoglutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00636</drugbank-id>
      <name>Clofibrate</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Clofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00769</drugbank-id>
      <name>Hydrocortamate</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Hydrocortamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Terbinafine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01011</drugbank-id>
      <name>Metyrapone</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Metyrapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01083</drugbank-id>
      <name>Orlistat</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Orlistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Ifosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01201</drugbank-id>
      <name>Rifapentine</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Rifapentine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Ketamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Cefradine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Aprobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Metamizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06708</drugbank-id>
      <name>Lumefantrine</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Lumefantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Seratrodast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Formestane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Osimertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Brigatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00163</drugbank-id>
      <name>Vitamin E</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Vitamin E.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01220</drugbank-id>
      <name>Rifaximin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Rifaximin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06717</drugbank-id>
      <name>Fosaprepitant</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Fosaprepitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00615</drugbank-id>
      <name>Rifabutin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Rifabutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04911</drugbank-id>
      <name>Oritavancin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Oritavancin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06413</drugbank-id>
      <name>Armodafinil</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Armodafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08909</drugbank-id>
      <name>Glycerol phenylbutyrate</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Glycerol phenylbutyrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11560</drugbank-id>
      <name>Lesinurad</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Lesinurad.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00471</drugbank-id>
      <name>Montelukast</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Montelukast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Piroxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Nilutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Phenelzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Meloxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Nicotine can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The metabolism of Torasemide can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The metabolism of Dapsone can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>The metabolism of Eszopiclone can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00799</drugbank-id>
      <name>Tazarotene</name>
      <description>The metabolism of Tazarotene can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The metabolism of Almotriptan can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The metabolism of Atorvastatin can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The metabolism of Domperidone can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The metabolism of Zopiclone can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>The metabolism of Halofantrine can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The metabolism of Mestranol can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The metabolism of Aminophenazone can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The metabolism of Antipyrine can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The metabolism of Licofelone can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06670</drugbank-id>
      <name>Odanacatib</name>
      <description>The metabolism of Odanacatib can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The metabolism of Ketobemidone can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The metabolism of Levomilnacipran can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The metabolism of Perospirone can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The metabolism of Riociguat can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The metabolism of Vortioxetine can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The metabolism of Olodaterol can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The metabolism of Tegafur can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The metabolism of Ixazomib can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The metabolism of Selexipag can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12130</drugbank-id>
      <name>Lorlatinib</name>
      <description>The metabolism of Lorlatinib can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01393</drugbank-id>
      <name>Bezafibrate</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Bezafibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01698</drugbank-id>
      <name>Rutin</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Rutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06729</drugbank-id>
      <name>Sulfaphenazole</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Sulfaphenazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11632</drugbank-id>
      <name>Opicapone</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Opicapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Triclabendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The metabolism of Lovastatin can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The metabolism of Dexibuprofen can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08502</drugbank-id>
      <name>Capravirine</name>
      <description>The metabolism of Capravirine can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The metabolism of Ketorolac can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The metabolism of Cisapride can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Colchicine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The metabolism of Amiodarone can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The metabolism of Phenprocoumon can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The metabolism of Paclitaxel can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00395</drugbank-id>
      <name>Carisoprodol</name>
      <description>The metabolism of Carisoprodol can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The metabolism of Ramelteon can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Praziquantel can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01131</drugbank-id>
      <name>Proguanil</name>
      <description>The metabolism of Proguanil can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The metabolism of Escitalopram can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05351</drugbank-id>
      <name>Dexlansoprazole</name>
      <description>The metabolism of Dexlansoprazole can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>The metabolism of Etizolam can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The metabolism of Lynestrenol can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13762</drugbank-id>
      <name>Dexrabeprazole</name>
      <description>The metabolism of Dexrabeprazole can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The metabolism of Thioridazine can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The metabolism of Zolpidem can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>The metabolism of Voriconazole can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>The metabolism of Artemether can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The metabolism of Esketamine can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14975</drugbank-id>
      <name>Voxelotor</name>
      <description>The metabolism of Voxelotor can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The metabolism of Nebivolol can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The metabolism of Vilazodone can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The metabolism of Clomipramine can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The metabolism of Imipramine can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Doxepin can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The metabolism of Acenocoumarol can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The risk or severity of liver enzyme elevations can be increased when Ethinylestradiol is combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The risk or severity of liver enzyme elevations can be increased when Ethinylestradiol is combined with Dasabuvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The metabolism of Amitriptyline can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The metabolism of Levothyroxine can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The serum concentration of Amineptine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>The serum concentration of Dimetacrine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>The serum concentration of Butriptyline can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The serum concentration of Dosulepin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>The serum concentration of Oxaprotiline can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The serum concentration of Opipramol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>The serum concentration of Amitriptylinoxide can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>The serum concentration of Dibenzepin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>The serum concentration of Quinupramine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>The serum concentration of Melitracen can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>The serum concentration of Lofepramine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>The serum concentration of Iprindole can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>The serum concentration of Imipramine oxide can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The serum concentration of Tianeptine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The metabolism of Adalimumab can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The metabolism of Infliximab can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The metabolism of Afelimomab can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The metabolism of Canakinumab can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The metabolism of Golimumab can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The metabolism of Certolizumab pegol can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The metabolism of Secukinumab can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The metabolism of Emapalumab can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Lymecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Clomocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00560</drugbank-id>
      <name>Tigecycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Tigecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Oxytetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Demeclocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Metacycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01301</drugbank-id>
      <name>Rolitetracycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Rolitetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13092</drugbank-id>
      <name>Meclocycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Meclocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Penimepicycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Doxycycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12329</drugbank-id>
      <name>Eravacycline</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Eravacycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14730</drugbank-id>
      <name>Calaspargase pegol</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Calaspargase pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>Ethinylestradiol may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The therapeutic efficacy of Heparin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>The therapeutic efficacy of Nitrofurantoin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The therapeutic efficacy of Furosemide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Liotrix.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Enzalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The therapeutic efficacy of Meclofenamic acid can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The therapeutic efficacy of Dantrolene can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The therapeutic efficacy of Etofenamate can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12425</drugbank-id>
      <name>Liothyronine I-131</name>
      <description>The therapeutic efficacy of Liothyronine I-131 can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The therapeutic efficacy of Metformin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The bioavailability of Ethinylestradiol can be increased when combined with Fluconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Butalbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Methohexital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Methylphenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Thiamylal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Amobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Hexobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Barbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Barbexaclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Pentobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Felbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The metabolism of Valproic acid can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Ethotoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Perampanel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The metabolism of Methsuximide can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The metabolism of Lacosamide can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The metabolism of Thiopental can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Topiramate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The metabolism of Levetiracetam can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>The metabolism of Tiagabine can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The metabolism of Zonisamide can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>The metabolism of Ezogabine can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>The metabolism of Eslicarbazepine acetate can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>The metabolism of Eslicarbazepine can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Secobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Primidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The metabolism of Trimethadione can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The metabolism of Mephenytoin can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The metabolism of Paramethadione can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The metabolism of Diazepam can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Acetazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Remacemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Doramectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The metabolism of Ethosuximide can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Lorazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Pregabalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Clorazepic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Zaleplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>The metabolism of Gabapentin can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The metabolism of Clonazepam can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>The metabolism of Estazolam can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The metabolism of Nitrazepam can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The metabolism of Flunarizine can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>The metabolism of Brivaracetam can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>The metabolism of Clomethiazole can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The metabolism of Cannabidiol can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The metabolism of Vinpocetine can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Metharbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Magnesium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Tizanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Riluzole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00832</drugbank-id>
      <name>Phensuximide</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Phensuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00837</drugbank-id>
      <name>Progabide</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Progabide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Vigabatrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01121</drugbank-id>
      <name>Phenacemide</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Phenacemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Delorazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with 7-Nitroindazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04165</drugbank-id>
      <name>Valpromide</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Valpromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Deramciclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06527</drugbank-id>
      <name>Tramiprosate</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Tramiprosate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06554</drugbank-id>
      <name>Gaboxadol</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Gaboxadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08329</drugbank-id>
      <name>Sulthiame</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Sulthiame.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Ifenprodil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09011</drugbank-id>
      <name>Beclamide</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Beclamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Paraldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Tiletamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Brexanolone</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Brexanolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11868</drugbank-id>
      <name>Etiracetam</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Etiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12338</drugbank-id>
      <name>Carisbamate</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Carisbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13362</drugbank-id>
      <name>Pheneturide</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Pheneturide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Neocitrullamon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Medazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Phenibut.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13799</drugbank-id>
      <name>Ethadione</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Ethadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14050</drugbank-id>
      <name>Cannabidivarin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Cannabidivarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15203</drugbank-id>
      <name>JNJ-26489112</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with JNJ-26489112.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The metabolism of Phenytoin can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Fosphenytoin can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with St. John's Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The therapeutic efficacy of Tolazamide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The therapeutic efficacy of Gliclazide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The therapeutic efficacy of Gliquidone can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The therapeutic efficacy of Glibornuride can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The therapeutic efficacy of Carbutamide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The therapeutic efficacy of Metahexamide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The therapeutic efficacy of Glyburide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The therapeutic efficacy of Glipizide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Oxcarbazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The therapeutic efficacy of Anastrozole can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14542</drugbank-id>
      <name>Hydrocortisone phosphate</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Hydrocortisone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Telaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Boceprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The therapeutic efficacy of Disopyramide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The therapeutic efficacy of Acarbose can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The therapeutic efficacy of Miglitol can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The therapeutic efficacy of Nateglinide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The therapeutic efficacy of Pentamidine can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The therapeutic efficacy of Phenformin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>The therapeutic efficacy of Mecasermin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>The therapeutic efficacy of Pramlintide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01382</drugbank-id>
      <name>Glymidine</name>
      <description>The therapeutic efficacy of Glymidine can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The therapeutic efficacy of Buformin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The therapeutic efficacy of Voglibose can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The therapeutic efficacy of NN344 can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05819</drugbank-id>
      <name>NBI-6024</name>
      <description>The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06011</drugbank-id>
      <name>AMG-222</name>
      <description>The therapeutic efficacy of AMG-222 can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06127</drugbank-id>
      <name>Bisegliptin</name>
      <description>The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>The therapeutic efficacy of Liraglutide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08382</drugbank-id>
      <name>Gosogliptin</name>
      <description>The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09022</drugbank-id>
      <name>Benfluorex</name>
      <description>The therapeutic efficacy of Benfluorex can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09043</drugbank-id>
      <name>Albiglutide</name>
      <description>The therapeutic efficacy of Albiglutide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The therapeutic efficacy of Insulin beef can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11698</drugbank-id>
      <name>Ipragliflozin</name>
      <description>The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11723</drugbank-id>
      <name>Dutogliptin</name>
      <description>The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11780</drugbank-id>
      <name>Allicin</name>
      <description>The therapeutic efficacy of Allicin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11824</drugbank-id>
      <name>Tofogliflozin</name>
      <description>The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11936</drugbank-id>
      <name>Bempedoic acid</name>
      <description>The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11950</drugbank-id>
      <name>Teneligliptin</name>
      <description>The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11992</drugbank-id>
      <name>Omarigliptin</name>
      <description>The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12268</drugbank-id>
      <name>Carmegliptin</name>
      <description>The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12412</drugbank-id>
      <name>Gemigliptin</name>
      <description>The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12417</drugbank-id>
      <name>Anagliptin</name>
      <description>The therapeutic efficacy of Anagliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12625</drugbank-id>
      <name>Evogliptin</name>
      <description>The therapeutic efficacy of Evogliptin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12713</drugbank-id>
      <name>Sotagliflozin</name>
      <description>The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12935</drugbank-id>
      <name>Remogliflozin etabonate</name>
      <description>The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13446</drugbank-id>
      <name>Guar gum</name>
      <description>The therapeutic efficacy of Guar gum can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13928</drugbank-id>
      <name>Semaglutide</name>
      <description>The therapeutic efficacy of Semaglutide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14027</drugbank-id>
      <name>Taspoglutide</name>
      <description>The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14035</drugbank-id>
      <name>Englitazone</name>
      <description>The therapeutic efficacy of Englitazone can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15171</drugbank-id>
      <name>Tirzepatide</name>
      <description>The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15217</drugbank-id>
      <name>Gastric inhibitory polypeptide</name>
      <description>The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00002</drugbank-id>
      <name>Cetuximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00028</drugbank-id>
      <name>Human immunoglobulin G</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Human immunoglobulin G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00043</drugbank-id>
      <name>Omalizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Omalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00057</drugbank-id>
      <name>Indium In-111 satumomab pendetide</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Trastuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Rituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00074</drugbank-id>
      <name>Basiliximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Basiliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00075</drugbank-id>
      <name>Muromonab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Muromonab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00076</drugbank-id>
      <name>Digoxin Immune Fab (Ovine)</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Alemtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00095</drugbank-id>
      <name>Efalizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Efalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00098</drugbank-id>
      <name>Antithymocyte immunoglobulin (rabbit)</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Natalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00110</drugbank-id>
      <name>Palivizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Palivizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00111</drugbank-id>
      <name>Daclizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Daclizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bevacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00113</drugbank-id>
      <name>Technetium Tc-99m arcitumomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01257</drugbank-id>
      <name>Eculizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Eculizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01269</drugbank-id>
      <name>Panitumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Panitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01270</drugbank-id>
      <name>Ranibizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ranibizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04901</drugbank-id>
      <name>Galiximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Galiximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04949</drugbank-id>
      <name>Pexelizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Pexelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04958</drugbank-id>
      <name>Epratuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Epratuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04962</drugbank-id>
      <name>Bectumomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bectumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04964</drugbank-id>
      <name>Oregovomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04988</drugbank-id>
      <name>IGN311</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of IGN311.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05006</drugbank-id>
      <name>Adecatumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Adecatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05097</drugbank-id>
      <name>Labetuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Labetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05101</drugbank-id>
      <name>Matuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Matuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05111</drugbank-id>
      <name>Fontolizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Fontolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05136</drugbank-id>
      <name>Bavituximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bavituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05139</drugbank-id>
      <name>CR002</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of CR002.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05209</drugbank-id>
      <name>Rozrolimupab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Rozrolimupab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05304</drugbank-id>
      <name>Girentuximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Girentuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05336</drugbank-id>
      <name>Obiltoxaximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Obiltoxaximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05405</drugbank-id>
      <name>XTL-001</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of XTL-001.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05437</drugbank-id>
      <name>NAV 1800</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of NAV 1800.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05459</drugbank-id>
      <name>Briakinumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Briakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05496</drugbank-id>
      <name>Otelixizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Otelixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05545</drugbank-id>
      <name>AMG 108</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of AMG 108.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05550</drugbank-id>
      <name>Iratumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Iratumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05555</drugbank-id>
      <name>Enokizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Enokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05578</drugbank-id>
      <name>Ramucirumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ramucirumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05595</drugbank-id>
      <name>Farletuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Farletuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05656</drugbank-id>
      <name>Veltuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Veltuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05679</drugbank-id>
      <name>Ustekinumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ustekinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05793</drugbank-id>
      <name>PRO-542</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of PRO-542.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05797</drugbank-id>
      <name>TNX-901</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of TNX-901.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05892</drugbank-id>
      <name>RI 624</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of RI 624.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05915</drugbank-id>
      <name>MYO-029</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of MYO-029.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05916</drugbank-id>
      <name>CT-011</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of CT-011.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05941</drugbank-id>
      <name>Leronlimab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Leronlimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05996</drugbank-id>
      <name>Glembatumumab vedotin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Glembatumumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06043</drugbank-id>
      <name>Olaratumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Olaratumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06049</drugbank-id>
      <name>IPH 2101</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of IPH 2101.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06050</drugbank-id>
      <name>TB-402</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of TB-402.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Caplacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06101</drugbank-id>
      <name>IMC-1C11</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of IMC-1C11.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06116</drugbank-id>
      <name>Eldelumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Eldelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06162</drugbank-id>
      <name>Lumiliximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lumiliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ipilimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06192</drugbank-id>
      <name>Nimotuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Nimotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06241</drugbank-id>
      <name>Clenoliximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Clenoliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06304</drugbank-id>
      <name>BIIB015</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of BIIB015.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06305</drugbank-id>
      <name>Sonepcizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Sonepcizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06310</drugbank-id>
      <name>Motavizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Motavizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06317</drugbank-id>
      <name>Elotuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Elotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06322</drugbank-id>
      <name>Carotuximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Carotuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06324</drugbank-id>
      <name>XmAb 2513</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of XmAb 2513.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06343</drugbank-id>
      <name>Teprotumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Teprotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06360</drugbank-id>
      <name>Lucatumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lucatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06366</drugbank-id>
      <name>Pertuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Pertuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06371</drugbank-id>
      <name>Siplizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Siplizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06467</drugbank-id>
      <name>Apolizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Apolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06474</drugbank-id>
      <name>Sibrotuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Sibrotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06550</drugbank-id>
      <name>Bivatuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bivatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06557</drugbank-id>
      <name>Lerdelimumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lerdelimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06599</drugbank-id>
      <name>Lexatumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lexatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06602</drugbank-id>
      <name>Reslizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Reslizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06606</drugbank-id>
      <name>Teplizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Teplizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06607</drugbank-id>
      <name>Catumaxomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Catumaxomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06612</drugbank-id>
      <name>Mepolizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Mepolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Denosumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06647</drugbank-id>
      <name>Volociximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Volociximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06650</drugbank-id>
      <name>Ofatumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ofatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08902</drugbank-id>
      <name>Raxibacumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Raxibacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09033</drugbank-id>
      <name>Vedolizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Vedolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09035</drugbank-id>
      <name>Nivolumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Nivolumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09037</drugbank-id>
      <name>Pembrolizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Pembrolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09057</drugbank-id>
      <name>Anthrax immune globulin human</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Anthrax immune globulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09105</drugbank-id>
      <name>Asfotase alfa</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Asfotase alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09264</drugbank-id>
      <name>Idarucizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Idarucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09302</drugbank-id>
      <name>Alirocumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Alirocumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09303</drugbank-id>
      <name>Evolocumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Evolocumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09312</drugbank-id>
      <name>Antilymphocyte immunoglobulin (horse)</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Antilymphocyte immunoglobulin (horse).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09331</drugbank-id>
      <name>Daratumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Daratumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09559</drugbank-id>
      <name>Necitumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11569</drugbank-id>
      <name>Ixekizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ixekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11580</drugbank-id>
      <name>Ravulizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ravulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11595</drugbank-id>
      <name>Atezolizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Atezolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11604</drugbank-id>
      <name>Tetanus Immune Globulin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tetanus Immune Globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11608</drugbank-id>
      <name>Eftrenonacog alfa</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Eftrenonacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11621</drugbank-id>
      <name>Human Varicella-Zoster Immune Globulin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Human Varicella-Zoster Immune Globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11646</drugbank-id>
      <name>Conatumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Conatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11657</drugbank-id>
      <name>Tabalumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tabalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11680</drugbank-id>
      <name>Ficlatuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ficlatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11685</drugbank-id>
      <name>Figitumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Figitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11714</drugbank-id>
      <name>Durvalumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Durvalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11715</drugbank-id>
      <name>Bapineuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bapineuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11731</drugbank-id>
      <name>Depatuxizumab mafodotin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Depatuxizumab mafodotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11746</drugbank-id>
      <name>Onartuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Onartuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11756</drugbank-id>
      <name>Solanezumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Solanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11771</drugbank-id>
      <name>Tremelimumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tremelimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11776</drugbank-id>
      <name>Brodalumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Brodalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11803</drugbank-id>
      <name>Sirukumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Sirukumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11826</drugbank-id>
      <name>Lampalizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lampalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11834</drugbank-id>
      <name>Guselkumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Guselkumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11840</drugbank-id>
      <name>Dalotuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Dalotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11849</drugbank-id>
      <name>Emibetuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Emibetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11850</drugbank-id>
      <name>Ublituximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ublituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11856</drugbank-id>
      <name>Ligelizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ligelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11857</drugbank-id>
      <name>Seribantumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Seribantumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11862</drugbank-id>
      <name>Landogrozumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Landogrozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11866</drugbank-id>
      <name>Romosozumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Romosozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11884</drugbank-id>
      <name>Vadastuximab Talirine</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Vadastuximab Talirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11914</drugbank-id>
      <name>Lebrikizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lebrikizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11930</drugbank-id>
      <name>Varlilumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Varlilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11945</drugbank-id>
      <name>Avelumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Avelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11959</drugbank-id>
      <name>Crenezumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Crenezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11972</drugbank-id>
      <name>Rilotumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Rilotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11976</drugbank-id>
      <name>Anifrolumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Anifrolumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11988</drugbank-id>
      <name>Ocrelizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ocrelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12023</drugbank-id>
      <name>Benralizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Benralizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12034</drugbank-id>
      <name>Gantenerumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Gantenerumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12053</drugbank-id>
      <name>Visilizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Visilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12077</drugbank-id>
      <name>Urelumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Urelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12090</drugbank-id>
      <name>Patritumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Patritumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12102</drugbank-id>
      <name>Fulranumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Fulranumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12104</drugbank-id>
      <name>Tarextumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tarextumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12118</drugbank-id>
      <name>Sotatercept</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Sotatercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12119</drugbank-id>
      <name>Gevokizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Gevokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12142</drugbank-id>
      <name>Duligotuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Duligotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12152</drugbank-id>
      <name>Simtuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Simtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12157</drugbank-id>
      <name>Fasinumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Fasinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12159</drugbank-id>
      <name>Dupilumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Dupilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12169</drugbank-id>
      <name>Tralokinumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tralokinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12189</drugbank-id>
      <name>Etrolizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Etrolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12202</drugbank-id>
      <name>Zalutumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Zalutumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12205</drugbank-id>
      <name>Ganitumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ganitumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12213</drugbank-id>
      <name>Etaracizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Etaracizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12246</drugbank-id>
      <name>Inclacumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Inclacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12250</drugbank-id>
      <name>Cixutumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Cixutumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12261</drugbank-id>
      <name>Ascrinvacumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ascrinvacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12274</drugbank-id>
      <name>Aducanumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Aducanumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12281</drugbank-id>
      <name>Luspatercept</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Luspatercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12296</drugbank-id>
      <name>GS-5745</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of GS-5745.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12317</drugbank-id>
      <name>Vanucizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Vanucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12331</drugbank-id>
      <name>Labetuzumab govitecan</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Labetuzumab govitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12335</drugbank-id>
      <name>Tanezumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12342</drugbank-id>
      <name>Ensituximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ensituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12344</drugbank-id>
      <name>Fezakinumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Fezakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12363</drugbank-id>
      <name>Dusigitumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Dusigitumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12396</drugbank-id>
      <name>Fresolimumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Fresolimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12413</drugbank-id>
      <name>Indusatumab vedotin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Indusatumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12456</drugbank-id>
      <name>Bococizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bococizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12498</drugbank-id>
      <name>Mogamulizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Mogamulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12520</drugbank-id>
      <name>Plozalizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Plozalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12530</drugbank-id>
      <name>Inebilizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Inebilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12534</drugbank-id>
      <name>Mavrilimumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Mavrilimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12560</drugbank-id>
      <name>Blosozumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Blosozumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12584</drugbank-id>
      <name>Bimagrumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bimagrumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12589</drugbank-id>
      <name>Dacetuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Dacetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12609</drugbank-id>
      <name>Tovetumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tovetumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12683</drugbank-id>
      <name>Lumretuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lumretuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12698</drugbank-id>
      <name>Ibalizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ibalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12701</drugbank-id>
      <name>Intetumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Intetumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12718</drugbank-id>
      <name>Carlumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Carlumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12734</drugbank-id>
      <name>Demcizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Demcizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12773</drugbank-id>
      <name>Sifalimumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Sifalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12775</drugbank-id>
      <name>Abituzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Abituzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12797</drugbank-id>
      <name>Ecromeximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ecromeximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12807</drugbank-id>
      <name>Naptumomab Estafenatox</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Naptumomab Estafenatox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12815</drugbank-id>
      <name>Crotedumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Crotedumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12820</drugbank-id>
      <name>Concizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Concizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12826</drugbank-id>
      <name>Depatuxizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Depatuxizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12844</drugbank-id>
      <name>Rontalizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Rontalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12845</drugbank-id>
      <name>Amatuximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Amatuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12849</drugbank-id>
      <name>Clazakizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Clazakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12891</drugbank-id>
      <name>Ozanezumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ozanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12893</drugbank-id>
      <name>Sacituzumab govitecan</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Sacituzumab govitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12917</drugbank-id>
      <name>Bimekizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bimekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12943</drugbank-id>
      <name>Milatuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Milatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12976</drugbank-id>
      <name>Robatumumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Robatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13017</drugbank-id>
      <name>Rovalpituzumab Tesirine</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Rovalpituzumab Tesirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13037</drugbank-id>
      <name>Namilumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Namilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13045</drugbank-id>
      <name>Racotumomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Racotumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13073</drugbank-id>
      <name>Tregalizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tregalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13127</drugbank-id>
      <name>Olokizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Olokizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13140</drugbank-id>
      <name>Bezlotoxumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bezlotoxumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13375</drugbank-id>
      <name>Edrecolomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Edrecolomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13535</drugbank-id>
      <name>Nebacumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Nebacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13886</drugbank-id>
      <name>Human cytomegalovirus immune globulin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Human cytomegalovirus immune globulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13923</drugbank-id>
      <name>Emicizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Emicizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13976</drugbank-id>
      <name>Sulesomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Sulesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13979</drugbank-id>
      <name>Besilesomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Besilesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14004</drugbank-id>
      <name>Tildrakizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14012</drugbank-id>
      <name>Burosumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Burosumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14039</drugbank-id>
      <name>Erenumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Erenumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14040</drugbank-id>
      <name>Eptinezumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Eptinezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14041</drugbank-id>
      <name>Fremanezumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Fremanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14042</drugbank-id>
      <name>Galcanezumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Galcanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14211</drugbank-id>
      <name>Fanolesomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Fanolesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14580</drugbank-id>
      <name>BAN-2401</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of BAN-2401.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14597</drugbank-id>
      <name>Lanadelumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lanadelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14707</drugbank-id>
      <name>Cemiplimab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Cemiplimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14762</drugbank-id>
      <name>Risankizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Risankizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14776</drugbank-id>
      <name>Camrelizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Camrelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14778</drugbank-id>
      <name>Setrusumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Setrusumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14784</drugbank-id>
      <name>Gancotamab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Gancotamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14809</drugbank-id>
      <name>Anetumab ravtansine</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Anetumab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14811</drugbank-id>
      <name>Isatuximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Isatuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14824</drugbank-id>
      <name>Icrucumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Icrucumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14843</drugbank-id>
      <name>Codrituzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Codrituzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14864</drugbank-id>
      <name>Brolucizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Brolucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14871</drugbank-id>
      <name>Xentuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Xentuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14877</drugbank-id>
      <name>Lintuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lintuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14891</drugbank-id>
      <name>Vobarilizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Vobarilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14897</drugbank-id>
      <name>Parsatuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Parsatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14905</drugbank-id>
      <name>Emactuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Emactuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14907</drugbank-id>
      <name>Bevacizumab zirconium Zr-89</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bevacizumab zirconium Zr-89.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14908</drugbank-id>
      <name>Refanezumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Refanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14919</drugbank-id>
      <name>Rozanolixizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Rozanolixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14947</drugbank-id>
      <name>Bermekimab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bermekimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14952</drugbank-id>
      <name>Pamrevlumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Pamrevlumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14959</drugbank-id>
      <name>Opicinumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Opicinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14967</drugbank-id>
      <name>Margetuximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Margetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14988</drugbank-id>
      <name>Dalantercept</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Dalantercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14997</drugbank-id>
      <name>Pateclizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Pateclizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15014</drugbank-id>
      <name>Gremubamab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Gremubamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15022</drugbank-id>
      <name>Apomab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Apomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15044</drugbank-id>
      <name>Tafasitamab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tafasitamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15045</drugbank-id>
      <name>Ipafricept</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ipafricept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15076</drugbank-id>
      <name>Abrilumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Abrilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15089</drugbank-id>
      <name>Frovocimab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Frovocimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15090</drugbank-id>
      <name>Tezepelumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tezepelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15101</drugbank-id>
      <name>Tigatuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tigatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15104</drugbank-id>
      <name>Telisotuzumab vedotin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Telisotuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15113</drugbank-id>
      <name>Utomilumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Utomilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15118</drugbank-id>
      <name>Zolbetuximab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Zolbetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15135</drugbank-id>
      <name>Ponezumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ponezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15160</drugbank-id>
      <name>Asunercept</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Asunercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15172</drugbank-id>
      <name>Suvratoxumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Suvratoxumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15225</drugbank-id>
      <name>Mitazalimab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Mitazalimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15252</drugbank-id>
      <name>Nemolizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Nemolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15253</drugbank-id>
      <name>Bleselumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Bleselumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15277</drugbank-id>
      <name>Gedivumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Gedivumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15336</drugbank-id>
      <name>Valanafusp alfa</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Valanafusp alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15349</drugbank-id>
      <name>Sofituzumab vedotin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Sofituzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15354</drugbank-id>
      <name>Evinacumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Evinacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15363</drugbank-id>
      <name>Istiratumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Istiratumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15383</drugbank-id>
      <name>Pidilizumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Pidilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15397</drugbank-id>
      <name>GMA-161</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of GMA-161.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15409</drugbank-id>
      <name>Ladiratuzumab vedotin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Ladiratuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15415</drugbank-id>
      <name>Tomaralimab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tomaralimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15428</drugbank-id>
      <name>Vesencumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Vesencumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15432</drugbank-id>
      <name>Pinatuzumab vedotin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Pinatuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15441</drugbank-id>
      <name>Lulizumab pegol</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lulizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15443</drugbank-id>
      <name>Lorukafusp alfa</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lorukafusp alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15453</drugbank-id>
      <name>Naratuximab emtansine</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Naratuximab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06318</drugbank-id>
      <name>AVE9633</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of AVE9633.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06342</drugbank-id>
      <name>Coltuximab ravtansine</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Coltuximab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Brentuximab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12089</drugbank-id>
      <name>Lorvotuzumab mertansine</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Lorvotuzumab mertansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12240</drugbank-id>
      <name>Polatuzumab vedotin</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Polatuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12489</drugbank-id>
      <name>Mirvetuximab Soravtansine</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Mirvetuximab Soravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15559</drugbank-id>
      <name>Zenocutuzumab</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Zenocutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Zidovudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The metabolism of Tramadol can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The metabolism of Morphine can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The metabolism of Acetaminophen can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The metabolism of Indomethacin can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00350</drugbank-id>
      <name>Minoxidil</name>
      <description>The metabolism of Minoxidil can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The metabolism of Cerivastatin can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>The metabolism of Raloxifene can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The metabolism of Diclofenac can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The metabolism of Labetalol can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The metabolism of Losartan can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The metabolism of Naltrexone can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The metabolism of Flurbiprofen can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The metabolism of Irinotecan can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The metabolism of Etoposide can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The metabolism of Estradiol can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The metabolism of Naproxen can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The metabolism of Propofol can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00916</drugbank-id>
      <name>Metronidazole</name>
      <description>The metabolism of Metronidazole can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The metabolism of Buprenorphine can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00947</drugbank-id>
      <name>Fulvestrant</name>
      <description>The metabolism of Fulvestrant can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>The metabolism of Ezetimibe can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The metabolism of Ketoprofen can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01048</drugbank-id>
      <name>Abacavir</name>
      <description>The metabolism of Abacavir can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The metabolism of Ibuprofen can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The metabolism of Fluvastatin can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The metabolism of Carvedilol can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03496</drugbank-id>
      <name>Alvocidib</name>
      <description>The metabolism of Alvocidib can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The metabolism of Belinostat can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05018</drugbank-id>
      <name>Migalastat</name>
      <description>The metabolism of Migalastat can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The metabolism of Indacaterol can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Eltrombopag can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06401</drugbank-id>
      <name>Bazedoxifene</name>
      <description>The metabolism of Bazedoxifene can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06510</drugbank-id>
      <name>Muraglitazar</name>
      <description>The metabolism of Muraglitazar can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The metabolism of Axitinib can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06741</drugbank-id>
      <name>Gavestinel</name>
      <description>The metabolism of Gavestinel can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06817</drugbank-id>
      <name>Raltegravir</name>
      <description>The metabolism of Raltegravir can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>The metabolism of Dolutegravir can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The metabolism of Propacetamol can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11799</drugbank-id>
      <name>Bictegravir</name>
      <description>The metabolism of Bictegravir can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>The metabolism of Delafloxacin can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11967</drugbank-id>
      <name>Binimetinib</name>
      <description>The metabolism of Binimetinib can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The metabolism of Elagolix can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The metabolism of Enasidenib can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The metabolism of Estradiol acetate can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The metabolism of Estradiol benzoate can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The metabolism of Estradiol cypionate can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The metabolism of Estradiol dienanthate can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The metabolism of Estradiol valerate can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Testosterone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12020</drugbank-id>
      <name>Tecovirimat</name>
      <description>The metabolism of Tecovirimat can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06077</drugbank-id>
      <name>Lumateperone</name>
      <description>The metabolism of Lumateperone can be increased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00027</drugbank-id>
      <name>Gramicidin D</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Azithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Pantoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00234</drugbank-id>
      <name>Reboxetine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Reboxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Amsacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Lidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Venlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Tenofovir disoproxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Gefitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Cetirizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Protriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Mefloquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00360</drugbank-id>
      <name>Sapropterin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Sapropterin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Nimodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Loxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Trimethoprim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Lansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Prazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Albendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00520</drugbank-id>
      <name>Caspofungin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Caspofungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Amoxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Doxazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ivermectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00613</drugbank-id>
      <name>Amodiaquine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Amodiaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fluphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Testosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Pentazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Flurazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Esomeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Scopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Benzquinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Dactinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01103</drugbank-id>
      <name>Quinacrine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Quinacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01110</drugbank-id>
      <name>Miconazole</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Miconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01117</drugbank-id>
      <name>Atovaquone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Atovaquone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01128</drugbank-id>
      <name>Bicalutamide</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Bicalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Terazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Estramustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ceftriaxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ergometrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Lapatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01319</drugbank-id>
      <name>Fosamprenavir</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fosamprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Cefoperazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02010</drugbank-id>
      <name>Staurosporine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Staurosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02587</drugbank-id>
      <name>Colforsin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Colforsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04216</drugbank-id>
      <name>Quercetin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Quercetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04540</drugbank-id>
      <name>Cholesterol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Cholesterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04851</drugbank-id>
      <name>Biricodar</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Biricodar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04877</drugbank-id>
      <name>Voacamine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Voacamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04881</drugbank-id>
      <name>Elacridar</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Elacridar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Tesmilifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04960</drugbank-id>
      <name>Tipifarnib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Tipifarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06191</drugbank-id>
      <name>Zosuquidar</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Zosuquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06240</drugbank-id>
      <name>Tariquidar</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Tariquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06420</drugbank-id>
      <name>Annamycin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Annamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06448</drugbank-id>
      <name>Lonafarnib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Lonafarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06636</drugbank-id>
      <name>Isavuconazonium</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Isavuconazonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06733</drugbank-id>
      <name>Bafilomycin A1</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Bafilomycin A1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06734</drugbank-id>
      <name>Bafilomycin B1</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Bafilomycin B1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Benzyl alcohol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07348</drugbank-id>
      <name>Brefeldin A</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Brefeldin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08820</drugbank-id>
      <name>Ivacaftor</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ivacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08874</drugbank-id>
      <name>Fidaxomicin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fidaxomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Linagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Canagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Afatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ledipasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Suvorexant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Netupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09102</drugbank-id>
      <name>Daclatasvir</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Daclatasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09291</drugbank-id>
      <name>Rolapitant</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Rolapitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Glycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11363</drugbank-id>
      <name>Alectinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Alectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11387</drugbank-id>
      <name>Chloroform</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Chloroform.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11430</drugbank-id>
      <name>Monensin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Monensin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11544</drugbank-id>
      <name>Salinomycin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Salinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Venetoclax.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Velpatasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11712</drugbank-id>
      <name>Tezacaftor</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Tezacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11828</drugbank-id>
      <name>Neratinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Neratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11869</drugbank-id>
      <name>Valspodar</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Valspodar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Glasdegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Abemaciclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Alpelisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Voxilaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Sarecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12582</drugbank-id>
      <name>Piperine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Piperine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12799</drugbank-id>
      <name>Laniquidar</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Laniquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Gallopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13125</drugbank-id>
      <name>Lusutrombopag</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Lusutrombopag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Testosterone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Testosterone enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Testosterone undecanoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14056</drugbank-id>
      <name>Nigericin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Nigericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14061</drugbank-id>
      <name>Hycanthone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Hycanthone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14062</drugbank-id>
      <name>Concanamycin A</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Concanamycin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Emopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Lomerizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14067</drugbank-id>
      <name>Dofequidar</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Dofequidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14069</drugbank-id>
      <name>ONT-093</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with ONT-093.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14070</drugbank-id>
      <name>HM-30181</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with HM-30181.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14071</drugbank-id>
      <name>Desmethylsertraline</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Desmethylsertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14072</drugbank-id>
      <name>Reversin 121</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Reversin 121.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ivosidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The serum concentration of Dihydroergotamine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The serum concentration of Nisoldipine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The serum concentration of Meperidine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The serum concentration of Buspirone can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The serum concentration of Nortriptyline can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>The serum concentration of Astemizole can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The serum concentration of Ergotamine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The serum concentration of Alfentanil can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The serum concentration of Fentanyl can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The serum concentration of Conivaptan can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The serum concentration of Tipranavir can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The serum concentration of Pimozide can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The serum concentration of Darunavir can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The serum concentration of Everolimus can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The serum concentration of Dronedarone can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08827</drugbank-id>
      <name>Lomitapide</name>
      <description>The serum concentration of Lomitapide can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>The serum concentration of Rilpivirine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>The serum concentration of Eliglustat can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Entrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fedratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00648</drugbank-id>
      <name>Mitotane</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Mitotane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Loperamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Atazanavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Itraconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Posaconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Rifamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13179</drugbank-id>
      <name>Troleandomycin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Troleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>The metabolism of Ethinylestradiol can be increased when combined with Metreleptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00173</drugbank-id>
      <name>Adenine</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Adenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Flunitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Regorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09276</drugbank-id>
      <name>Sodium aurothiomalate</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Sodium aurothiomalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09298</drugbank-id>
      <name>Silibinin</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Silibinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Ertugliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Dacomitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12010</drugbank-id>
      <name>Fostamatinib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Fostamatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Rucaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Pibrentasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Glecaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12978</drugbank-id>
      <name>Pexidartinib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Pexidartinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00205</drugbank-id>
      <name>Pyrimethamine</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Pyrimethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Ticlopidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08875</drugbank-id>
      <name>Cabozantinib</name>
      <description>The metabolism of Ethinylestradiol can be decreased when combined with Cabozantinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The serum concentration of Clonidine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The serum concentration of Digitoxin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The serum concentration of Trastuzumab deruxtecan can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Octreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00126</drugbank-id>
      <name>Ascorbic acid</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ascorbic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Cabergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Conjugated estrogens.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Chlorambucil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Mitomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Tacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Gemcitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Teniposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Cisplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Nizatidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Sumatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Lamivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Mannitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Tetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Olopatadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00882</drugbank-id>
      <name>Clomifene</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Clomifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ondansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The serum concentration of Cytarabine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The serum concentration of Hydroxyurea can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The serum concentration of Melphalan can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The serum concentration of Tegaserod can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The serum concentration of Arsenic trioxide can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The serum concentration of Acebutolol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The serum concentration of Nadolol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The serum concentration of Sparfloxacin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The serum concentration of Docetaxel can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The serum concentration of Vecuronium can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01400</drugbank-id>
      <name>Neostigmine</name>
      <description>The serum concentration of Neostigmine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The serum concentration of Ketazolam can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Stanolone</name>
      <description>The serum concentration of Stanolone can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03203</drugbank-id>
      <name>Sphingosine</name>
      <description>The serum concentration of Sphingosine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03825</drugbank-id>
      <name>Rhodamine 6G</name>
      <description>The serum concentration of Rhodamine 6G can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>The serum concentration of Estriol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>The serum concentration of Camptothecin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The serum concentration of Debrisoquine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The serum concentration of Celiprolol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The serum concentration of Cobimetinib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The serum concentration of Trastuzumab emtansine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The serum concentration of Romidepsin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>The serum concentration of Silodosin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The serum concentration of Ambrisentan can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The serum concentration of Panobinostat can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The serum concentration of Fesoterodine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The serum concentration of Carfilzomib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The serum concentration of Mirabegron can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The serum concentration of Pomalidomide can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>The serum concentration of Sofosbuvir can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The serum concentration of Ceritinib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The serum concentration of Olaparib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The serum concentration of Umeclidinium can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The serum concentration of Nintedanib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09099</drugbank-id>
      <name>Somatostatin</name>
      <description>The serum concentration of Somatostatin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09161</drugbank-id>
      <name>Technetium Tc-99m sestamibi</name>
      <description>The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The serum concentration of Ubidecarenone can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11431</drugbank-id>
      <name>Moxidectin</name>
      <description>The serum concentration of Moxidectin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11447</drugbank-id>
      <name>Phenothiazine</name>
      <description>The serum concentration of Phenothiazine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11574</drugbank-id>
      <name>Elbasvir</name>
      <description>The serum concentration of Elbasvir can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11575</drugbank-id>
      <name>Grazoprevir</name>
      <description>The serum concentration of Grazoprevir can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The serum concentration of Vinflunine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11760</drugbank-id>
      <name>Talazoparib</name>
      <description>The serum concentration of Talazoparib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The serum concentration of Talinolol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The serum concentration of Baricitinib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The serum concentration of Revefenacin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>The serum concentration of Duvelisib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11995</drugbank-id>
      <name>Avatrombopag</name>
      <description>The serum concentration of Avatrombopag can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The serum concentration of Gilteritinib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The serum concentration of Bromperidol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The serum concentration of Omadacycline can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>The serum concentration of Copanlisib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12836</drugbank-id>
      <name>Grapiprant</name>
      <description>The serum concentration of Grapiprant can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13146</drugbank-id>
      <name>Fluciclovine (18F)</name>
      <description>The serum concentration of Fluciclovine (18F) can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13173</drugbank-id>
      <name>Cerliponase alfa</name>
      <description>The serum concentration of Cerliponase alfa can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13951</drugbank-id>
      <name>Stanolone acetate</name>
      <description>The serum concentration of Stanolone acetate can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>The serum concentration of Larotrectinib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The serum concentration of Clozapine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The serum concentration of Amprenavir can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The serum concentration of Cyclosporine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The serum concentration of Sildenafil can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The serum concentration of Indinavir can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The serum concentration of Terfenadine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The serum concentration of Simvastatin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>The serum concentration of Vardenafil can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The serum concentration of Tacrolimus can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The serum concentration of Sirolimus can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The serum concentration of Quinidine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The serum concentration of Bromocriptine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The serum concentration of Saquinavir can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The serum concentration of Dasatinib can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The serum concentration of Tolvaptan can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The serum concentration of Temsirolimus can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The serum concentration of Ticagrelor can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Donepezil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The serum concentration of Metoclopramide can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The serum concentration of Flecainide can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Eletriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>The serum concentration of Naloxone can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The serum concentration of Quetiapine can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The serum concentration of Rivaroxaban can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Fexofenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13007</drugbank-id>
      <name>Enfortumab vedotin</name>
      <description>The serum concentration of Enfortumab vedotin can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12941</drugbank-id>
      <name>Darolutamide</name>
      <description>The serum concentration of Darolutamide can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Erdafitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The serum concentration of Propranolol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Lasmiditan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Cenobamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Ranolazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The serum concentration of Cilostazol can be increased when it is combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09280</drugbank-id>
      <name>Lumacaftor</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Lumacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06404</drugbank-id>
      <name>Human C1-esterase inhibitor</name>
      <description>The risk or severity of thromboembolism can be increased when Ethinylestradiol is combined with Human C1-esterase inhibitor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09228</drugbank-id>
      <name>Conestat alfa</name>
      <description>The risk or severity of thromboembolism can be increased when Ethinylestradiol is combined with Conestat alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The serum concentration of Ethinylestradiol can be decreased when it is combined with Pitolisant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Isavuconazole.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.63</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>6.77e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(1S,10R,11S,14R,15S)-14-ethynyl-15-methyltetracyclo[8.7.0.0Â²,â·.0Â¹Â¹,Â¹âµ]heptadeca-2(7),3,5-triene-5,14-diol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>ethinyl estradiol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>296.4034</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>296.177630012</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C20H24O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>BFPYWIDHMRZLRN-SLHNCBLASA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>40.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>87.37</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>34.53</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>10.33</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-1.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>11.3 mg/L (at 27 Â°C)</value>
      <source>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>142-144</value>
      <source>Inhoffen, H.H. and Hohlweg, W.; U.S. Patent 2,265,976; December 9, 1941; assigned to Schering Corp.</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.67</value>
      <source>HANSCH,C ET AL. (1995)</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.3</value>
      <source>ADME Research, USCD</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7426</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>4903</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5991</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508618</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07534</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00554</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5770</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50187243</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449527</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>3WF</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001018</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Ethinylestradiol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL691</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/estinyl.htm</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00977</drugbank-id>
        <name>Ethinylestradiol</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02136</drugbank-id>
        <name>Ethinylestradiol-3-sulfate</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET02136</drugbank-id>
        <name>Ethinylestradiol-3-sulfate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02137</drugbank-id>
        <name>Ethinylestradiol-2-hydroxyl-3-sulfate</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET02136</drugbank-id>
        <name>Ethinylestradiol-3-sulfate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02138</drugbank-id>
        <name>Ethinylestradiol-4-hydroxyl-3-sulfate</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET02136</drugbank-id>
        <name>Ethinylestradiol-3-sulfate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02139</drugbank-id>
        <name>Ethinylestradiol-6-hydroxyl-3-sulfate</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET02136</drugbank-id>
        <name>Ethinylestradiol-3-sulfate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02140</drugbank-id>
        <name>Ethinylestradiol-16-hydroxyl-3-sulfate</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000123</id>
      <name>Estrogen receptor alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6026</ref-id>
            <pubmed-id>17095591</pubmed-id>
            <citation>Micevych PE, Chaban V, Ogi J, Dewing P, Lu JK, Sinchak K: Estradiol stimulates progesterone synthesis in hypothalamic astrocyte cultures. Endocrinology. 2007 Feb;148(2):782-9. Epub 2006 Nov 9.</citation>
          </article>
          <article>
            <ref-id>A1192</ref-id>
            <pubmed-id>17124377</pubmed-id>
            <citation>Garcia-Segura LM, Sanz A, Mendez P: Cross-talk between IGF-I and estradiol in the brain: focus on neuroprotection. Neuroendocrinology. 2006;84(4):275-9. Epub 2006 Nov 23.</citation>
          </article>
          <article>
            <ref-id>A5624</ref-id>
            <pubmed-id>17125913</pubmed-id>
            <citation>Brama M, Gnessi L, Basciani S, Cerulli N, Politi L, Spera G, Mariani S, Cherubini S, Scotto d'Abusco A, Scandurra R, Migliaccio S: Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):102-8. Epub 2006 Nov 27.</citation>
          </article>
          <article>
            <ref-id>A5625</ref-id>
            <pubmed-id>17138652</pubmed-id>
            <citation>Lehnes K, Winder AD, Alfonso C, Kasid N, Simoneaux M, Summe H, Morgan E, Iann MC, Duncan J, Eagan M, Tavaluc R, Evans CH Jr, Russell R, Wang A, Hu F, Stoica A: The effect of estradiol on in vivo tumorigenesis is modulated by the human epidermal growth factor receptor 2/phosphatidylinositol 3-kinase/Akt1 pathway. Endocrinology. 2007 Mar;148(3):1171-80. Epub 2006 Nov 30.</citation>
          </article>
          <article>
            <ref-id>A6027</ref-id>
            <pubmed-id>17142999</pubmed-id>
            <citation>Mukai H, Tsurugizawa T, Ogiue-Ikeda M, Murakami G, Hojo Y, Ishii H, Kimoto T, Kawato S: Local neurosteroid production in the hippocampus: influence on synaptic plasticity of memory. Neuroendocrinology. 2006;84(4):255-63. Epub 2006 Dec 1.</citation>
          </article>
          <article>
            <ref-id>A6028</ref-id>
            <pubmed-id>19237207</pubmed-id>
            <citation>Notch EG, Mayer GD: 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8. doi: 10.1016/j.aquatox.2009.01.001. Epub  2009 Jan 23.</citation>
          </article>
          <article>
            <ref-id>A6029</ref-id>
            <pubmed-id>19434891</pubmed-id>
            <citation>Bennink HJ: Reprint of Are all estrogens the same? Maturitas. 2008 Sep-Oct;61(1-2):195-201.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P03372" source="Swiss-Prot">
        <name>Estrogen receptor</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.</specific-function>
        <gene-name>ESR1</gene-name>
        <locus>6q25.1</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.14</theoretical-pi>
        <molecular-weight>66215.45</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3467</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ESR1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X03635</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31234</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>620</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>620</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P03372</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ESR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ER</synonym>
          <synonym>ER-alpha</synonym>
          <synonym>ESR</synonym>
          <synonym>Estradiol receptor</synonym>
          <synonym>NR3A1</synonym>
          <synonym>Nuclear receptor subfamily 3 group A member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000246|Estrogen receptor
MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAY
EFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPF
LQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAK
ETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQAC
RLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKR
SKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINW
AKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEG
MVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLD
KITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLL
LEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021831|Estrogen receptor (ESR1)
ATGACCATGACCCTCCACACCAAAGCATCTGGGATGGCCCTACTGCATCAGATCCAAGGG
AACGAGCTGGAGCCCCTGAACCGTCCGCAGCTCAAGATCCCCCTGGAGCGGCCCCTGGGC
GAGGTGTACCTGGACAGCAGCAAGCCCGCCGTGTACAACTACCCCGAGGGCGCCGCCTAC
GAGTTCAACGCCGCGGCCGCCGCCAACGCGCAGGTCTACGGTCAGACCGGCCTCCCCTAC
GGCCCCGGGTCTGAGGCTGCGGCGTTCGGCTCCAACGGCCTGGGGGGTTTCCCCCCACTC
AACAGCGTGTCTCCGAGCCCGCTGATGCTACTGCACCCGCCGCCGCAGCTGTCGCCTTTC
CTGCAGCCCCACGGCCAGCAGGTGCCCTACTACCTGGAGAACGAGCCCAGCGGCTACACG
GTGCGCGAGGCCGGCCCGCCGGCATTCTACAGGCCAAATTCAGATAATCGACGCCAGGGT
GGCAGAGAAAGATTGGCCAGTACCAATGACAAGGGAAGTATGGCTATGGAATCTGCCAAG
GAGACTCGCTACTGTGCAGTGTGCAATGACTATGCTTCAGGCTACCATTATGGAGTCTGG
TCCTGTGAGGGCTGCAAGGCCTTCTTCAAGAGAAGTATTCAAGGACATAACGACTATATG
TGTCCAGCCACCAACCAGTGCACCATTGATAAAAACAGGAGGAAGAGCTGCCAGGCCTGC
CGGCTCCGCAAATGCTACGAAGTGGGAATGATGAAAGGTGGGATACGAAAAGACCGAAGA
GGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTG
GGGTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGC
TCTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTGTTG
GATGCTGAGCCCCCCATACTCTATTCCGAGTATGATCCTACCAGACCCTTCAGTGAAGCT
TCGATGATGGGCTTACTGACCAACCTGGCAGACAGGGAGCTGGTTCACATGATCAACTGG
GCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATCAGGTCCACCTTCTAGAA
TGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGGG
AAGCTACTGTTTGCTCCTAACTTGCTCTTGGACAGGAACCAGGGAAAATGTGTAGAGGGC
ATGGTGGAGATCTTCGACATGCTGCTGGCTACATCATCTCGGTTCCGCATGATGAATCTG
CAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACA
TTTCTGTCCAGCACCCTGAAGTCTCTGGAAGAGAAGGACCATATCCACCGAGTCCTGGAC
AAGATCACAGACACTTTGATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAGCAG
CACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAA
GGCATGGAGCATCTGTACAGCATGAAGTGCAAGAACGTGGTGCCCCTCTATGACCTGCTG
CTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCCGTG
GAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAA
AAGTATTACATCACGGGGGAGGCAGAGGGTTTCCCTGCCACGGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
          <pfam>
            <identifier>PF02159</identifier>
            <name>Oest_recep</name>
          </pfam>
          <pfam>
            <identifier>PF12743</identifier>
            <name>ESR1_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear chromatin</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transcriptionally active chromatin</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-catenin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>core promoter sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>estrogen receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>estrogen response element binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nitric-oxide synthase regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II core promoter proximal region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antral ovarian follicle growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to estradiol stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chromatin remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell proliferation involved in mammary gland duct elongation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular estrogen receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular steroid hormone receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland alveolus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland branching involved in pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fibroblast proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric-oxide synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostate epithelial cord elongation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of branching involved in prostate gland morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>uterus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vagina development</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0000956</id>
      <name>Nuclear receptor subfamily 1 group I member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12096</ref-id>
            <pubmed-id>17327420</pubmed-id>
            <citation>Xue Y, Moore LB, Orans J, Peng L, Bencharit S, Kliewer SA, Redinbo MR: Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol. 2007 May;21(5):1028-38. Epub 2007 Feb 27.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O75469" source="Swiss-Prot">
        <name>Nuclear receptor subfamily 1 group I member 2</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and isoflavones. Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes.</specific-function>
        <gene-name>NR1I2</gene-name>
        <locus>3q12-q13.3</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.44</theoretical-pi>
        <molecular-weight>49761.245</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7968</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NR1I2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF061056</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3511138</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>606</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>606</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O75469</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NR1I2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Orphan nuclear receptor PAR1</synonym>
          <synonym>Orphan nuclear receptor PXR</synonym>
          <synonym>Pregnane X receptor</synonym>
          <synonym>PXR</synonym>
          <synonym>Steroid and xenobiotic receptor</synonym>
          <synonym>SXR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001903|Nuclear receptor subfamily 1 group I member 2
MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATGYHFNVMTCEG
CKGFFRRAMKRNARLRCPFRKGACEITRKTRRQCQACRLRKCLESGMKKEMIMSDEAVEE
RRALIKRKKSERTGTQPLGVQGLTEEQRMMIRELMDAQMKTFDTTFSHFKNFRLPGVLSS
GCELPESLQAPSREEAAKWSQVRKDLCSLKVSLQLRGEDGSVWNYKPPADSGGKEIFSLL
PHMADMSTYMFKGIISFAKVISYFRDLPIEDQISLLKGAAFELCQLRFNTVFNAETGTWE
CGRLSYCLEDTAGGFQQLLLEPMLKFHYMLKKLQLHEEEYVLMQAISLFSPDRPGVLQHR
VVDQLQEQFAITLKSYIECNRPQPAHRFLFLKIMAMLTELRSINAQHTQRLLRIQDIHPF
ATPLMQELFGITGS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010672|Nuclear receptor subfamily 1 group I member 2 (NR1I2)
CTGGAGGTGAGACCCAAAGAAAGCTGGAACCATGCTGACTTTGTACACTGTGAGGACACA
GAGTCTGTTCCTGGAAAGCCCAGTGTCAACGCAGATGAGGAAGTCGGAGGTCCCCAAATC
TGCCGTGTATGTGGGGACAAGGCCACTGGCTATCACTTCAATGTCATGACATGTGAAGGA
TGCAAGGGCTTTTTCAGGAGGGCCATGAAACGCAACGCCCGGCTGAGGTGCCCCTTCCGG
AAGGGCGCCTGCGAGATCACCCGGAAGACCCGGCGACAGTGCCAGGCCTGCCGCCTGCGC
AAGTGCCTGGAGAGCGGCATGAAGAAGGAGATGATCATGTCCGACGAGGCCGTGGAGGAG
AGGCGGGCCTTGATCAAGCGGAAGAAAAGTGAACGGACAGGGACTCAGCCACTGGGAGTG
CAGGGGCTGACAGAGGAGCAGCGGATGATGATCAGGGAGCTGATGGACGCTCAGATGAAA
ACCTTTGACACTACCTTCTCCCATTTCAAGAATTTCCGGCTGCCAGGGGTGCTTAGCAGT
GGCTGCGAGTTGCCAGAGTCTCTGCAGGCCCCATCGAGGGAAGAAGCTGCCAAGTGGAGC
CAGGTCCGGAAAGATCTGTGCTCTTTGAAGGTCTCTCTGCAGCTGCGGGGGGAGGATGGC
AGTGTCTGGAACTACAAACCCCCAGCCGACAGTGGCGGGAAAGAGATCTTCTCCCTGCTG
CCCCACATGGCTGACATGTCAACCTACATGTTCAAAGGCATCATCAGCTTTGCCAAAGTC
ATCTCCTACTTCAGGGACTTGCCCATCGAGGACCAGATCTCCCTGCTGAAGGGGGCCGCT
TTCGAGCTGTGTCAACTGAGATTCAACACAGTGTTCAACGCGGAGACTGGAACCTGGGAG
TGTGGCCGGCTGTCCTACTGCTTGGAAGACACTGCAGGTGGCTTCCAGCAACTTCTACTG
GAGCCCATGCTGAAATTCCACTACATGCTGAAGAAGCTGCAGCTGCATGAGGAGGAGTAT
GTGCTGATGCAGGCCATCTCCCTCTTCTCCCCAGACCGCCCAGGTGTGCTGCAGCACCGC
GTGGTGGACCAGCTGCAGGAGCAATTCGCCATTACTCTGAAGTCCTACATTGAATGCAAT
CGGCCCCAGCCTGCTCATAGGTTCTTGTTCCTGAAGATCATGGCTATGCTCACCGAGCTC
CGCAGCATCAATGCTCAGCACACCCAGCGGCTGCTGCGCATCCAGGACATACACCCCTTT
GCTACGCCCCTCATGCAGGAGTTGTTCGGCATCACAGGTAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II regulatory region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug export</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0000685</id>
      <name>Sex hormone-binding globulin</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A20240</ref-id>
            <pubmed-id>25349334</pubmed-id>
            <citation>Hong H, Branham WS, Ng HW, Moland CL, Dial SL, Fang H, Perkins R, Sheehan D, Tong W: Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and alpha-fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04278" source="Swiss-Prot">
        <name>Sex hormone-binding globulin</name>
        <general-function>Androgen binding</general-function>
        <specific-function>Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.</specific-function>
        <gene-name>SHBG</gene-name>
        <locus>17p13-p12</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-29</signal-regions>
        <theoretical-pi>6.7</theoretical-pi>
        <molecular-weight>43778.755</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10839</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SHBG</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X16349</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>296673</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04278</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SHBG_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ABP</synonym>
          <synonym>SBP</synonym>
          <synonym>Sex steroid-binding protein</synonym>
          <synonym>SHBG</synonym>
          <synonym>TeBG</synonym>
          <synonym>Testis-specific androgen-binding protein</synonym>
          <synonym>Testosterone-estradiol-binding globulin</synonym>
          <synonym>Testosterone-estrogen-binding globulin</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001366|Sex hormone-binding globulin
MESRGPLATSRLLLLLLLLLLRHTRQGWALRPVLPTQSAHDPPAVHLSNGPGQEPIAVMT
FDLTKITKTSSSFEVRTWDPEGVIFYGDTNPKDDWFMLGLRDGRPEIQLHNHWAQLTVGA
GPRLDDGRWHQVEVKMEGDSVLLEVDGEEVLRLRQVSGPLTSKRHPIMRIALGGLLFPAS
NLRLPLVPALDGCLRRDSWLDKQAEISASAPTSLRSCDVESNPGIFLPPGTQAEFNLRDI
PQPHAEPWAFSLDLGLKQAAGSGHLLALGTPENPSWLSLHLQDQKVVLSSGSGPGLDLPL
VLGLPLQLKLSMSRVVLSQGSKMKALALPPLGLAPLLNLWAKPQGRLFLGALPGEDSSTS
FCLNGLWAQGQRLDVDQALNRSHEIWTHSCPQSPGNGTDASH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010477|Sex hormone-binding globulin (SHBG)
ATGGAGAGCAGAGGCCCACTGGCTACCTCGCGCCTGCTGCTGTTGCTGCTGTTGCTACTA
CTGCGTCACACCCGCCAGGGATGGGCCCTGAGACCTGTTCTCCCCACCCAGAGTGCCCAC
GACCCTCCGGCTGTCCACCTCAGCAATGGCCCAGGACAAGAGCCTATCGCTGTCATGACC
TTTGACCTCACCAAGATCACAAAAACCTCCTCCTCCTTTGAGGTTCGAACCTGGGACCCA
GAGGGAGTGATTTTTTATGGGGATACCAACCCTAAGGATGACTGGTTTATGCTGGGACTT
CGAGACGGCAGGCCTGAGATCCAACTGCACAATCACTGGGCCCAGCTTACGGTGGGTGCT
GGACCACGGCTGGATGATGGGAGATGGCACCAGGTGGAAGTCAAGATGGAGGGGGACTCT
GTGCTGCTGGAGGTGGATGGGGAGGAGGTGCTGCGCCTGAGACAGGTCTCTGGGCCCCTG
ACCAGCAAACGCCATCCCATCATGAGGATTGCGCTTGGGGGGCTGCTCTTCCCCGCTTCC
AACCTTCGGTTGCCGCTGGTTCCTGCCCTGGATGGCTGCCTGCGCCGGGATTCCTGGCTG
GACAAACAGGCCGAGATCTCAGCATCTGCCCCCACTAGCCTCAGAAGCTGTGATGTAGAA
TCAAATCCCGGGATATTTCTCCCTCCAGGGACTCAGGCAGAATTCAATCTCCGAGACATT
CCCCAGCCTCATGCAGAGCCCTGGGCCTTCTCTTTGGACCTGGGACTCAAGCAGGCAGCA
GGCTCAGGCCACCTCCTTGCTCTTGGGACACCAGAGAACCCATCTTGGCTCAGTCTCCAC
CTCCAAGATCAAAAGGTGGTGTTGTCTTCTGGGTCGGGGCCAGGGCTGGATCTGCCCCTG
GTCTTGGGACTCCCTCTTCAGCTGAAGCTGAGTATGTCCAGGGTGGTCTTGAGCCAAGGG
TCGAAGATGAAGGCCCTTGCCCTGCCTCCCTTAGGCCTGGCTCCCCTCCTTAACCTCTGG
GCCAAGCCTCAAGGGCGTCTCTTCCTGGGGGCTTTACCAGGAGAAGACTCTTCCACCTCT
TTTTGCCTGAATGGCCTTTGGGCACAAGGTCAGAGGCTGGATGTGGACCAGGCCCTGAAC
AGAAGCCATGAGATCTGGACTCACAGCTGCCCCCAGAGCCCAGGCAATGGCACTGACGCT
TCCCATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00054</identifier>
            <name>Laminin_G_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>androgen binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>primary spermatocyte growth</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A14926</ref-id>
            <pubmed-id>15304426</pubmed-id>
            <citation>Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE: The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12. Epub 2004 Aug 10.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
        <name>Cytochrome P450 3A4</name>
        <general-function>Vitamin d3 25-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
        <gene-name>CYP3A4</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2-22</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.25</theoretical-pi>
        <molecular-weight>57342.67</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M18907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1337</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08684</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Albendazole monooxygenase</synonym>
          <synonym>Albendazole sulfoxidase</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP3A3</synonym>
          <synonym>CYPIIIA3</synonym>
          <synonym>CYPIIIA4</synonym>
          <synonym>Cytochrome P450 3A3</synonym>
          <synonym>Cytochrome P450 HLp</synonym>
          <synonym>Cytochrome P450 NF-25</synonym>
          <synonym>Cytochrome P450-PCN1</synonym>
          <synonym>Nifedipine oxidase</synonym>
          <synonym>Quinine 3-monooxygenase</synonym>
          <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>albendazole monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quinine 3-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone 6-beta-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D3 25-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcitriol biosynthetic process from calciol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="2">
      <id>BE0002887</id>
      <name>Cytochrome P450 2C8</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15162</ref-id>
            <pubmed-id>15601807</pubmed-id>
            <citation>Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10632" source="Swiss-Prot">
        <name>Cytochrome P450 2C8</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti-cancer drug paclitaxel (taxol).</specific-function>
        <gene-name>CYP2C8</gene-name>
        <locus>10q23.33</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.62</theoretical-pi>
        <molecular-weight>55824.275</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2622</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2C8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M17397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1325</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10632</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2C8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIIC8</synonym>
          <synonym>Cytochrome P450 form 1</synonym>
          <synonym>Cytochrome P450 IIC2</synonym>
          <synonym>Cytochrome P450 MP-12</synonym>
          <synonym>Cytochrome P450 MP-20</synonym>
          <synonym>S-mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005650|Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021338|Cytochrome P450 2C8 (CYP2C8)
ATGGAACCTTTTGTGGTCCTGGTGCTGTGTCTCTCTTTTATGCTTCTCTTTTCACTCTGG
AGACAGAGCTGTAGGAGAAGGAAGCTCCCTCCTGGCCCCACTCCTCTTCCTATTATTGGA
AATATGCTACAGATAGATGTTAAGGACATCTGCAAATCTTTCACCAATTTCTCAAAAGTC
TATGGTCCTGTGTTCACCGTGTATTTTGGCATGAATCCCATAGTGGTGTTTCATGGATAT
GAGGCAGTGAAGGAAGCCCTGATTGATAATGGAGAGGAGTTTTCTGGAAGAGGCAATTCC
CCAATATCTCAAAGAATTACTAAAGGACTTGGAATCATTTCCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCACAACCTTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
GTTGTTTTCCAGAAACGATTTGATTATAAAGATCAGAATTTTCTCACCCTGATGAAAAGA
TTCAATGAAAACTTCAGGATTCTGAACTCCCCATGGATCCAGGTCTGCAATAATTTCCCT
CTACTCATTGATTGTTTCCCAGGAACTCACAACAAAGTGCTTAAAAATGTTGCTCTTACA
CGAAGTTACATTAGGGAGAAAGTAAAAGAACACCAAGCATCACTGGATGTTAACAATCCT
CGGGACTTTATCGATTGCTTCCTGATCAAAATGGAGCAGGAAAAGGACAACCAAAAGTCA
GAATTCAATATTGAAAACTTGGTTGGCACTGTAGCTGATCTATTTGTTGCTGGAACAGAG
ACAACAAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGATCATGTAATTGGCAGACACAGGAGCCCCTGCATGCAG
GATAGGAGCCACATGCCTTACACTGATGCTGTAGTGCACGAGATCCAGAGATACAGTGAC
CTTGTCCCCACCGGTGTGCCCCATGCAGTGACCACTGATACTAAGTTCAGAAACTACCTC
ATCCCCAAGGGCACAACCATAATGGCATTACTGACTTCCGTGCTACATGATGACAAAGAA
TTTCCTAATCCAAATATCTTTGACCCTGGCCACTTTCTAGATAAGAATGGCAACTTTAAG
AAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGAATTTGTGCAGGAGAAGGACTT
GCCCGCATGGAGCTATTTTTATTTCTAACCACAATTTTACAGAACTTTAACCTGAAATCT
GTTGATGATTTAAAGAACCTCAATACTACTGCAGTTACCAAAGGGATTGTTTCTCTGCCA
CCCTCATACCAGATCTGCTTCATCCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="6">
      <id>BE0003541</id>
      <name>UDP-glucuronosyltransferase 1-1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A34242</ref-id>
            <pubmed-id>15304429</pubmed-id>
            <citation>Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P22309" source="Swiss-Prot">
        <name>UDP-glucuronosyltransferase 1-1</name>
        <general-function>Steroid binding</general-function>
        <specific-function>UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naphthol, paranitrophenol, scopoletin, and umbelliferone. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.</specific-function>
        <gene-name>UGT1A1</gene-name>
        <locus>2q37</locus>
        <cellular-location>Microsome</cellular-location>
        <transmembrane-regions>491-507</transmembrane-regions>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>8.09</theoretical-pi>
        <molecular-weight>59590.91</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12530</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M57899</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>184473</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P22309</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UD11_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.1.17</synonym>
          <synonym>Bilirubin-specific UDPGT isozyme 1</synonym>
          <synonym>GNT1</synonym>
          <synonym>hUG-BR1</synonym>
          <synonym>UDP-glucuronosyltransferase 1-A</synonym>
          <synonym>UDP-glucuronosyltransferase 1A1</synonym>
          <synonym>UDPGT 1-1</synonym>
          <synonym>UGT-1A</synonym>
          <synonym>UGT1</synonym>
          <synonym>UGT1A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006823|UDP-glucuronosyltransferase 1-1
MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVL
APDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDS
AMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLE
FEATQCPNPFSYVPRPLSSHSDHMTFLQRVKNMLIAFSQNFLCDVVYSPYATLASEFLQR
EVTVQDLLSSASVWLFRSDFVKDYPRPIMPNMVFVGGINCLHQNPLSQEFEAYINASGEH
GIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDL
LGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTS
EDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHD
LTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021360|UDP-glucuronosyltransferase 1-1 (UGT1A1)
ATGGCTGTGGAGTCCCAGGGCGGACGCCCACTTGTCCTGGGCCTGCTGCTGTGTGTGCTG
GGCCCAGTGGTGTCCCATGCTGGGAAGATACTGTTGATCCCAGTGGATGGCAGCCACTGG
CTGAGCATGCTTGGGGCCATCCAGCAGCTGCAGCAGAGGGGACATGAAATAGTTGTCCTA
GCACCTGACGCCTCGTTGTACATCAGAGACGGAGCATTTTACACCTTGAAGACGTACCCT
GTGCCATTCCAAAGGGAGGATGTGAAAGAGTCTTTTGTTAGTCTCGGGCATAATGTTTTT
GAGAATGATTCTTTCCTGCAGCGTGTGATCAAAACATACAAGAAAATAAAAAAGGACTCT
GCTATGCTTTTGTCTGGCTGTTCCCACTTACTGCACAACAAGGAGCTCATGGCCTCCCTG
GCAGAAAGCAGCTTTGATGTCATGCTGACGGACCCTTTCCTTCCTTGCAGCCCCATCGTG
GCCCAGTACCTGTCTCTGCCCACTGTATTCTTCTTGCATGCACTGCCATGCAGCCTGGAA
TTTGAGGCTACCCAGTGCCCCAACCCATTCTCCTACGTGCCCAGGCCTCTCTCCTCTCAT
TCAGATCACATGACCTTCCTGCAGCGGGTGAAGAACATGCTCATTGCCTTTTCACAGAAC
TTTCTGTGCGACGTGGTTTATTCCCCGTATGCAACCCTTGCCTCAGAATTCCTTCAGAGA
GAGGTGACTGTCCAGGACCTATTGAGCTCTGCATCTGTCTGGCTGTTTAGAAGTGACTTT
GTGAAGGATTACCCTAGGCCCATCATGCCCAATATGGTTTTTGTTGGTGGAATCAACTGC
CTTCACCAAAATCCACTATCCCAGGAATTTGAAGCCTACATTAATGCTTCTGGAGAACAT
GGAATTGTGGTTTTCTCTTTGGGATCAATGGTCTCAGAAATTCCAGAGAAGAAAGCTATG
GCAATTGCTGATGCTTTGGGCAAAATCCCTCAGACAGTCCTGTGGCGGTACACTGGAACC
CGACCATCGAATCTTGCGAACAACACGATACTTGTTAAGTGGCTACCCCAAAACGATCTG
CTTGGTCACCCGATGACCCGTGCCTTTATCACCCATGCTGGTTCCCATGGTGTTTATGAA
AGCATATGCAATGGCGTTCCCATGGTGATGATGCCCTTGTTTGGTGATCAGATGGACAAT
GCAAAGCGCATGGAGACTAAGGGAGCTGGAGTGACCCTGAATGTTCTGGAAATGACTTCT
GAAGATTTAGAAAATGCTCTAAAAGCAGTCATCAATGACAAAAGTTACAAGGAGAACATC
ATGCGCCTCTCCAGCCTTCACAAGGACCGCCCGGTGGAGCCGCTGGACCTGGCCGTGTTC
TGGGTGGAGTTTGTGATGAGGCACAAGGGCGCGCCACACCTGCGCCCCGCAGCCCACGAC
CTCACCTGGTACCAGTACCATTCCTTGGACGTGATTGGTTTCCTCTTGGCCGTCGTGCTG
ACAGTGGCCTTCATCACCTTTAAATGTTGTGCTTATGGCTACCGGAAATGCTTGGGGAAA
AAAGGGCGAGTTAAGAAAGCCCACAAATCCAAGACCCATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00201</identifier>
            <name>UDPGT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytochrome complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum chaperone complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute-phase response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bilirubin conjugation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>biphenyl catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to glucocorticoid stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>estrogen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heme catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>liver development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of catalytic activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organ regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="7">
      <id>BE0003536</id>
      <name>Cytochrome P450 2C19</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A181367</ref-id>
            <pubmed-id>23844835</pubmed-id>
            <citation>Pedersen RS, Noehr-Jensen L, Brosen K: Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele. Clin Exp Pharmacol Physiol. 2013 Oct;40(10):683-8. doi: 10.1111/1440-1681.12153.</citation>
          </article>
          <article>
            <ref-id>A181370</ref-id>
            <pubmed-id>12895199</pubmed-id>
            <citation>Palovaara S, Tybring G, Laine K: The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003 Aug;56(2):232-7. doi: 10.1046/j.1365-2125.2003.01868.x.</citation>
          </article>
          <article>
            <ref-id>A184766</ref-id>
            <pubmed-id>19454483</pubmed-id>
            <citation>Chang SY, Chen C, Yang Z, Rodrigues AD: Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. Drug Metab Dispos. 2009 Aug;37(8):1667-75. doi: 10.1124/dmd.109.026997. Epub 2009 May 19.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P33261" source="Swiss-Prot">
        <name>Cytochrome P450 2C19</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.</specific-function>
        <gene-name>CYP2C19</gene-name>
        <locus>10q24.1-q24.3</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.42</theoretical-pi>
        <molecular-weight>55930.545</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2621</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M61854</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181344</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1328</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P33261</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2CJ_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>(R)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 7-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>CYPIIC17</synonym>
          <synonym>CYPIIC19</synonym>
          <synonym>Cytochrome P450-11A</synonym>
          <synonym>Cytochrome P450-254C</synonym>
          <synonym>Mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020694|Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020695|Cytochrome P450 2C19 (CYP2C19)
ATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGAACGCATGGTGGTGCTGCATGGATAT
GAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATCGTTTTCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCAGAAACGTTTCGATTATAAAGATCAGCAATTTCTTAACTTGATGGAAAAA
TTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCC
ACTATCATTGATTATTTCCCGGGAACCCATAACAAATTACTTAAAAACCTTGCTTTTATG
GAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCT
CGGGACTTTATTGATTGCTTCCTGATCAAAATGGAGAAGGAAAAGCAAAACCAACAGTCT
GAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAG
ACAACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAG
GACAGGGGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATCGAC
CTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTC
ATTCCCAAGGGCACAACCATATTAACTTCCCTCACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAG
AAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAGGGCCTG
GCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCT
CTGATTGACCCAAAGGACCTTGACACAACTCCTGTTGTCAATGGATTTGCTTCTGTCCCG
CCCTTCTATCAGCTGTGCTTCATTCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(R)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 7-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters>
    <transporter position="1">
      <id>BE0000703</id>
      <name>Bile salt export pump</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15805</ref-id>
            <pubmed-id>10611165</pubmed-id>
            <citation>Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL: Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology. 2000 Jan;118(1):163-72.</citation>
          </article>
          <article>
            <ref-id>A15806</ref-id>
            <pubmed-id>10869290</pubmed-id>
            <citation>Huang L, Smit JW, Meijer DK, Vore M: Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. Hepatology. 2000 Jul;32(1):66-72.</citation>
          </article>
          <article>
            <ref-id>A16122</ref-id>
            <pubmed-id>10648470</pubmed-id>
            <citation>Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O95342" source="Swiss-Prot">
        <name>Bile salt export pump</name>
        <general-function>Transporter activity</general-function>
        <specific-function>Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.</specific-function>
        <gene-name>ABCB11</gene-name>
        <locus>2q24</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>63-83
148-168
216-236
241-261
320-340
354-374
756-776
795-815
870-890
891-911
980-1000
1012-1032</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.52</theoretical-pi>
        <molecular-weight>146405.83</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:42</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB11</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF091582</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3873243</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>778</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O95342</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ABCBB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family B member 11</synonym>
          <synonym>BSEP</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010492|Bile salt export pump
MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQLFRFSSSTDIW
LMFVGSLCAFLHGIAQPGVLLIFGTMTDVFIDYDVELQELQIPGKACVNNTIVWTNSSLN
QNMTNGTRCGLLNIESEMIKFASYYAGIAVAVLITGYIQICFWVIAAARQIQKMRKFYFR
RIMRMEIGWFDCNSVGELNTRFSDDINKINDAIADQMALFIQRMTSTICGFLLGFFRGWK
LTLVIISVSPLIGIGAATIGLSVSKFTDYELKAYAKAGVVADEVISSMRTVAAFGGEKRE
VERYEKNLVFAQRWGIRKGIVMGFFTGFVWCLIFLCYALAFWYGSTLVLDEGEYTPGTLV
QIFLSVIVGALNLGNASPCLEAFATGRAAATSIFETIDRKPIIDCMSEDGYKLDRIKGEI
EFHNVTFHYPSRPEVKILNDLNMVIKPGEMTALVGPSGAGKSTALQLIQRFYDPCEGMVT
VDGHDIRSLNIQWLRDQIGIVEQEPVLFSTTIAENIRYGREDATMEDIVQAAKEANAYNF
IMDLPQQFDTLVGEGGGQMSGGQKQRVAIARALIRNPKILLLDMATSALDNESEAMVQEV
LSKIQHGHTIISVAHRLSTVRAADTIIGFEHGTAVERGTHEELLERKGVYFTLVTLQSQG
NQALNEEDIKDATEDDMLARTFSRGSYQDSLRASIRQRSKSQLSYLVHEPPLAVVDHKST
YEEDRKDKDIPVQEEVEPAPVRRILKFSAPEWPYMLVGSVGAAVNGTVTPLYAFLFSQIL
GTFSIPDKEEQRSQINGVCLLFVAMGCVSLFTQFLQGYAFAKSGELLTKRLRKFGFRAML
GQDIAWFDDLRNSPGALTTRLATDASQVQGAAGSQIGMIVNSFTNVTVAMIIAFSFSWKL
SLVILCFFPFLALSGATQTRMLTGFASRDKQALEMVGQITNEALSNIRTVAGIGKERRFI
EALETELEKPFKTAIQKANIYGFCFAFAQCIMFIANSASYRYGGYLISNEGLHFSYVFRV
ISAVVLSATALGRAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKIDF
VDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLERFYDPDQGKVMID
GHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNIKYGDNTKEIPMERVIAAAKQAQLHDF
VMSLPEKYETNVGSQGSQLSRGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVA
LDKAREGRTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLVTTGSPI
S</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010493|Bile salt export pump (ABCB11)
ATGTCTGACTCAGTAATTCTTCGAAGTATAAAGAAATTTGGAGAGGAGAATGATGGTTTT
GAGTCAGATAAATCATATAATAATGATAAGAAATCAAGGTTACAAGATGAGAAGAAAGGT
GATGGCGTTAGAGTTGGCTTCTTTCAATTGTTTCGGTTTTCTTCATCAACTGACATTTGG
CTGATGTTTGTGGGAAGTTTGTGTGCATTTCTCCATGGAATAGCCCAGCCAGGCGTGCTA
CTCATTTTTGGCACAATGACAGATGTTTTTATTGACTACGACGTTGAGTTACAAGAACTC
CAGATTCCAGGAAAAGCATGTGTGAATAACACCATTGTATGGACTAACAGTTCCCTCAAC
CAGAACATGACAAATGGAACACGTTGTGGGTTGCTGAACATCGAGAGCGAAATGATCAAA
TTTGCCAGTTACTATGCTGGAATTGCTGTCGCAGTACTTATCACAGGATATATTCAAATA
TGCTTTTGGGTCATTGCCGCAGCTCGTCAGATACAGAAAATGAGAAAATTTTACTTTAGG
AGAATAATGAGAATGGAAATAGGGTGGTTTGACTGCAATTCAGTGGGGGAGCTGAATACA
AGATTCTCTGATGATATTAATAAAATCAATGATGCCATAGCTGACCAAATGGCCCTTTTC
ATTCAGCGCATGACCTCGACCATCTGTGGTTTCCTGTTGGGATTTTTCAGGGGTTGGAAA
CTGACCTTGGTTATTATTTCTGTCAGCCCTCTCATTGGGATTGGAGCAGCCACCATTGGT
CTGAGTGTGTCCAAGTTTACGGACTATGAGCTGAAGGCCTATGCCAAAGCAGGGGTGGTG
GCTGATGAAGTCATTTCATCAATGAGAACAGTGGCTGCTTTTGGTGGTGAGAAAAGAGAG
GTTGAAAGGTATGAGAAAAATCTTGTGTTCGCCCAGCGTTGGGGAATTAGAAAAGGAATA
GTGATGGGATTCTTTACTGGATTCGTGTGGTGTCTCATCTTTTTGTGTTATGCACTGGCC
TTCTGGTACGGCTCCACACTTGTCCTGGATGAAGGAGAATATACACCAGGAACCCTTGTC
CAGATTTTCCTCAGTGTCATAGTAGGAGCTTTAAATCTTGGCAATGCCTCTCCTTGTTTG
GAAGCCTTTGCAACTGGACGTGCAGCAGCCACCAGCATTTTTGAGACAATAGACAGGAAA
CCCATCATTGACTGCATGTCAGAAGATGGTTACAAGTTGGATCGAATCAAGGGTGAAATT
GAATTCCATAATGTGACCTTCCATTATCCTTCCAGACCAGAGGTGAAGATTCTAAATGAC
CTCAACATGGTCATTAAACCAGGGGAAATGACAGCTCTGGTAGGACCCAGTGGAGCTGGA
AAAAGTACAGCACTGCAACTCATTCAGCGATTCTATGACCCCTGTGAAGGAATGGTGACC
GTGGATGGCCATGACATTCGCTCTCTTAACATTCAGTGGCTTAGAGATCAGATTGGGATA
GTGGAGCAAGAGCCAGTTCTGTTCTCTACCACCATTGCAGAAAATATTCGCTATGGCAGA
GAAGATGCAACAATGGAAGACATAGTCCAAGCTGCCAAGGAGGCCAATGCCTACAACTTC
ATCATGGACCTGCCACAGCAATTTGACACCCTTGTTGGAGAAGGAGGAGGCCAGATGAGT
GGTGGCCAGAAACAAAGGGTAGCTATCGCCAGAGCCCTCATCCGAAATCCCAAGATTCTG
CTTTTGGACATGGCCACCTCAGCTCTGGACAATGAGAGTGAAGCCATGGTGCAAGAAGTG
CTGAGTAAGATTCAGCATGGGCACACAATCATTTCAGTTGCTCATCGCTTGTCTACGGTC
AGAGCTGCAGATACCATCATTGGTTTTGAACATGGCACTGCAGTGGAAAGAGGGACCCAT
GAAGAATTACTGGAAAGGAAAGGTGTTTACTTCACTCTAGTGACTTTGCAAAGCCAGGGA
AATCAAGCTCTTAATGAAGAGGACATAAAGGATGCAACTGAAGATGACATGCTTGCGAGG
ACCTTTAGCAGAGGGAGCTACCAGGATAGTTTAAGGGCTTCCATCCGGCAACGCTCCAAG
TCTCAGCTTTCTTACCTGGTGCACGAACCTCCATTAGCTGTTGTAGATCATAAGTCTACC
TATGAAGAAGATAGAAAGGACAAGGACATTCCTGTGCAGGAAGAAGTTGAACCTGCCCCA
GTTAGGAGGATTCTGAAATTCAGTGCTCCAGAATGGCCCTACATGCTGGTAGGGTCTGTG
GGTGCAGCTGTGAACGGGACAGTCACACCCTTGTATGCCTTTTTATTCAGCCAGATTCTT
GGGACTTTTTCAATTCCTGATAAAGAGGAACAAAGGTCACAGATCAATGGTGTGTGCCTA
CTTTTTGTAGCAATGGGCTGTGTATCTCTTTTCACCCAATTTCTACAGGGATATGCCTTT
GCTAAATCTGGGGAGCTCCTAACAAAAAGGCTACGTAAATTTGGTTTCAGGGCAATGCTG
GGGCAAGATATTGCCTGGTTTGATGACCTCAGAAATAGCCCTGGAGCATTGACAACAAGA
CTTGCTACAGATGCTTCCCAAGTTCAAGGGGCTGCCGGCTCTCAGATCGGGATGATAGTC
AATTCCTTCACTAACGTCACTGTGGCCATGATCATTGCCTTCTCCTTTAGCTGGAAGCTG
AGCCTGGTCATCTTGTGCTTCTTCCCCTTCTTGGCTTTATCAGGAGCCACACAGACCAGG
ATGTTGACAGGATTTGCCTCTCGAGATAAGCAGGCCCTGGAGATGGTGGGACAGATTACA
AATGAAGCCCTCAGTAACATCCGCACTGTTGCTGGAATTGGAAAGGAGAGGCGGTTCATT
GAAGCACTTGAGACTGAGCTGGAGAAGCCCTTCAAGACAGCCATTCAGAAAGCCAATATT
TACGGATTCTGCTTTGCCTTTGCCCAGTGCATCATGTTTATTGCGAATTCTGCTTCCTAC
AGATATGGAGGTTACTTAATCTCCAATGAGGGGCTCCATTTCAGCTATGTGTTCAGGGTG
ATCTCTGCAGTTGTACTGAGTGCAACAGCTCTTGGAAGAGCCTTCTCTTACACCCCAAGT
TATGCAAAAGCTAAAATATCAGCTGCACGCTTTTTTCAACTGCTGGACCGACAACCCCCA
ATCAGTGTATACAATACTGCAGGTGAAAAATGGGACAACTTCCAGGGGAAGATTGATTTT
GTTGATTGTAAATTTACATATCCTTCTCGACCTGACTCGCAAGTTCTGAATGGTCTCTCA
GTGTCGATTAGTCCAGGGCAGACACTGGCGTTTGTTGGGAGCAGTGGATGTGGCAAAAGC
ACTAGCATTCAGCTGTTGGAACGTTTCTATGATCCTGATCAAGGGAAGGTGATGATAGAT
GGTCATGACAGCAAAAAAGTAAATGTCCAGTTCCTCCGCTCAAACATTGGAATTGTTTCC
CAGGAACCAGTGTTGTTTGCCTGTAGCATAATGGACAATATCAAGTATGGAGACAACACC
AAAGAAATTCCCATGGAAAGAGTCATAGCAGCTGCAAAACAGGCTCAGCTGCATGATTTT
GTCATGTCACTCCCAGAGAAATATGAAACTAACGTTGGGTCCCAGGGGTCTCAACTCTCT
AGAGGGGAGAAACAACGCATTGCTATTGCTCGGGCCATTGTACGAGATCCTAAAATCTTG
CTACTAGATGAAGCCACTTCTGCCTTAGACACAGAAAGTGAAAAGACGGTGCAGGTTGCT
CTAGACAAAGCCAGAGAGGGTCGGACCTGCATTGTCATTGCCCATCGCTTGTCCACCATC
CAGAACGCGGATATCATTGCTGTCATGGCACAGGGGGTGGTGATTGAAAAGGGGACCCAT
GAAGAACTGATGGCCCAAAAAGGAGCCTACTACAAACTAGTCACCACTGGATCCCCCATC
AGTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intercellular canaliculus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid-exporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>canalicular bile acid transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-exporting ATPase activity, phosphorylative mechanism</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>canalicular bile acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="2">
      <id>BE0003644</id>
      <name>Sodium/bile acid cotransporter</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15805</ref-id>
            <pubmed-id>10611165</pubmed-id>
            <citation>Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL: Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology. 2000 Jan;118(1):163-72.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q14973" source="Swiss-Prot">
        <name>Sodium/bile acid cotransporter</name>
        <general-function>Virus receptor activity</general-function>
        <specific-function>The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.</specific-function>
        <gene-name>SLC10A1</gene-name>
        <locus>14q24.1</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>25-45
60-80
91-111
120-140
156-176
191-211
220-240
283-303</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.94</theoretical-pi>
        <molecular-weight>38118.64</molecular-weight>
        <chromosome-location>14</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10905</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L21893</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>410214</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>959</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q14973</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NTCP_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Cell growth-inhibiting gene 29 protein</synonym>
          <synonym>Na(+)/bile acid cotransporter</synonym>
          <synonym>Na(+)/taurocholate transport protein</synonym>
          <synonym>NTCP</synonym>
          <synonym>Sodium/taurocholate cotransporting polypeptide</synonym>
          <synonym>Solute carrier family 10 member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017172|Sodium/bile acid cotransporter
MEAHNASAPFNFTLPPNFGKRPTDLALSVILVFMLFFIMLSLGCTMEFSKIKAHLWKPKG
LAIALVAQYGIMPLTAFVLGKVFRLKNIEALAILVCGCSPGGNLSNVFSLAMKGDMNLSI
VMTTCSTFCALGMMPLLLYIYSRGIYDGDLKDKVPYKGIVISLVLVLIPCTIGIVLKSKR
PQYMRYVIKGGMIIILLCSVAVTVLSAINVGKSIMFAMTPLLIATSSLMPFIGFLLGYVL
SALFCLNGRCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPLLYMIFQLGEGLLL
IAIFWCYEKFKTPKDKTKMIYTAATTEETIPGALGNGTYKGEDCSPCTA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017173|Sodium/bile acid cotransporter (SLC10A1)
ATGGAGGCCCACAACGCGTCTGCCCCATTCAACTTCACCCTGCCACCCAACTTTGGCAAG
CGCCCCACAGACCTGGCACTGAGCGTCATCCTGGTGTTCATGTTGTTCTTCATCATGCTC
TCGCTGGGCTGCACCATGGAGTTCAGCAAGATCAAGGCTCACTTATGGAAGCCTAAAGGG
CTGGCCATCGCCCTGGTGGCACAGTATGGCATCATGCCCCTCACGGCCTTTGTGCTGGGC
AAGGTCTTCCGGCTGAAGAACATTGAGGCACTGGCCATCTTGGTCTGTGGCTGCTCACCT
GGAGGGAACCTGTCCAATGTCTTCAGTCTGGCCATGAAGGGGGACATGAACCTCAGCATT
GTGATGACCACCTGCTCCACCTTCTGTGCCCTTGGCATGATGCCTCTCCTCCTGTACATC
TACTCCAGGGGGATCTATGATGGGGACCTGAAGGACAAGGTGCCCTATAAAGGCATCGTG
ATATCACTGGTCCTGGTTCTCATTCCTTGCACCATAGGGATCGTCCTCAAATCCAAACGG
CCACAATACATGCGCTATGTCATCAAGGGAGGGATGATCATCATTCTCTTGTGCAGTGTG
GCCGTCACAGTTCTCTCTGCCATCAATGTGGGGAAGAGCATCATGTTTGCCATGACACCA
CTCTTGATTGCCACCTCCTCCCTGATGCCTTTTATTGGCTTTCTGCTGGGTTATGTTCTC
TCTGCTCTCTTCTGCCTCAATGGACGGTGCAGACGCACTGTCAGCATGGAGACTGGATGC
CAAAATGTCCAACTCTGTTCCACCATCCTCAATGTGGCCTTTCCACCTGAAGTCATTGGA
CCACTTTTCTTCTTTCCCCTCCTCTACATGATTTTCCAGCTTGGAGAAGGGCTTCTCCTC
ATTGCCATATTTTGGTGCTATGAGAAATTCAAGACTCCCAAGGATAAAACAAAAATGATC
TACACAGCTGCCACAACTGAAGAAACAATTCCAGGAGCTCTGGGAAATGGCACCTACAAA
GGGGAGGACTGCTCCCCTTGCACAGCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01758</identifier>
            <name>SBF</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>bile acid</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>virus receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="3">
      <id>BE0001069</id>
      <name>Canalicular multispecific organic anion transporter 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16004</ref-id>
            <pubmed-id>9571149</pubmed-id>
            <citation>Kauffmann HM, Schrenk D: Sequence analysis and functional characterization of the 5'-flanking region of the rat multidrug resistance protein 2 (mrp2) gene. Biochem Biophys Res Commun. 1998 Apr 17;245(2):325-31.</citation>
          </article>
          <article>
            <ref-id>A16009</ref-id>
            <pubmed-id>9207286</pubmed-id>
            <citation>Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, Suchy FJ, Keppler D, Boyer JL: The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology. 1997 Jul;113(1):255-64.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q92887" source="Swiss-Prot">
        <name>Canalicular multispecific organic anion transporter 1</name>
        <general-function>Organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.</specific-function>
        <gene-name>ABCC2</gene-name>
        <locus>10q24</locus>
        <cellular-location>Apical cell membrane</cellular-location>
        <transmembrane-regions>28-48
69-89
94-114
127-147
166-186
314-334
361-381
438-458
462-482
545-565
588-608
972-992
1034-1054
1098-1118
1120-1140
1212-1232
1235-1255</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.46</theoretical-pi>
        <molecular-weight>174205.64</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:53</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCC2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U63970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1764162</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>780</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q92887</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MRP2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family C member 2</synonym>
          <synonym>Canalicular multidrug resistance protein</synonym>
          <synonym>CMOAT</synonym>
          <synonym>CMOAT1</synonym>
          <synonym>CMRP</synonym>
          <synonym>MRP2</synonym>
          <synonym>Multidrug resistance-associated protein 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010748|Canalicular multispecific organic anion transporter 1
MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPWQLLHVYKSRTKRSS
TTKLYLAKQVFVGFLLILAAIELALVLTEDSGQATVPAVRYTNPSLYLGTWLLVLLIQYS
RQWCVQKNSWFLSLFWILSILCGTFQFQTLIRTLLQGDNSNLAYSCLFFISYGFQILILI
FSAFSENNESSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKTLVS
KFETHMKRELQKARRALQRRQEKSSQQNSGARLPGLNKNQSQSQDALVLEDVEKKKKKSG
TKKDVPKSWLMKALFKTFYMVLLKSFLLKLVNDIFTFVSPQLLKLLISFASDRDTYLWIG
YLCAILLFTAALIQSFCLQCYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYTVGET
VNLMSVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGVMVLVIPINAIL
STKSKTIQVKNMKNKDKRLKIMNEILSGIKILKYFAWEPSFRDQVQNLRKKELKNLLAFS
QLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNILRFPLSMLPMMI
SSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFDKAMQFSEASFTWEHDSEATVRDVNLD
IMAGQLVAVIGPVGSGKSSLISAMLGEMENVHGHITIKGTTAYVPQQSWIQNGTIKDNIL
FGTEFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLARATYQNLD
IYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVTHSMHFLPQVDEIVVLGNGTIV
EKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEEEDDDYGLISSVEEIPEDAAS
ITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRNVNSLKEDEELVKGQKLIKKEFIETG
KVKFSIYLEYLQAIGLFSIFFIILAFVMNSVAFIGSNLWLSAWTSDSKIFNSTDYPASQR
DMRVGVYGALGLAQGIFVFIAHFWSAFGFVHASNILHKQLLNNILRAPMRFFDTTPTGRI
VNRFAGDISTVDDTLPQSLRSWITCFLGIISTLVMICMATPVFTIIVIPLGIIYVSVQMF
YVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVIRAFEHQQRFLKHNEVRIDTNQKCVFSW
ITSNRWLAIRLELVGNLTVFFSALMMVIYRDTLSGDTVGFVLSNALNITQTLNWLVRMTS
EIETNIVAVERITEYTKVENEAPWVTDKRPPPDWPSKGKIQFNNYQVRYRPELDLVLRGI
TCDIGSMEKIGVVGRTGAGKSSLTNCLFRILEAAGGQIIIDGVDIASIGLHDLREKLTII
PQDPILFSGSLRMNLDPFNNYSDEEIWKALELAHLKSFVASLQLGLSHEVTEAGGNLSIG
QRQLLCLGRALLRKSKILVLDEATAAVDLETDNLIQTTIQNEFAHCTVITIAHRLHTIMD
SDKVMVLDNGKIIECGSPEELLQIPGPFYFMAKEAGIENVNSTKF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010749|Canalicular multispecific organic anion transporter 1 (ABCC2)
ATGCTGGAGAAGTTCTGCAACTCTACTTTTTGGAATTCCTCATTCCTGGACAGTCCGGAG
GCAGACCTGCCACTTTGTTTTGAGCAAACTGTTCTGGTGTGGATTCCCTTGGGCTTCCTA
TGGCTCCTGGCCCCCTGGCAGCTTCTCCACGTGTATAAATCCAGGACCAAGAGATCCTCT
ACCACCAAACTCTATCTTGCTAAGCAGGTATTCGTTGGTTTTCTTCTTATTCTAGCAGCC
ATAGAGCTGGCCCTTGTACTCACAGAAGACTCTGGACAAGCCACAGTCCCTGCTGTTCGA
TATACCAATCCAAGCCTCTACCTAGGCACATGGCTCCTGGTTTTGCTGATCCAATACAGC
AGACAATGGTGTGTACAGAAAAACTCCTGGTTCCTGTCCCTATTCTGGATTCTCTCGATA
CTCTGTGGCACTTTCCAATTTCAGACTCTGATCCGGACACTCTTACAGGGTGACAATTCT
AATCTAGCCTACTCCTGCCTGTTCTTCATCTCCTACGGATTCCAGATCCTGATCCTGATC
TTTTCAGCATTTTCAGAAAATAATGAGTCATCAAATAATCCATCATCCATAGCTTCATTC
CTGAGTAGCATTACCTACAGCTGGTATGACAGCATCATTCTGAAAGGCTACAAGCGTCCT
CTGACACTCGAGGATGTCTGGGAAGTTGATGAAGAGATGAAAACCAAGACATTAGTGAGC
AAGTTTGAAACGCACATGAAGAGAGAGCTGCAGAAAGCCAGGCGGGCACTCCAGAGACGG
CAGGAGAAGAGCTCCCAGCAGAACTCTGGAGCCAGGCTGCCTGGCTTGAACAAGAATCAG
AGTCAAAGCCAAGATGCCCTTGTCCTGGAAGATGTTGAAAAGAAAAAAAAGAAGTCTGGG
ACCAAAAAAGATGTTCCAAAATCCTGGTTGATGAAGGCTCTGTTCAAAACTTTCTACATG
GTGCTCCTGAAATCATTCCTACTGAAGCTAGTGAATGACATCTTCACGTTTGTGAGTCCT
CAGCTGCTGAAATTGCTGATCTCCTTTGCAAGTGACCGTGACACATATTTGTGGATTGGA
TATCTCTGTGCAATCCTCTTATTCACTGCGGCTCTCATTCAGTCTTTCTGCCTTCAGTGT
TATTTCCAACTGTGCTTCAAGCTGGGTGTAAAAGTACGGACAGCTATCATGGCTTCTGTA
TATAAGAAGGCATTGACCCTATCCAACTTGGCCAGGAAGGAGTACACCGTTGGAGAAACA
GTGAACCTGATGTCTGTGGATGCCCAGAAGCTCATGGATGTGACCAACTTCATGCACATG
CTGTGGTCAAGTGTTCTACAGATTGTCTTATCTATCTTCTTCCTATGGAGAGAGTTGGGA
CCCTCAGTCTTAGCAGGTGTTGGGGTGATGGTGCTTGTAATCCCAATTAATGCGATACTG
TCCACCAAGAGTAAGACCATTCAGGTCAAAAATATGAAGAATAAAGACAAACGTTTAAAG
ATCATGAATGAGATTCTTAGTGGAATCAAGATCCTGAAATATTTTGCCTGGGAACCTTCA
TTCAGAGACCAAGTACAAAACCTCCGGAAGAAAGAGCTCAAGAACCTGCTGGCCTTTAGT
CAACTACAGTGTGTAGTAATATTCGTCTTCCAGTTAACTCCAGTCCTGGTATCTGTGGTC
ACATTTTCTGTTTATGTCCTGGTGGATAGCAACAATATTTTGGATGCACAAAAGGCCTTC
ACCTCCATTACCCTCTTCAATATCCTGCGCTTTCCCCTGAGCATGCTTCCCATGATGATC
TCCTCCATGCTCCAGGCCAGTGTTTCCACAGAGCGGCTAGAGAAGTACTTGGGAGGGGAT
GACTTGGACACATCTGCCATTCGACATGACTGCAATTTTGACAAAGCCATGCAGTTTTCT
GAGGCCTCCTTTACCTGGGAACATGATTCGGAAGCCACAGTCCGAGATGTGAACCTGGAC
ATTATGGCAGGCCAACTTGTGGCTGTGATAGGCCCTGTCGGCTCTGGGAAATCCTCCTTG
ATATCAGCCATGCTGGGAGAAATGGAAAATGTCCACGGGCACATCACCATCAAGGGCACC
ACTGCCTATGTCCCACAGCAGTCCTGGATTCAGAATGGCACCATAAAGGACAACATCCTT
TTTGGAACAGAGTTTAATGAAAAGAGGTACCAGCAAGTACTGGAGGCCTGTGCTCTCCTC
CCAGACTTGGAAATGCTGCCTGGAGGAGATTTGGCTGAGATTGGAGAGAAGGGTATAAAT
CTTAGTGGGGGTCAGAAGCAGCGGATCAGCCTGGCCAGAGCTACCTACCAAAATTTAGAC
ATCTATCTTCTAGATGACCCCCTGTCTGCAGTGGATGCTCATGTAGGAAAACATATTTTT
AATAAGGTCTTGGGCCCCAATGGCCTGTTGAAAGGCAAGACTCGACTCTTGGTTACACAT
AGCATGCACTTTCTTCCTCAAGTGGATGAGATTGTAGTTCTGGGGAATGGAACAATTGTA
GAGAAAGGATCCTACAGTGCTCTCCTGGCCAAAAAAGGAGAGTTTGCTAAGAATCTGAAG
ACATTTCTAAGACATACAGGCCCTGAAGAGGAAGCCACAGTCCATGATGGCAGTGAAGAA
GAAGACGATGACTATGGGCTGATATCCAGTGTGGAAGAGATCCCCGAAGATGCAGCCTCC
ATAACCATGAGAAGAGAGAACAGCTTTCGTCGAACACTTAGCCGCAGTTCTAGGTCCAAT
GGCAGGCATCTGAAGTCCCTGAGAAACTCCTTGAAAACTCGGAATGTGAATAGCCTGAAG
GAAGACGAAGAACTAGTGAAAGGACAAAAACTAATTAAGAAGGAATTCATAGAAACTGGA
AAGGTGAAGTTCTCCATCTACCTGGAGTACCTACAAGCAATAGGATTGTTTTCGATATTC
TTCATCATCCTTGCGTTTGTGATGAATTCTGTGGCTTTTATTGGATCCAACCTCTGGCTC
AGTGCTTGGACCAGTGACTCTAAAATCTTCAATAGCACCGACTATCCAGCATCTCAGAGG
GACATGAGAGTTGGAGTCTACGGAGCTCTGGGATTAGCCCAAGGTATATTTGTGTTCATA
GCACATTTCTGGAGTGCCTTTGGTTTCGTCCATGCATCAAATATCTTGCACAAGCAACTG
CTGAACAATATCCTTCGAGCACCTATGAGATTTTTTGACACAACACCCACAGGCCGGATT
GTGAACAGGTTTGCCGGCGATATTTCCACAGTGGATGACACCCTGCCTCAGTCCTTGCGC
AGCTGGATTACATGCTTCCTGGGGATAATCAGCACCCTTGTCATGATCTGCATGGCCACT
CCTGTCTTCACCATCATCGTCATTCCTCTTGGCATTATTTATGTATCTGTTCAGATGTTT
TATGTGTCTACCTCCCGCCAGCTGAGGCGTCTGGACTCTGTCACCAGGTCCCCAATCTAC
TCTCACTTCAGCGAGACCGTATCAGGTTTGCCAGTTATCCGTGCCTTTGAGCACCAGCAG
CGATTTCTGAAACACAATGAGGTGAGGATTGACACCAACCAGAAATGTGTCTTTTCCTGG
ATCACCTCCAACAGGTGGCTTGCAATTCGCCTGGAGCTGGTTGGGAACCTGACTGTCTTC
TTTTCAGCCTTGATGATGGTTATTTATAGAGATACCCTAAGTGGGGACACTGTTGGCTTT
GTTCTGTCCAATGCACTCAATATCACACAAACCCTGAACTGGCTGGTGAGGATGACATCA
GAAATAGAGACCAACATTGTGGCTGTTGAGCGAATAACTGAGTACACAAAAGTGGAAAAT
GAGGCACCCTGGGTGACTGATAAGAGGCCTCCGCCAGATTGGCCCAGCAAAGGCAAGATC
CAGTTTAACAACTACCAAGTGCGGTACCGACCTGAGCTGGATCTGGTCCTCAGAGGGATC
ACTTGTGACATCGGTAGCATGGAGAAGATTGGTGTGGTGGGCAGGACAGGAGCTGGAAAG
TCATCCCTCACAAACTGCCTCTTCAGAATCTTAGAGGCTGCCGGTGGTCAGATTATCATT
GATGGAGTAGATATTGCTTCCATTGGGCTCCACGACCTCCGAGAGAAGCTGACCATCATC
CCCCAGGACCCCATCCTGTTCTCTGGAAGCCTGAGGATGAATCTCGACCCTTTCAACAAC
TACTCAGATGAGGAGATTTGGAAGGCCTTGGAGCTGGCTCACCTCAAGTCTTTTGTGGCC
AGCCTGCAACTTGGGTTATCCCACGAAGTGACAGAGGCTGGTGGCAACCTGAGCATAGGC
CAGAGGCAGCTGCTGTGCCTGGGCAGGGCTCTGCTTCGGAAATCCAAGATCCTGGTCCTG
GATGAGGCCACTGCTGCGGTGGATCTAGAGACAGACAACCTCATTCAGACGACCATCCAA
AACGAGTTCGCCCACTGCACAGTGATCACCATCGCCCACAGGCTGCACACCATCATGGAC
AGTGACAAGGTAATGGTCCTAGACAACGGGAAGATTATAGAGTGCGGCAGCCCTGAAGAA
CTGCTACAAATCCCTGGACCCTTTTACTTTATGGCTAAGGAAGCTGGCATTGAGAATGTG
AACAGCACAAAATTCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular chloride ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to arsenic-containing substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to methotrexate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to oxidative stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thyroid hormone transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="4">
      <id>BE0001032</id>
      <name>P-glycoprotein 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15897</ref-id>
            <pubmed-id>15290871</pubmed-id>
            <citation>Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08183" source="Swiss-Prot">
        <name>Multidrug resistance protein 1</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.</specific-function>
        <gene-name>ABCB1</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>45-67
117-137
187-208
216-236
293-316
331-352
712-732
757-777
833-853
855-874
935-957
974-995</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.44</theoretical-pi>
        <molecular-weight>141477.255</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:40</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M14758</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307180</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08183</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MDR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.6.3.44</synonym>
          <synonym>ATP-binding cassette sub-family B member 1</synonym>
          <synonym>MDR1</synonym>
          <synonym>P-glycoprotein 1</synonym>
          <synonym>PGY1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037114|Multidrug resistance protein 1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC
AAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G2/M transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stem cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>